

Tuesday, March 27, 2018

Volume 34 No. 3



NOTICE – Items in this issue will be listed online weekly and printed monthly.

### NAME CHANGES

(For details on individual listings, see the News Section of this issue)

Clean Diesel Technologies Inc. (to CDTi Advanced Materials Inc)

### 12 RETECH CORP

**Acquisition Completed** On Mar. 12, 2018, Co. acquired 10,000,000 shares of E-motion Apparel, Inc. ("E-motion"), a company that manufactures apparel for women, representing 100% of the issued and outstanding equity of E-motion from the E-motion Shareholders, in exchange of 1,000,000 common shares of Co. As a result E-motion became a wholly-owned subsidiary of Co.

### ABEONA THERAPEUTICS INC

#### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
License revenues	602,000	602,000	602,000
Royalties	235,000	287,000	438,000
Total revenues	837,000	889,000	1,040,000
Research & development expenses	16,989,000	10,655,000	4,715,000
General & administrative expenses	10,943,000	13,290,000	14,320,000
Depreciation & amortization	741,000	825,000	551,000
Income (loss) from operations	(27,836,000)	(23,881,000)	(18,546,000)
Interest & miscellaneous income (expense)	525,000	2,014,000	4,026,000
Interest & other expense	8,000	6,000	6,000
Total other income (expense)	517,000	2,008,000	4,020,000
<b>Net income (loss)</b>	<b>(27,319,000)</b>	<b>(21,873,000)</b>	<b>(14,526,000)</b>
Weighted average shares outstanding - basic	41,636,752	34,180,253	27,597,434
Weighted average shares outstanding - diluted	41,636,752	34,180,253	27,597,434
Year end shares outstanding	46,888,108	40,254,457	32,743,013
Net income (loss) per share - basic	\$(0.66)	\$(0.64)	\$(0.53)
Net income (loss) per share - diluted	\$(0.66)	\$(0.64)	\$(0.53)
Number of full time employees	42	19	15
Number of common stockholders	9,300	8,600	7,300

Reclassified to conform with 2016 presentation; As of March 16, 2018; As of March 30, 2017; As of March 30, 2016; Approximately; As of March 15, 2018; As of March 29, 2016

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Cash & cash equivalents	137,750,000	69,142,000	
Receivables	107,000	124,000	
Prepaid expenses & other current assets	2,735,000	155,000	
Total current assets	140,592,000	69,421,000	

Equipment laboratory	627,000	473,000	
Furniture & office equipment	449,000	309,000	
Leasehold improvements	229,000	118,000	
Construction work in progress	455,000		
Property & equipment, net	1,760,000	900,000	
Less: accumulated depreciation & amortization	386,000	179,000	
Property & equipment, net	1,374,000	721,000	
Licensed technology, net	3,977,000	8,384,000	
Goodwill	32,466,000	32,466,000	
Other assets & restricted cash	357,000	66,000	
Total assets	178,766,000	111,058,000	
Accounts payable	2,393,000	3,694,000	
Payable due Plasma Technologies, LLC		4,000,000	
Current portion of deferred revenue	3,214,000	602,000	
Total current liabilities	5,607,000	8,296,000	
Deferred revenue, net of current portion	3,061,000	3,664,000	
Total liabilities	8,668,000	11,960,000	
Common stock	469,000	403,000	
Additional paid-in capital	529,421,000	431,168,000	
Retained earnings (accumulated deficit)	(359,792,000)	(332,473,000)	
Total stockholders' equity (deficit)	170,098,000	99,098,000	

Reclassified to conform with 2017 presentation

#### Recent Dividends:

**1. Abeona Therapeutics Inc series B cumulative convertible preferred.**

No dividends paid.

**2. Abeona Therapeutics Inc series A cumulative convertible preferred.**

No dividends paid.

**3. Abeona Therapeutics Inc common.**

No dividends paid.

#### Annual Dividends:

**1. Abeona Therapeutics Inc series B cumulative convertible preferred.**

No dividends paid.

**2. Abeona Therapeutics Inc series A cumulative convertible preferred.**

No dividends paid.

**3. Abeona Therapeutics Inc common.**

No dividends paid.

### ABRAXAS PETROLEUM CORP.

#### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Oil revenue	73,584,000	50,965,000	59,270,000
Gas revenue	6,898,000	3,978,000	5,854,000
Natural gas liquids	5,707,000	1,550,000	1,878,000
Oil & gas production revenues	86,189,000	56,493,000	67,002,000
Other revenues	75,000	62,000	28,000
Total revenues	86,264,000	56,555,000	67,030,000
Lease operating expense	15,197,000	18,205,000	23,074,000

Production taxes	7,228,000	5,454,000	6,679,000
Rig expense		664,000	
Depreciation, depletion & amortization expenses	26,226,000	24,431,000	38,721,000
Proved property impairment		67,626,000	128,573,000
General & administrative expenses	16,276,000	13,562,000	11,788,000
Total operating costs & expenses	64,927,000	129,942,000	208,835,000
Operating income (loss)	21,337,000	(73,387,000)	(141,805,000)
Interest income	1,000	1,000	2,000
Interest expense	2,948,000	4,319,000	3,906,000
Amortization of deferred financing fees	423,000	1,019,000	643,000
Gain (loss) on sale of properties	102,000	374,000	
Gain (loss) on derivative contracts	(1,849,000)	(18,028,000)	19,301,000
Other income (expense)	(214,000)		(318,000)
Total other income (expense)	(5,331,000)	(22,991,000)	14,436,000
Income (loss) from operations before income tax & noncontrolling interest	16,006,000	(96,378,000)	(127,369,000)
Current federal income tax (benefit)			(242,000)
Current state income tax (benefit)			(37,000)
Total current income tax (benefit)			(279,000)
Income tax benefit (expense)			(279,000)
Income from continuing operations	16,006,000	(96,378,000)	(127,090,000)
Net income (loss) from discontinued operations - net of tax			(20,000)
<b>Net income (loss)</b>	<b>16,006,000</b>	<b>(96,378,000)</b>	<b>(127,110,000)</b>
Weighted average shares outstanding - basic	161,141,000	122,132,000	104,605,000
Weighted average shares outstanding - diluted	162,844,000	122,132,000	104,605,000
Year end shares outstanding	165,889,901	135,094,017	106,346,678
Income (loss) per share from continuing operations - basic	\$0.10	\$(0.79)	\$(1.21)
Net income (loss) per share - basic	\$0.10	\$(0.79)	\$(1.21)
Income (loss) per share from			

continuing operations - diluted	\$0.10	\$(0.79)	\$(1.21)
Net income (loss) per share - diluted	\$0.10	\$(0.79)	\$(1.21)
Foreign currency translation adjustments	...	607,000	...

□ Reclassified to conform with 2017 presentation; □ Including stock-based compensation - General and administrative expenses: \$3,238,000; □ Including stock-based compensation - General and administrative expenses: \$3,194,000; □ Including stock-based compensation - General and administrative expenses: \$3,912,000; □ Shares increased due to issuance of common stock for offering & for acquisition of oil & gas properties

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2017	2016	(revised)
Cash & cash equivalents	1,618,000	...	...
Account receivable - joint owners - net	14,218,000	677,000	...
Account receivable - oil & gas production sales	17,789,000	11,595,000	...
Accounts receivable - other	86,000	1,252,000	...
Total accounts receivable, net	32,093,000	13,524,000	...
Derivative asset	...	54,000	...
Assets held for sale	...	9,685,000	...
Other current assets	778,000	676,000	...
Total current assets	34,489,000	23,939,000	...
Proved oil & gas properties, full cost method of accounting	923,237,000	794,634,000	...
Other property & equipment	39,136,000	38,569,000	...
Total property & equipment, at cost	962,373,000	833,203,000	...
Less: accumulated depreciation, depletion & amortization	724,606,000	696,892,000	...
Total property & equipment - net	237,767,000	136,311,000	...
Deferred financing fees, net	1,285,000	818,000	...
Other assets	265,000	580,000	...
Total assets	273,806,000	161,648,000	...
Accounts payable	45,570,000	18,397,000	...
Joint interest oil & gas production payable	11,502,000	8,937,000	...
Accrued interest	140,000	44,000	...
Other accrued expenses	539,000	571,000	...
Derivative liability	10,837,000	2,382,000	...
Current maturities of long-term debt	262,000	786,000	...
Total current liabilities	68,850,000	31,117,000	...
Senior secured credit facility	84,000,000	93,000,000	...
Rig loan agreement	...	535,000	...
Real estate lien note	3,616,000	3,867,000	...
Less: current maturities	262,000	786,000	...
Long-term debt - less current maturities	87,354,000	96,616,000	...
Derivative liability	2,387,000	6,630,000	...
Other liabilities	132,000	157,000	...
Future site restoration	8,775,000	8,623,000	...
Total liabilities	167,498,000	143,143,000	...
Common stock	1,659,000	1,351,000	...
Additional paid-in capital	415,471,000	343,982,000	...
Retained earnings (accumulated deficit)	(310,822,000)	(326,828,000)	...
Total stockholders' equity	106,308,000	18,505,000	...

**Recent Dividends:**

1. Abraxas Petroleum Corp. common.

No dividends paid.

**Annual Dividends:**

1. Abraxas Petroleum Corp. common.

No dividends paid.

**ACER THERAPEUTICS INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Option revenue	2,905,165	2,556,329	...
Research & development expenses	8,725,026	6,497,531	10,039,496
General & administrative expenses	5,223,101	3,122,337	4,258,147
Depreciation & amortization	...	238,127	351,403
Impairment loss	...	1,036,467	...
Gain (loss) on disposal of fixed assets	...	(2,320)	(1,167)
Total operating expenses	13,948,127	...	...
Income (loss) from operations	(13,948,127)	(7,991,617)	(12,093,884)
Interest income	14,848	874	5,911
Interest & other expense	245,061	...	...
Foreign currency translation gain (loss)	(16,091)	...	...
Other income & expense, net	...	10,629	68,695
Total other income (expense), net	(246,304)	...	...
<b>Net income (loss)</b>	<b>(14,194,431)</b>	<b>(7,980,114)</b>	<b>(12,019,278)</b>
Weighted average shares	...	...	...
outstanding-basic	3,694,388	□680,667	565,344
Weighted average shares	...	...	...
outstanding-diluted	3,694,388	□680,667	565,344
Year end shares	...	...	...
outstanding	7,497,433	□689,589	674,317
Net income (loss) per share-basic	\$(3.84)	□\$(11.70)	\$(21.23)
Net income (loss) per share-diluted	\$(3.84)	□\$(11.70)	\$(21.23)
Number of full time employees	6	□2	□26
Number of common stockholders	□□200	□□206	□□216

□ 2016 and prior periods for Opexa Therapeutics, Inc., prior to reverse merger with Acer Therapeutics Inc.; □ Adjusted for 1-for-10.355527 stock split, Sept. 21, 2017; □ As of March 27, 2017; □ As of March 10, 2016; □ Approximate; □ As of March 1, 2018; □ As of March 10, 2017

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Cash & cash equivalents	15,644,355	3,444,952	...
Prepaid expenses	881,887	...	...
Deferred offering costs	...	111,641	...
Prepaid expenses	...	259,921	...
Total current assets	16,526,242	3,816,514	...
Computer equipment	...	173,147	...
Computer hardware & software	16,555	...	...
Office furniture & equipment	...	238,661	...
Software	...	125,412	...
Laboratory equipment	...	1,117,173	...
Leasehold improvements	7,968	684,515	...
Furniture & fixtures	42,503	...	...
Manufacturing equipment	...	905,121	...
Property & equipment, gross	...	3,244,029	...
Less: accumulated depreciation	4,042	3,194,029	...
Property & equipment, net	62,984	50,000	...
Goodwill	7,647,267	...	...
In-process research & development	118,600	...	...

Other assets	13,648	...	...
Total assets	24,368,741	3,866,514	...
Accounts payable	95,873	377,956	...
Accrued legal	174,592	...	...
Accrued pre-commercial costs	341,159	...	...
Accrued consulting	102,156	...	...
Accrued audit & tax	111,250	...	...
Accrued license fees	817,578	...	...
Accrued contract manufacturing	218,108	...	...
Accrued contract research	99,140	...	...
Accrued miscellaneous expenses	73,348	...	...
Accrued expenses	1,937,331	625,890	...
Notes payable - insurance	...	156,642	...
Total current liabilities	...	1,160,488	...
Total liabilities	2,033,204	1,160,488	...
Common stock	74,974	71,411	...
Additional paid in capital	47,812,215	163,954,215	...
Retained earnings (accumulated deficit)	(25,551,652)	(161,319,600)	...
Total stockholders' equity	22,335,537	2,706,026	...

□ 2016 and prior periods for Opexa Therapeutics, Inc., prior to reverse merger with Acer Therapeutics Inc.

**Recent Dividends:**

1. Acer Therapeutics Inc common.

No dividends paid.

**Annual Dividends:**

1. Acer Therapeutics Inc common.

No dividends paid.

**ACER THERAPEUTICS INC****Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Wolf & Company, P.C., as it appeared in Co.'s 2017 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Acer Therapeutics Inc. (the "Company") as of December 31, 2017 and 2016, and the related consolidated statements of operations, changes in redeemable preferred stock and stockholders' equity (deficit) and cash flows for years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Emphasis of Matter The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has recurring losses from operations which raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**ADAMIS PHARMACEUTICALS CORP.****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Revenue, net	13,073,259	6,473,978	...
Cost of goods sold	7,419,988	4,853,664	...
Gross profit	5,653,271	1,620,314	...
Selling, general & administrative expenses	22,819,224	17,127,555	9,007,289
Research & development	7,526,784	9,697,136	4,843,139
Loss on impairment of fixed assets	96,346	...	...
Income (loss) from operations	(24,789,083)	(25,204,377)	(13,850,428)
Interest expense	231,291	214,396	...
Interest income	102,233	9,285	...
Inducement expense for exercise of warrants	960,230	...	...
Change in fair value of warrant	...	...	...

liability	1,049,330	433,898
Change in fair value of warrant derivative liabilities	348,141	(155,467)
Total other income (expense)	(1,089,288)	1,192,360
Net income (loss) before income taxes	(25,878,371)	(24,012,017)
Income tax expense (benefit)	(339,391)	(4,574,765)
<b>Net income (loss)</b>	<b>(25,538,980)</b>	<b>(19,437,252)</b>
Deemed dividend on preferred stock	1,374,229	
Net income (loss) applicable to common stockholders	(25,538,980)	(20,811,481)
Weighted average shares outstanding - basic	28,349,368	17,500,827
Weighted average shares outstanding - diluted	28,349,368	17,500,827
Year end shares outstanding	33,389,380	21,991,543
Net earnings (loss) per share - basic	\$(0.90)	\$(1.19)
Net earnings (loss) per share - diluted	\$(0.90)	\$(1.19)
Number of full time employees	108	15
Number of part time employees	18	1
Total number of employees	126	16
Number of common stockholders	91	92

payable	126,248
Accrued bonuses	1,069,021
Bank loans - working capital line of credit	2,000,000
Bank loans - building & equipment, current portion	483,992
Total current liabilities	8,787,563
Deferred tax liability, net	485,002
Building & equipment loans, net of current portion	2,583,109
Total liabilities	11,855,674
Series A convertible preferred stock	62
Common stock	3,369
Additional paid-in capital	153,546,932
Retained earnings (accumulated deficit)	(113,997,588)
Treasury stock, at cost	5,229
Total stockholders' equity (deficit)	39,547,484

settlement with former foundry supplier	1,962
Total operating expenses	32,306
Income (loss) from operations	(4,831)
Interest expense, net	753
Other income (expense), net	(3)
Total other income (expense), net	(756)
Income before income taxes - United States	(5,974)
Income before income taxes - Foreign	387
Income (loss) before provision for income taxes	(5,587)
Current state income taxes	3
Current foreign income taxes	98
Current income taxes	101
Deferred federal income taxes	1
Deferred income taxes	1
Provision for income taxes	101
<b>Net income (loss)</b>	<b>(5,688)</b>
Weighted average shares outstanding - basic	18,591
Weighted average shares outstanding - diluted	18,591
Year end shares outstanding	21,292
Net earnings (loss) per share - basic	\$(0.31)
Net earnings (loss) per share - diluted	\$(0.31)
Number of full time employees	102
Number of common stockholders	38
Foreign currency translation adjustments	(84)

**Recent Dividends:**

- 1. Adamis Pharmaceuticals Corp. series A convertible preferred.**  
No dividends paid.
- 2. Adamis Pharmaceuticals Corp. series A-2 convertible preferred.**  
No dividends paid.
- 3. Adamis Pharmaceuticals Corp. common.**  
No dividends paid.

**Annual Dividends:**

- 1. Adamis Pharmaceuticals Corp. series A convertible preferred.**  
No dividends paid.
- 2. Adamis Pharmaceuticals Corp. series A-2 convertible preferred.**  
No dividends paid.
- 3. Adamis Pharmaceuticals Corp. common.**  
No dividends paid.

**ADAMIS PHARMACEUTICALS CORP.**

**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Mayer Hoffman McCann P.C., as it appeared in Co.'s 2017 10-K: "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred recurring losses from operations, and is dependent on additional financing to fund operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are described in Note 2 to the consolidated financial statements. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty."

**ADESTO TECHNOLOGIES CORP**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31**

	2017	2016	2015
		(revised)	(revised)
Revenue	56,112	43,968	43,259
Cost of revenue	28,637	22,618	24,775
Gross profit	27,475	21,350	18,484
Research & development	14,094	15,896	12,795
Sales & marketing expenses	11,064	11,026	8,345
General & administrative expenses	7,148	6,693	3,978
Gain from			

Weighted average shares outstanding - basic	18,591	15,086	3,008
Weighted average shares outstanding - diluted	18,591	15,086	3,008
Year end shares outstanding	21,292	15,494	14,975
Net earnings (loss) per share - basic	\$(0.31)	\$(0.77)	\$(2.79)
Net earnings (loss) per share - diluted	\$(0.31)	\$(0.77)	\$(2.79)
Number of full time employees	102	101	95
Number of common stockholders	38	44	42
Foreign currency translation adjustments		(84)	(143)

Shares increased due to the effect of proceeds from follow-on offering; As is; As of February 20, 2018; As of March 8, 2017; As of March 27, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016
		(revised)
Cash & cash equivalents	30,078	19,719
Accounts receivable, gross	12,500	8,800
Less: allowance for ship from stock & debits (SSDs)	3,832	2,689
Accounts receivable, net	8,668	6,111
Raw materials	2,213	212
Work in process	2,408	3,793
Finished goods	1,193	1,177
Inventories	5,814	5,182
Prepaid expenses	993	462
Other current assets	105	105
Total current assets	45,605	31,579
Machinery & equipment	9,457	7,351
Furniture & fixtures	83	77
Leasehold improvements	4,252	4,252
Computer software	675	668
Construction in progress	1,301	1,098
Property & equipment, at cost	15,768	13,446
Less: accumulated		

Reclassified to conform with 2016 presentation; Approximately

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
		(revised)
Cash	17,323,241	4,090,651
Restricted cash	1,009,461	1,005,109
Accounts receivable, gross	914,090	826,660
Provision for bad debt	84,000	21,288
Accounts receivable, net	830,090	805,372
Finished goods	256,050	329,195
Raw materials	560,828	389,569
Devices	1,007,680	223,303
Inventories	1,824,558	942,067
Prepaid insurance	75,592	144,765
Other prepaid expenses	390,569	39,775
Other current assets	8,019	42,500
Total current assets	21,461,239	7,070,239
Security deposits	54,655	42,500
Intangible assets, net	15,686,687	18,136,044
Goodwill	7,640,622	7,640,622
Land	460,000	460,000
Buildings	3,040,000	3,040,000
Machinery & equipment	1,525,643	1,393,226
Furniture & fixtures	126,654	129,630
Automobile	9,395	9,395
Leasehold improvements	284,037	284,037
Property & equipment, gross	5,445,729	5,316,288
Less: accumulated depreciation	959,380	523,552
Construction work in progress - equipment	2,073,315	104,271
Fixed assets, net	6,559,664	4,897,007
Total assets	51,403,158	37,786,412
Accounts payable	2,919,120	2,150,583
Deferred revenue	14,758	54,478
Accrued commissions	247,197	253,005
Accrued expenses	950,063	429,865
Accrued PTO	265,445	174,709
Accrued salaries	345,695	205,700
Accrued sales taxes	480,895	372,675
Accrued sate tax	4,594	12,200
Deferred rent	6,783	35,223
Health insurance claims		

depreciation & amortization	8,935	7,484	provision	23,880	2,015	622	Total liabilities	10,072,929	11,031,101
Property & equipment, net	6,833	5,962	Deferred income taxes provision - U.S. federal	483	6,124	...	Common stock	961	928
Intangible assets, net	7,452	8,324	Deferred income taxes provision - state & local	1,322	42	...	Additional paid in capital	89,907,766	88,582,470
Other non-current assets	900	296	Total deferred income taxes	1,805	6,166	...	Treasury stock	1,257,100	...
Goodwill	22	22	Provision for income taxes	25,685	8,181	622	Accumulated other comprehensive income (loss)	(16,907)	...
Total assets	60,812	46,183	Net income (loss)	1,141,255	3,733,707	(270,342)	Retained earnings (accumulated deficit)	(42,409,741)	(43,550,996)
Accounts payable	7,075	5,167	Accretion of dividends on preferred convertible stock	...	1,537,021	2,444,954	Total stockholders' equity (deficit)	46,224,979	45,032,402
Accrued compensation & benefits	2,614	1,599	Net income (loss) attributable to common stockholders	1,141,255	2,196,686	(2,715,296)			
Accrued sales commissions payable	310	366	Weighted average shares outstanding - basic	9,485,271	3,373,316	651,593			
Accrued manufacturing expenses	265	149	Weighted average shares outstanding - diluted	10,361,373	4,667,503	651,593			
Deferred rent	422	388	Year end shares outstanding	9,481,992	9,275,062	665,842			
Liabilities to certain customers	468	663	Net income (loss) per share - basic	\$0.12	\$0.65	\$(4.17)			
Other accrued liabilities	894	610	Net income (loss) per share - diluted	\$0.11	\$0.40	\$(4.30)			
Line of credit, current	1,500	1,807	Total number of employees	79	38	33			
Term loan, current	926	6,466	Number of common stockholders	81	98	103			
Total current liabilities	14,474	17,215							
Term loan, non-current	10,908	9,775							
Other non-current liabilities	75	...							
Deferred rent, non-current	2,404	2,826							
Deferred tax liability, non-current	1	2							
Total liabilities	27,862	29,818							
Common stock	2	2							
Additional paid-in capital	133,087	110,749							
Accumulated other comprehensive income (loss)	(295)	(230)							
Retained earnings (accumulated deficit)	(99,844)	(94,156)							
Total stockholders' equity (deficit)	32,950	16,365							

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. Adesto Technologies Corp common.

No dividends paid.

#### Annual Dividends:

##### 1. Adesto Technologies Corp common.

No dividends paid.

#### AIRGAIN INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	2015 (revised)
Sales	49,521,171	43,433,867	27,793,073
Cost of goods sold	26,218,965	24,156,792	16,148,163
Gross profit	23,302,206	19,277,075	11,644,910
Research & development expense	7,319,575	5,622,132	4,257,400
Sales & marketing	7,012,829	5,670,625	4,035,591
General & administrative expenses	8,000,602	4,532,151	3,453,288
IPO cost	...	...	229,332
Total operating expenses	22,333,006	15,824,908	11,975,611
Income (loss) from operations	969,200	3,452,167	(330,701)
Interest income	296,451	7,803	...
Interest expense	98,711	178,371	39,489
Exercise & expiration of warrants	...	...	15,145
Total other income	197,740	289,721	60,981
Income (loss) before income taxes	1,166,940	3,741,888	(269,720)
Current income taxes provision - U.S. federal	21,272	...	...
Current income taxes provision - state & local	2,608	2,015	622
Total current income taxes	23,880	2,015	622

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016
Cash & cash equivalents	15,026,068	45,161,403
Short term investments	21,287,064	...
Trade accounts receivable	8,418,132	5,154,996
Inventory	741,557	146,815
Prepaid expenses & other current assets	609,786	349,550
Total current assets	46,082,607	50,812,764
Lab equipment	1,914,911	1,314,060
Computer equipment	169,366	165,415
Computer software	299,227	299,227
Furniture & fixtures	202,218	184,233
Tenant improvements	763,898	763,898
Other office equipment	63,825	20,591
Property & equipment, gross	3,413,445	2,747,424
Less: accumulated depreciation	2,376,585	1,940,338
Property & equipment, net	1,036,860	807,086
Goodwill	3,700,447	1,249,956
Customer relationships, net	4,075,918	2,822,918
Intangible assets, net	1,052,333	286,719
Other assets	349,743	84,060
Total assets	56,297,908	56,063,503
Accounts payable	3,969,083	3,949,005
Accrued bonus	2,224,517	1,748,551
Accrued liabilities	1,121,833	1,072,242
Deferred purchase price	1,000,000	1,000,000
Current portion of long-term notes payable	1,333,333	1,388,563
Current portion of deferred rent obligation under operating lease	81,332	81,332
Total current liabilities	9,730,098	9,239,693
Long-term notes payable	...	1,333,333
Deferred tax liability	7,971	6,166
Deferred rent obligation under operating lease	334,860	451,909

#### Recent Dividends:

##### 1. Airgain Inc common.

No dividends paid.

#### Annual Dividends:

##### 1. Airgain Inc common.

No dividends paid.

#### ALLIQUA BIOMEDICAL INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Revenue, net of returns, allowances & discounts	19,565,000	16,294,000	12,177,000
Cost of revenues	6,763,000	6,051,000	5,227,000
Gross profit (loss)	12,802,000	10,243,000	6,950,000
Selling, general & administrative	28,090,000	35,325,000	34,340,000
Royalties	820,000	1,093,000	...
Research & product development	121,000	859,000	715,000
Milestone expense to licensor	...	1,000,000	...
Acquisition-related expenses	(365,000)	2,959,000	2,876,000
Change in fair value of contingent consideration liability	35,000	(10,065,000)	(1,474,000)
Impairment charges	10,300,000	10,895,000	...
Total operating expenses	39,001,000	42,066,000	36,457,000
Income (loss) from operations	(26,199,000)	(31,823,000)	(29,507,000)
Interest expense	2,282,000	2,541,000	1,565,000
Interest income	...	...	42,000
Change in value of warrant liability	692,000	841,000	2,095,000
Warrant modification expense	803,000	...	...
Loss on early extinguishment of debt, net	(214,000)	(373,000)	...
Other income	206,000	142,000	...
Total other income (expense)	(2,401,000)	(1,931,000)	572,000
Income (loss) from continuing operations before tax	(28,600,000)	(33,754,000)	(28,935,000)
Deferred income tax provision (benefit) - federal	(664,000)	(627,000)	(1,509,000)
Current income tax provision - state & local	6,000	4,000	3,000
Deferred income tax provision (benefit) - state & local	(85,000)	(92,000)	(212,000)
Income tax provision (benefit)	(743,000)	(715,000)	(1,718,000)
Income (loss) from continuing operations	(27,857,000)	(33,039,000)	(27,217,000)
Income from discontinued operations, net of tax	454,000	1,485,000	1,200,000
Gain on sale of	...	...	...

assets, net of tax	1,696,000	3,311,000	...
Income from discontinued operations, net of tax	2,150,000	4,796,000	1,200,000
<b>Net income (loss)</b>	<b>(25,707,000)</b>	<b>(28,243,000)</b>	<b>(26,017,000)</b>
Weighted average shares outstanding - basic	4,291,600	<sup>1</sup> 2,796,563	2,306,193
Weighted average shares outstanding - diluted	4,291,600	<sup>2</sup> 2,796,563	2,306,193
Year end shares outstanding	4,986,034	<sup>3</sup> 2,966,904	2,766,891
Earnings (loss) per share from continuing operations - basic	\$(6.49)	<sup>4</sup> \$(11.81)	\$(11.80)
Earnings per share - income from discontinued operations - basic	\$0.11	\$0.53	...
Earnings per share - gain on sale of assets - basic	\$0.40	\$1.18	...
Earnings per share discontinued operations - basic	\$0.51	<sup>5</sup> \$1.71	\$0.50
Net earnings (loss) per share - basic	\$(5.98)	<sup>6</sup> \$(10.10)	\$(11.30)
Earnings (loss) per share from continuing operations - diluted	\$(6.49)	<sup>7</sup> \$(11.81)	\$(11.80)
Earnings per share - income from discontinued operations - diluted	\$0.11	\$0.53	...
Earnings per share - gain on sale of assets - diluted	\$0.40	\$1.18	...
Earnings per share discontinued operations - diluted	\$0.51	<sup>8</sup> \$1.71	\$0.50
Net earnings (loss) per share - diluted	\$(5.98)	<sup>9</sup> \$(10.10)	\$(11.30)
Number of full time employees	60	...	87
Number of common stockholders	<sup>10</sup> 263	...	<sup>11</sup> 241

<sup>1</sup> Restated to reflect the sale of the Company's rights and the unsold inventory of TheraBond products and work in process as discontinued operations; <sup>2</sup> Restated to reflect the discontinued operation of Company's rights, including all distribution, exclusivity, intellectual property and marketing rights and the unsold inventory of sorbion products; <sup>3</sup> Adjusted for 1-for-10 stock split, October 6, 2017; <sup>4</sup> Approximately; <sup>5</sup> As of February 28, 2018; <sup>6</sup> As of February 17, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	<sup>1</sup> 2016 (revised)
Cash & cash equivalents	2,181,000	5,580,000
Accounts receivable, gross	<sup>2</sup> 3,550,000	<sup>2</sup> 2,666,000
Allowance for doubtful accounts	<sup>3</sup> 307,000	<sup>4</sup> 213,000
Accounts receivable, net	3,243,000	2,453,000
Raw materials	98,000	134,000
Work in process	...	20,000
Finished goods	1,521,000	1,998,000
Less: inventory reserve for excess & slow moving inventory	68,000	...
Inventory, net	1,551,000	2,152,000
Prepaid expenses & other current assets	185,000	735,000
Current assets of		

discontinued operations	317,000	857,000
Total current assets	7,477,000	11,777,000
Machinery & equipment	4,911,000	5,041,000
Office furniture & equipment	344,000	337,000
Leasehold improvements	594,000	595,000
Property & equipment, gross	5,849,000	5,973,000
Less: accumulated depreciation & amortization	4,286,000	3,881,000
Improvements & equipment, net	1,563,000	2,092,000
Intangible assets, net	22,069,000	26,605,000
Goodwill, net	1,659,000	11,959,000
Other assets	173,000	173,000
Assets of discontinued operations - noncurrent	...	1,893,000
Total assets	32,941,000	54,499,000
Accounts payable	1,641,000	2,614,000
Salaries, benefits & incentive compensation	1,981,000	3,007,000
Milestone payment to licensor	1,000,000	1,000,000
Professional fees	538,000	692,000
Royalty fees	227,000	197,000
Deferred revenue	365,000	181,000
Other accrued expenses	159,000	147,000
Contingent consideration, current	...	675,000
Senior secured term loan, net	10,929,000	11,541,000
Warrant liability	130,000	20,000
Current liabilities of discontinued operations	...	60,000
Total current liabilities	16,970,000	20,134,000
Contingent consideration, long-term	...	1,141,000
Deferred tax liability	...	749,000
Other long-term liabilities	304,000	385,000
Total liabilities	17,274,000	22,409,000
Common stock	5,000	3,000
Additional paid-in capital	165,672,000	156,390,000
Retained earnings (accumulated deficit)	(150,010,000)	(124,303,000)
Total stockholders' equity (deficiency)	15,667,000	32,090,000

<sup>1</sup> Restated to reflect the sale of the Company's rights and the unsold inventory of TheraBond products and work in process as discontinued operations; <sup>2</sup> Approximately

**Recent Dividends:**  
**1. Alliqua BioMedical Inc common.**  
 No dividends paid.

**Annual Dividends:**  
**1. Alliqua BioMedical Inc common.**  
 No dividends paid.

**ALLIQUA BIOMEDICAL INC**  
**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s December 31, 2017 10K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Alliqua BioMedical, Inc. and Subsidiaries (the "Company") as of December 31, 2017 and 2016, the related consolidated statements of operations, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph ¶ Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 3, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. The Company is currently in default of

a covenant pertaining to trailing twelve-month revenue and a minimum cash balance requirement under its Credit Agreement and Guaranty with Perceptive Credit Opportunities Fund, L.P. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**AQUA METALS INC**  
**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	<sup>1</sup> 2016 (revised)	<sup>2</sup> 2015 (revised)
Product sales	2,088,000	...	...
Cost of product sales	9,541,000	...	...
Research & development cost	8,103,000	6,348,000	2,280,000
General & administrative expenses	6,891,000	6,610,000	3,171,000
Impairment charge	2,411,000	...	...
Total operating expenses	26,946,000	12,958,000	5,451,000
Income (loss) from operations	(24,858,000)	(12,958,000)	(5,451,000)
Increase in fair value of derivative liabilities	...	...	(5,776,000)
Interest expense	1,761,000	639,000	1,128,000
Interest & other income	41,000	41,000	26,000
Total other expenses, net	(1,720,000)	(598,000)	(6,878,000)
Income (loss) before income tax expense (benefit) - United States	(26,578,000)	(13,556,000)	(12,329,000)
Loss before income tax expense (benefit)	(26,578,000)	(13,556,000)	(12,329,000)
Current state income taxes	2,000	1,000	3,000
Income tax expense (benefit)	2,000	1,000	3,000
<b>Net income (loss)</b>	<b>(26,580,000)</b>	<b>(13,557,000)</b>	<b>(12,332,000)</b>
Weighted average shares outstanding - basic	20,293,100	15,267,233	8,404,311
Weighted average shares outstanding - diluted	20,293,100	15,267,233	8,404,311
Year end shares outstanding	27,554,076	17,878,725	<sup>3</sup> 14,137,442
Net earnings (loss) per share - basic	\$(1.31)	\$(0.89)	\$(1.47)
Net earnings (loss) per share - diluted	\$(1.31)	\$(0.89)	\$(1.47)
Number of full time employees	69	67	21
Number of part time employees	...	...	7
Total number of employees	...	...	28
Number of common stockholders	<sup>4</sup> 18	<sup>5</sup> 30	<sup>6</sup> 78

<sup>1</sup> Reclassified to conform with 2017 presentation; <sup>2</sup> Shares increased due to issuance of common shares in initial public offering and conversion of convertible notes; <sup>3</sup> As of March 9, 2018; <sup>4</sup> As of February 28, 2017; <sup>5</sup> As of March 17, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	<sup>1</sup> 2016 (revised)
Cash & cash equivalents	22,793,000	25,458,000
Restricted cash	...	1,124,000
Accounts receivable	882,000	...
Inventory	1,239,000	59,000
Prepaid expenses & other current assets	770,000	729,000
Total current assets	25,684,000	27,370,000
Operational equipment	15,457,000	15,132,000
Lab equipment	685,000	547,000

Computer equipment	174,000	140,000
Office furniture & equipment	326,000	298,000
Leasehold improvements	1,408,000	1,408,000
Land	1,047,000	1,047,000
Building	24,847,000	21,962,000
Asset Retirement Cost	670,000	...
Equipment under construction	4,552,000	1,635,000
Property & equipment, gross	49,166,000	42,169,000
Less - accumulated depreciation	3,433,000	777,000
Property & equipment, net	45,733,000	41,392,000
Intellectual property, net	1,461,000	1,137,000
Other assets	1,564,000	1,630,000
Total non-current assets	48,758,000	44,159,000
Total assets	74,442,000	71,529,000
Accounts payable	1,436,000	1,572,000
Fixed asset related	232,000	1,330,000
Payroll related	470,000	359,000
Use tax accrual	75,000	156,000
Professional services	88,000	29,000
Estimated Interstate Battery settlement	600,000	...
Other accrued expenses	336,000	101,000
Accrued expenses	1,801,000	1,975,000
Deferred rent, current portion	192,000	177,000
Notes payable, current portion	405,000	307,000
Total current liabilities	3,834,000	4,031,000
Deferred rent, non-current portion	771,000	963,000
Asset retirement obligation	701,000	...
Notes payables, non-current portion	8,839,000	9,238,000
Convertible note payable, non-current portion	1,332,000	307,000
Total liabilities	15,477,000	14,539,000
Common stock	27,000	18,000
Additional paid-in capital	113,780,000	85,234,000
Accumulated earnings (accumulated deficit)	(54,842,000)	(28,262,000)
Total stockholders' equity (deficit)	58,965,000	56,990,000

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. Aqua Metals Inc common.

No dividends paid.

#### Annual Dividends:

##### 1. Aqua Metals Inc common.

No dividends paid.

#### AQUABOUNTY TECHNOLOGIES INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	□2016 (revised)	□□2015 (revised)
Product revenues	53,278	...	...
Cost of goods sold	50,777	...	...
Sales & marketing	799,009	860,365	993,706
Research & development	3,371,767	3,429,400	3,338,411
General & administrative	5,063,824	3,775,289	2,696,369
Total cost & expenses	9,285,377	8,065,054	7,028,486
Operating income (loss)	(9,232,099)	(8,065,054)	(7,028,486)
Gain on disposal of equipment	941	2,861	1,912
Interest expense	21,537	402,554	10
Other income (expense), net	(5,952)	(5,914)	(4,928)
Total other income (expense)	(26,548)	(405,607)	(3,026)
Net income (loss)	(9,258,647)	(8,470,661)	(7,031,512)
Weighted average			

shares outstanding - basic	8,772,494	□5,303,114	5,037,368
Weighted average shares outstanding - diluted	8,772,494	□5,303,114	5,037,368
Year end shares outstanding	8,895,094	□9,463,936	5,247,604
Net earnings (loss) per share - basic	\$(1.06)	□\$(1.60)	\$(1.40)
Net earnings (loss) per share - diluted	\$(1.06)	□\$(1.60)	\$(1.40)
Total number of employees	37	25	...
Number of common stockholders	□□349	□□302	...

□ Reclassified to conform with 2017 presentation; □ Reclassified to conform with 2016 presentation; □ Adjusted for 1-for-30 reverse stock split, January 5, 2017; □ Approximately; □ As of March 2, 2018; □ As of March 10, 2017

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	□2016 (revised)
Cash & cash equivalents	492,861	3,324,609
Certificate of deposit	13,422	10,666
Other receivables	183,926	164,743
Feed	60,161	...
Eggs	73,967	...
Fish in process	38,235	...
Inventories	172,363	...
Prepaid insurance	84,801	35,544
Prepaid supplies	33,132	17,066
Prepaid professional services	16,059	17,533
Prepaid rent & lease deposits, short term	5,852	2,840
Deferred costs of public offering	387,478	...
Total current assets	1,389,894	3,573,001
Land	676,083	157,107
Buildings & improvements	9,187,160	1,436,814
Construction in progress	5,119,961	277,352
Equipment	8,211,510	1,037,549
Office furniture & equipment	136,091	78,780
Vehicles	29,135	27,201
Total property & equipment	23,359,940	3,014,803
Less: accumulated depreciation & amortization	1,556,964	1,291,096
Property, plant & equipment, net	21,802,976	1,723,707
Definite lived intangible assets, net	184,995	198,698
Indefinite lived intangible assets	191,800	191,800
Other assets	162,093	21,628
Total assets	23,731,758	5,708,834
Accounts payable	1,089,919	161,768
Accrued payroll including vacation	364,368	242,436
Accrued professional fees	438,378	500,430
Accrued research & development costs	4,800	87,751
Accrued franchise & excise taxes	240,880	22,994
Accrued construction costs	509,950	...
Accrued other	18,560	2,472
Current debt	49,794	17,913
Total current liabilities	2,716,649	1,035,764
Long-term debt	3,034,420	2,645,015
Total liabilities	5,751,069	3,680,779
Common stock	8,895	6,464
Additional paid-in capital	126,718,186	101,581,724
Accumulated other comprehensive income (loss)	(213,884)	(286,272)
Retained earnings (accumulated deficit)	(108,532,508)	(99,273,861)

Total stockholders' equity (deficit) 17,980,689 2,028,055

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. AquaBounty Technologies Inc common.

No dividends paid.

#### Annual Dividends:

##### 1. AquaBounty Technologies Inc common.

No dividends paid.

#### ARO LIQUIDATION INC

**Bankruptcy Proceedings** On Mar. 16, 2018, Co. filed with the U.S. Bankruptcy Court a Second Revised Third Amended Plan, which explains, "The Plan Administrator shall reserve an amount sufficient to pay holders of Disputed Administrative Expense Claims and Disputed Priority Tax Claims the amount such holders would be entitled to receive under the Plan if such Claims were to become Allowed Claims. After the resolution of all Disputed Administrative Expense Claims and Disputed Priority Tax Claims, the Plan Administrator shall treat any amounts that were reserved for Disputed Administrative Expense and Disputed Priority Tax Claims that do not become Allowed Claims as Available Cash."

#### ASPEN GROUP INC

##### Earnings, 9 mos. to Jan 31(Consol. - \$):

	2018	2017
Total revenues	14,796,483	9,957,467
Cost & expenses	17,257,899	9,743,600
Deprec., depl. & amort.	631,969	422,782
Operating income	(3,093,385)	(208,915)
Other income (expense), net	140,567	3,047
Net before taxes	(3,396,575)	(381,530)
Net income	(3,396,575)	(381,530)
Earnings common share		
Primary	\$(0.25)	\$(0.03)
Fully Diluted	\$(0.25)	\$(0.03)
Common Shares:		
Full Diluted	13,862,992	11,419,270
Year-end	15,055,665	11,484,012

#### ATHERSYS INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2017	2016 (revised)	2015 (revised)
Contract revenue	2,843	16,238	10,298
Grant revenue	865	1,109	1,650
Total revenues	3,708	17,347	11,948
Research & development expenses	□27,841	□24,838	□21,316
General & administrative expenses	□8,466	□7,835	□7,536
Depreciation expenses	684	382	267
Total costs & expenses	36,991	33,055	29,119
Gain from insurance proceeds, net	...	682	...
Income (loss) from operations	(33,283)	(15,026)	(17,171)
Income (expense) from change in fair value of warrants, net	728	(557)	772
Other income (expense), net	314	209	(61)
Income (loss) before income taxes	(32,241)	(15,374)	(16,460)
Income tax expense (benefit)	...	(37)	(38)
Net income (loss)	(32,241)	(15,337)	(16,422)
Weighted average shares outstanding - basic	112,053	84,715	82,144
Weighted average shares outstanding - diluted	112,053	84,715	82,851
Year end shares outstanding	122,077	86,629	83,720
Net earnings (loss)			

per share - basic	\$(0.29)	\$(0.18)	\$(0.20)
Net earnings (loss)			
per share - diluted	\$(0.29)	\$(0.18)	\$(0.20)
Number of full time employees	66	60	60
Number of common stockholders	511	525	530

□ Including stock compensation expense - Research and development: \$1,232,000; □ Including stock compensation expense - Research and development: \$1,192,000; □ Including stock compensation expense - Research and development: \$1,277,000; □ Including stock compensation expense - General & administrative: \$1,812,000; □ Including stock compensation expense - General & administrative: \$1,676,000; □ Including stock compensation expense - General & administrative: \$1,652,000; □ As is; □ Approximately; □ As of February 28, 2018; □ As of February 28, 2017; □ As of March 1, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
		(revised)	(revised)
Cash & cash equivalents	29,316	14,753	14,753
Accounts receivable	739	598	598
Prepaid expenses & other current assets	1,135	929	929
Total current assets	31,190	16,280	16,280
Laboratory equipment	6,262	6,196	6,196
Office equipment & leasehold improvements	3,039	3,040	3,040
Process development equipment not yet in service	363	965	965
Equipment, gross	9,664	10,201	10,201
Less: accumulated depreciation	7,458	7,596	7,596
Equipment, net	2,206	2,605	2,605
Other assets	197	175	175
Total assets	33,593	19,060	19,060
Accounts payable	4,469	4,761	4,761
Accrued compensation & related benefits	1,065	1,190	1,190
Accrued clinical trial costs	1,453	389	389
Accrued expenses	425	535	535
Accrued license fee expense	1,900	...	...
Deferred revenue	771	...	...
Total current liabilities	10,083	6,875	6,875
Advance from customer	134	...	...
Warrant liabilities	...	1,004	1,004
Common stock	122	87	87
Additional paid-in capital	373,884	329,373	329,373
Retained earnings (accumulated deficit)	(350,630)	(318,279)	(318,279)
Total stockholders' equity	23,376	11,181	11,181

□ Reclassified to conform with 2017 presentation

**Recent Dividends:**

**1. Athersys Inc common.**

No dividends paid.

**Annual Dividends:**

**1. Athersys Inc common.**

No dividends paid.

**ATOMERA INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
			(revised)
Revenue	110,000	...	...
Cost of revenue	39,000	...	...
Gross margin	71,000	...	...
Research & development	5,826,000	3,993,000	2,022,000
General & administrative	5,796,000	5,105,000	3,441,000
Selling & marketing	1,659,000	901,000	36,000
Total operating expenses	13,281,000	9,999,000	5,499,000

Income (loss) from operations	(13,210,000)	(9,999,000)	(5,499,000)
Interest income	148,000	29,000	5,000
Interest expense	...	2,640,000	1,930,000
Loss on settlement of options & warrants	...	...	2,089,000
Other expenses	6,000	...	...
Total other expense, net	142,000	(2,611,000)	(4,014,000)
<b>Net income (loss)</b>	(13,068,000)	(12,610,000)	(9,513,000)
Weighted average shares outstanding-basic	12,124,000	5,682,000	1,260,000
Weighted average shares outstanding-diluted	12,124,000	5,682,000	1,260,000
Year end shares outstanding	12,161,000	12,025,000	1,617,000
Net earnings (loss) per share - basic	\$(1.08)	\$(2.22)	\$(7.55)
Net earnings (loss) per share - diluted	\$(1.08)	\$(2.22)	\$(7.55)
Number of full time employees	16	15	12
Number of common stockholders	373	512	278

□ Reclassified to conform with 2016 presentation; □ Shares increased due to the effect of sale of stock, conversion of secured notes, stock-based compensation, and stock option exercise; □ As of Aug. 10, 2016; □ As of February 23, 2018; □ As of March 27, 2017; □ Approximately

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
Cash & cash equivalents	17,369,000	26,718,000
Accounts receivable	110,000	...
Prepaid expenses & other current assets	248,000	96,000
Total current assets	17,727,000	26,814,000
Computer equipment	77,000	60,000
Laboratory equipment	76,000	55,000
Software	6,000	5,000
Office equipment	1,000	2,000
Furniture & fixtures	1,000	...
Property & equipment, gross	161,000	122,000
Less: accumulated depreciation & amortization	94,000	94,000
Property & equipment, net	67,000	28,000
Security deposit	13,000	37,000
Total assets	17,807,000	26,879,000
Accounts payable	198,000	353,000
Accrued expenses	239,000	168,000
Accrued payroll related expenses	512,000	510,000
Total liabilities	949,000	1,031,000
Common stock	12,000	12,000
Additional paid-in capital	125,911,000	121,833,000
Retained earnings (accumulated deficit)	(109,065,000)	(95,997,000)
Total stockholders' equity (deficit)	16,858,000	25,848,000

**Recent Dividends:**

**1. Atomera Inc common.**

No dividends paid.

**Annual Dividends:**

**1. Atomera Inc common.**

No dividends paid.

**AUTOWEB INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
		(revised)	(revised)
Lead fees revenues	107,045	130,684	120,678
Advertising	...	...	...

revenues	34,142	24,508	10,534
Other revenues	938	1,492	2,014
Total revenues	142,125	156,684	133,226
Cost of revenues	99,352	98,771	81,586
Gross profit	42,773	57,913	51,640
Sales & marketing	14,315	18,118	15,956
Technology support	12,567	13,986	11,740
General & administrative	12,110	14,663	13,189
Depreciation & amortization	4,781	5,068	3,106
Litigation settlements	(109)	(50)	(108)
Goodwill impairment	37,688	...	...
Total operating expenses	81,352	51,785	43,883
Operating income (loss)	(38,579)	6,128	7,757
Interest & other income (expense), net	(946)	558	322
Income (loss) before income taxes - United States	(40,090)	6,448	8,079
Income (loss) before income taxes - International	565	238	...
Income (loss) before income taxes	(39,525)	6,686	8,079
Current federal income tax provision (benefit)	...	244	212
Current state income tax provision (benefit)	36	508	226
Current foreign income taxes	139	69	...
Total current income tax provision (benefit)	175	821	438
Deferred federal income tax provision (benefit)	(2,916)	1,726	2,997
Deferred state income tax provision (benefit)	(175)	1,040	586
Total deferred income tax provision (benefit)	(3,091)	2,766	3,583
Change in federal tax rate	11,693	...	...
Valuation allowance release	16,662	(772)	(588)
Income tax provision (benefit)	25,439	2,815	3,433
<b>Net income (loss) &amp; comprehensive income</b>	(64,964)	3,871	4,646
Weighted average shares outstanding - basic	11,853	10,673	9,907
Weighted average shares outstanding - diluted	11,853	13,303	12,662
Year end shares outstanding	13,059	11,013	10,627
Net earnings (loss) per share - basic	\$(5.48)	\$0.36	\$0.47
Net earnings (loss) per share - diluted	\$(5.48)	\$0.29	\$0.37
Total number of employees	228	254	200
Number of common stockholders	228	220	205

□ Reclassified to conform with 2017 presentation; □ As is; □ As of March 12, 2018; □ As of March 6, 2017; □ As of March 7, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016
		(revised)
Cash & cash equivalents	24,993	38,512
Short-term investments	254	251
Accounts receivable,	...	...

	2017	2016	2015	Other intangible assets, net	2017	2016	2015
gross	26,803	34,649					
Allowances for bad debts & customer credits	892	1,015					
Accounts receivable, net	25,911	33,634					
Deferred tax asset		4,669					
Prepaid expenses & other current assets	1,805	901					
Total current assets	52,963	77,967					
Computer software & hardware	11,065	12,027					
Capitalized internal use software	5,774	5,359					
Furniture & equipment	1,703	1,332					
Leasehold improvements	1,539	1,139					
Property & equipment, gross	20,081	19,857					
Less - accumulated depreciation & amortization	15,770	15,427					
Property & equipment, net	4,311	4,430					
Investments	100	680					
Intangible assets, net	29,113	23,783					
Goodwill	5,133	42,821					
Long-term deferred tax asset	692	14,799					
Other assets	601	801					
Total assets	92,913	165,281					
Accounts payable	7,083	9,764					
Accrued employee-related benefits	2,411	4,530					
Other accrued expenses	6,307	7,278					
Amounts due to customers	438	466					
Other current liabilities	507	571					
Other accrued expenses & other current liabilities	7,252	8,315					
Current portion of term loan payable		6,563					
Total current liabilities	16,746	29,172					
Convertible note payable	1,000	1,000					
Long-term portion of term loan payable		7,500					
Borrowings under revolving credit facility	8,000	8,000					
Total liabilities	25,746	45,672					
Common stock	13	11					
Additional paid-in capital	356,054	350,022					
Retained earnings (accumulated deficit)	(288,900)	(230,424)					
Total stockholders' equity	67,167	119,609					

**Recent Dividends:****1. AutoWeb Inc common.**

No dividends paid.

**2. AutoWeb Inc series B junior participating convertible preferred.**

No dividends paid.

**Annual Dividends:****1. AutoWeb Inc common.**

No dividends paid.

**2. AutoWeb Inc series B junior participating convertible preferred.**

No dividends paid.

**AVID BIOSERVICES INC****Earnings, 9 mos. to Jan 31(Consol. - \$):**

	2018	2017
Cost & expenses	61,172,000	40,079,000
Operating income	(14,494,000)	(353,000)
Income contin. oper.	(14,429,000)	(284,000)
Income discont. oper.	(10,404,000)	(22,603,000)
<b>Net income</b>	<b>(24,833,000)</b>	<b>(22,887,000)</b>
Balance for common	(28,437,000)	(26,445,000)
Earnings common share		
Primary	\$(0.63)	\$(0.75)
Fully Diluted	\$(0.63)	\$(0.75)
Common Shares:		
Full Diluted	45,032,335	35,486,782
Year-end	45,257,180	

**BIODELIVERY SCIENCES INTERNATIONAL INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Product sales	34,922,000	8,266,000	4,157,000
Product royalty revenue	5,070,000	3,646,000	1,406,000
Research & development reimbursements	799,000	1,134,000	909,000
Contract revenue	21,194,000	2,500,000	41,759,000
Total revenues	61,985,000	15,546,000	48,231,000
Cost of sales	19,496,000	11,258,000	8,101,000
Research & development expense	13,040,000	18,878,000	20,624,000
Selling, general & administrative expense	58,869,000	49,345,000	54,685,000
Total expenses	71,909,000	68,223,000	75,309,000
Income (loss) from operations	(29,420,000)	(63,935,000)	(35,179,000)
Interest income (expense), net	(8,577,000)	(3,267,000)	(2,518,000)
Bargain purchase gain	27,336,000		
Other income (expenses), net	(26,000)	64,000	25,000
Income (loss) before income taxes	(10,687,000)	(67,138,000)	(37,672,000)
Income tax expense (benefit)	(15,972,000)		
<b>Net income (loss)</b>	<b>5,285,000</b>	<b>(67,138,000)</b>	<b>(37,672,000)</b>
Net income (loss) attributable to common stockholders	5,285,000	(67,138,000)	(37,672,000)
Weighted average shares outstanding - basic	55,355,802	53,679,134	52,384,876
Weighted average shares outstanding - diluted	55,355,802	53,679,134	52,384,876
Year end shares outstanding	55,888,581	54,118,020	52,715,308
Earnings (loss) per share - basic	\$0.10	\$(1.25)	\$(0.72)
Earnings (loss) per share - diluted	\$0.09	\$(1.25)	\$(0.72)
Number of full time employees	115	99	40
Number of part time employees	1		
Number of common stockholders	111	112	113

Reclassified to conform with 2017 presentation; As of March 13, 2018; As of March 14, 2017; As of March 7, 2016; Approximately

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Cash	21,195,000	32,019,000	
Accounts receivable, net	8,852,000	2,967,000	
Raw materials & supplies	1,338,000	978,000	
Work in process	3,135,000	1,660,000	
Finished goods	1,861,000	730,000	
Finished goods reserve	243,000		
Inventory	6,091,000	3,368,000	
Prepaid expenses & other current assets	3,610,000	4,136,000	
Total current assets	39,748,000	42,490,000	
Machinery & equipment	5,428,000	4,476,000	
Computer equipment & software	399,000	464,000	
Office furniture & equipment	169,000	202,000	
Leasehold improvements	44,000	53,000	
Idle equipment	766,000	1,486,000	
Less: accumulated depreciation	3,028,000	2,451,000	
Goodwill	2,715,000	2,715,000	
BELBUCA textsuperscripttextregistered license & distribution rights intangible asset, net	40,500,000		

net	1,360,000	2,285,000
Total assets	88,101,000	51,720,000
Accounts payable	12,236,000	9,397,000
Accrued rebates	5,648,000	3,842,000
Accrued compensation & benefits	3,472,000	2,052,000
Accrued acquisition costs	2,311,000	
Accrued return	915,000	
Accrued royalties	488,000	518,000
Accrued clinical trial costs	234,000	615,000
Accrued legal	216,000	490,000
Accrued manufacturing costs		200,000
Accrued sales & marketing costs		193,000
Other accrued expenses	629,000	265,000
Accounts payable & accrued liabilities	26,149,000	17,572,000
Deferred revenue, current		1,716,000
Total current liabilities	26,149,000	19,288,000
Notes payable, less current maturities, net	47,660,000	29,272,000
Deferred revenue, long-term		20,000,000
Other long-term liabilities	5,415,000	825,000
Total liabilities	79,224,000	69,385,000
Preferred stock	2,000	2,000
Common stock	56,000	54,000
Additional paid-in capital	313,922,000	292,667,000
Treasury stock, at cost	47,000	47,000
Retained earnings (accumulated deficit)	(305,056,000)	(310,341,000)
Total stockholders' equity (deficit)	8,877,000	(17,665,000)

Reclassified to conform with 2017 presentation

**Recent Dividends:****1. BioDelivery Sciences International Inc series A non-voting convertible preferred.**

No dividends paid.

**2. BioDelivery Sciences International Inc common.**

No dividends paid.

**3. BioDelivery Sciences International Inc series B convertible preferred.**

No dividends paid.

**4. BioDelivery Sciences International Inc series A convertible preferred.**

No dividends paid.

**Annual Dividends:****1. BioDelivery Sciences International Inc series A non-voting convertible preferred.**

No dividends paid.

**2. BioDelivery Sciences International Inc common.**

No dividends paid.

**3. BioDelivery Sciences International Inc series B convertible preferred.**

No dividends paid.

**4. BioDelivery Sciences International Inc series A convertible preferred.**

No dividends paid.

**BIOLASE, INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Products & services revenues	46,798,000	51,661,000	48,269,000
License fees & royalty revenue	128,000	149,000	206,000
Net revenue	46,926,000	51,810,000	48,475,000
Cost of revenue	31,800,000	31,502,000	32,525,000
Gross profit (loss)	15,126,000	20,308,000	15,950,000
Sales & marketing expense	16,718,000	17,018,000	18,696,000
General & administrative expense	9,712,000	10,453,000	10,256,000
Engineering & development expense	6,229,000	7,799,000	7,283,000



Disposal of internally developed software	(505,000)	...	...
Excise tax	...	...	361,000
Legal settlement	...	...	(731,000)
Income (loss) from operations	(18,038,000)	(14,962,000)	(19,915,000)
Gain (loss) on foreign currency transactions	563,000	(332,000)	(259,000)
Interest income, net	42,000	74,000	74,000
Non-operating income (loss), net	605,000	(258,000)	(185,000)
Income (loss) before income tax provision	(17,433,000)	(15,220,000)	(20,100,000)
Current state income tax provision (benefit)	19,000	22,000	30,000
Current foreign income tax provision (benefit)	93,000	69,000	87,000
Total current income tax provision (benefit)	112,000	91,000	117,000
Deferred federal income tax provision (benefit)	(694,000)	60,000	61,000
Total deferred income tax provision (benefit)	(694,000)	60,000	61,000
Income tax provision (benefit)	(582,000)	151,000	178,000
<b>Net income (loss)</b>	<b>(16,851,000)</b>	<b>(15,371,000)</b>	<b>(20,278,000)</b>
Deemed dividend on convertible preferred stock	3,978,000	2,184,000	...
Net income (loss) attributable to common stockholders	(20,829,000)	(17,555,000)	...
Weighted average shares outstanding - basic	73,759,000	60,664,000	58,189,000
Weighted average shares outstanding - diluted	73,759,000	60,664,000	58,189,000
Year end shares outstanding	102,340,000	67,565,951	58,228,000
Net income (loss) per share - basic	\$(0.28)	\$(0.29)	\$(0.35)
Net income (loss) per share - diluted	\$(0.28)	\$(0.29)	\$(0.35)
Total number of employees	195	225	200
Number of common stockholders	170	180	180
Foreign currency translation adjustments	...	(75,000)	(244,000)

Reclassified to conform with 2017 presentation; Approximately; As of March 7, 2018; As of March 6, 2017; As of February 29, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	11,645,000	8,924,000
Restricted cash	251,000	251,000
Accounts receivable, gross	10,926,000	10,993,000
Less: allowance for accounts receivable	802,000	1,209,000
Accounts receivable, net	10,124,000	9,784,000
Raw materials	3,953,000	4,837,000
Work-in-process	1,162,000	2,261,000
Finished goods	7,183,000	6,425,000
Inventory, net	12,298,000	13,523,000
Prepaid expenses & other current assets	1,732,000	1,505,000
Total current assets	36,050,000	33,987,000
Building	220,000	196,000
Leasehold improvements	2,005,000	2,003,000

Equipment & computers	6,883,000	6,163,000
Furniture & fixtures	634,000	599,000
Construction in progress	1,182,000	1,590,000
Less: accumulated depreciation & amortization	7,426,000	6,225,000
Land	176,000	152,000
Property, plant & equipment, net	3,674,000	4,478,000
Goodwill	2,926,000	2,926,000
Other assets	334,000	550,000
Total assets	42,984,000	41,941,000
Accounts payable	5,109,000	9,125,000
Accrued payroll & benefits	2,115,000	2,147,000
Accrued warranty, current portion	1,120,000	933,000
Accrued taxes	544,000	638,000
Accrued professional services	584,000	782,000
Accrued capital lease, current portion	...	159,000
Accrued insurance premium	870,000	906,000
Other accrued liabilities	376,000	213,000
Customer deposits	27,000	101,000
Deferred revenue, current portion	2,625,000	3,010,000
Total current liabilities	13,370,000	18,014,000
Deferred income taxes, net	104,000	798,000
Deferred revenue - long-term	11,000	23,000
Warranty accrual, long term	70,000	773,000
Other liabilities - long-term	169,000	268,000
Total liabilities	13,724,000	19,876,000
Common stock	102,000	68,000
Additional paid-in capital	224,910,000	201,198,000
Accumulated other comprehensive gain (loss)	(576,000)	(876,000)
Retained earnings (accumulated deficit)	(195,176,000)	(178,325,000)
Total stockholders' equity (deficit)	29,260,000	22,065,000

Reclassified to conform with 2017 presentation

**Recent Dividends:**  
**1. Biolase, Inc common.**  
 No dividends paid.  
**Annual Dividends:**  
**1. Biolase, Inc common.**  
 No dividends paid.

**BIOLASE, INC Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditor, BDO USA, LLP, as it appeared in Co.'s 2017 10-K: "We have audited the accompanying consolidated balance sheets of BIOLASE, Inc. and subsidiaries (collectively, the "Company") as of December 31, 2017 and 2016, the related consolidated statements of operation and comprehensive loss, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2017, and the related notes and schedule listed in the index appearing under Item 15(a)(2) (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and subsidiaries at December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has negative cash flows from operations for each of the three years in the period ended December 31, 2017. These factors, among others, raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**BIOXCEL THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016
Research & development	2,690	1,399
General & administrative expenses	1,847	721
Total operating expenses	4,537	2,120
Income (loss) from operations	(4,537)	(2,120)
Interest expense	2	...
<b>Net income (loss)</b>	<b>(4,539)</b>	<b>(2,120)</b>
Weighted average shares outstanding - basic	9,685	9,480
Weighted average shares outstanding - diluted	9,685	9,480
Year end shares outstanding	9,908	...
Net earnings (loss) per share - basic	\$(0.47)	\$(0.22)
Net earnings (loss) per share - diluted	\$(0.47)	\$(0.22)
Number of full time employees	4	...

As is

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016
Cash	887	...
Prepaid expenses & other current assets	3	2
Total current assets	890	2
Deferred offering costs	461	...
Computer	5	5
Less accumulated depreciation & amortization	1	...
Equipment, net	4	5
Total assets	1,355	7
Accounts payable	444	279
Accrued salaries & benefits	79	27
Professional & consultant fees	120	15
Legal expenses	413	10
Materials & clinical trial expenses	403	...
Accrued expenses	1,015	52
Payable to parent for services	67	...
Notes payable to parent	371	...
Due to parent	440	...
Total current liabilities	2,337	331
Common stock	10	...
Additional paid-in capital	3,458	...
Net liabilities assumed from parent	...	(324)
Retained earnings (accumulated deficit)	(4,450)	...
Total stockholders' equity (deficit) & net parent investment	(982)	(324)

**Recent Dividends:**  
**1. BioXcel Therapeutics Inc common.**  
 No dividends paid.  
**Annual Dividends:**  
**1. BioXcel Therapeutics Inc common.**  
 No dividends paid.

**BRAINSTORM CELL THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)	2015 (revised)
Research & development	6,795	3,435	6,335
Less: participation by the Israeli	...	...	...

office of the chief scientist.....	(1,393)	(1,185)	(1,386)
Less: participation by the CIRM.....	(4,425)	...	...
Research & development, net.....	977	2,250	4,949
General & administrative expenses.....	4,022	2,833	3,587
Financial expenses (income), net.....	(47)	(101)	(48)
<b>Net income (loss)</b> .....	<b>(4,952)</b>	<b>(4,982)</b>	<b>(8,488)</b>
Weighted average shares outstanding - basic.....	18,777	18,663	18,406
Weighted average shares outstanding - diluted.....	18,777	18,663	18,406
Year end shares outstanding.....	18,976	18,688	18,643
Net income (loss) per share - basic.....	\$(0.26)	\$(0.27)	\$(0.46)
Net income (loss) per share - diluted.....	\$(0.26)	\$(0.27)	\$(0.46)
Number of full time employees.....	24	19	17
Other number of employees.....	...	3	3
Total number of employees.....	24	22	20
Number of common stockholders.....	45	41	46

Reclassified to conform with 2016 presentation; As is; Approximately; As of March 6, 2018; As of March 24, 2017; As of January 29, 2016

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016	2015
Cash & cash equivalents.....	2,483	547	547
Short-term deposit.....	5,273	9,443	9,443
Accounts receivable.....	672	306	306
Prepaid expenses & other current assets.....	1,195	148	148
Total current assets.....	9,623	10,444	10,444
Prepaid expenses & other long-term assets.....	1,408	25	25
Office furniture & equipment, cost.....	73	73	73
Computer software & electronic equipment, cost.....	189	182	182
Laboratory equipment, cost.....	875	702	702
Leasehold improvements, cost.....	716	716	716
Property & equipment, cost.....	1,853	1,673	1,673
Less: accumulated depreciation - office furniture & equipment.....	23	18	18
Less: accumulated depreciation - computer software & electronic equipment.....	176	166	166
Less: accumulated depreciation - laboratory equipment.....	552	492	492
Less: accumulated depreciation - leasehold improvements.....	710	700	700
Less: accumulated depreciation.....	1,461	1,376	1,376
Property & equipment, net.....	392	297	297
Total long-term assets.....	1,800	322	322
Total assets.....	11,423	10,766	10,766
Accounts payables.....	1,424	345	345
Accrued expenses.....	817	152	152
Deferred grant income.....	2,625	...	...
Other accounts payable.....	677	367	367
Total current liabilities.....	5,543	864	864
Total liabilities.....	5,543	864	864

Common stock.....	11	11	11
Additional paid-in-capital.....	85,944	85,014	85,014
Retained earnings (accumulated deficit).....	(80,075)	(75,123)	(75,123)
Total stockholders' equity (deficiency).....	5,880	9,902	9,902

Reclassified to conform with 2017 presentation

#### Recent Dividends:

1. Brainstorm Cell Therapeutics Inc common.

No dividends paid.

#### Annual Dividends:

1. Brainstorm Cell Therapeutics Inc common.

No dividends paid.

#### BRAINSTORM CELL THERAPEUTICS INC Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Brightman Almagor Zohar & Co, as it appeared in Co.'s 2017 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Brainstorm Cell Therapeutics Inc. and subsidiaries (the "Company") as of December 31, 2017 and 2016 and the related consolidated statements comprehensive loss, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company's lack of revenues and substantial operating losses raise substantial doubt about its ability to continue as a going concern. Management's plans concerning these matters are also described in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties."

#### CATALYST PHARMACEUTICALS INC

##### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	2015
Research & development expenses.....	11,375,237	11,369,941	11,801,342
General & administrative expenses.....	7,304,399	7,910,260	8,597,010
Total operating costs & expenses.....	18,679,636	19,280,201	20,398,352
Income (loss) from operations.....	(18,679,636)	(19,280,201)	(20,398,352)
Other income, net.....	454,163	321,612	100,389
Change in fair value of warrants liability.....	(186,904)	886,137	65,005
Income (loss) before income taxes.....	(18,412,377)	(18,072,452)	(20,232,958)
<b>Net income (loss)</b> .....	<b>(18,412,377)</b>	<b>(18,072,452)</b>	<b>(20,232,958)</b>
Weighted average shares outstanding - basic.....	85,802,487	82,875,281	80,858,393
Weighted average shares outstanding - diluted.....	85,802,487	82,875,281	80,858,393
Year end shares outstanding.....	102,549,498	82,972,316	82,850,619
Net income (loss) per share - basic.....	\$(0.21)	\$(0.22)	\$(0.25)
Net income (loss) per share - diluted.....	\$(0.21)	\$(0.22)	\$(0.25)
Total number of employees.....	21	18	23
Number of common stockholders.....	40	44	44
Number of beneficiary stockholders.....	9,000	9,000	9,000

As of March 9, 2018; As of March 15, 2017; As of March 11, 2016; As of March 10, 2017; Approximately

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016
Cash & cash equivalents.....	57,496,702	13,893,064
Short-term investments.....	26,516,711	26,512,753
Prepaid research fees.....	388,977	334,565
Prepaid insurance.....	638,139	598,909
Prepaid pre-commercialization fees.....	65,000	35,500
Prepaid subscriptions fees.....	23,347	22,770
Prepaid rent.....	...	19,756
Other prepaid expenses.....	58,281	36,444
Total current assets.....	85,187,157	41,453,761
Computer equipment.....	27,915	27,915
Furniture & equipment.....	169,931	177,061
Leasehold improvements.....	152,708	152,708
Property & equipment, gross.....	350,554	357,684
Less: accumulated depreciation.....	159,169	113,480
Property & equipment, net.....	191,385	244,204
Deposits.....	8,888	8,888
Total assets.....	85,387,430	41,706,853
Accounts payable.....	1,945,575	933,176
Accrued preclinical & clinical trial expenses.....	970,649	623,855
Accrued professional fees.....	227,457	102,673
Accrued compensation & benefits.....	821,935	264,237
Accrued license fees.....	252,500	152,500
Deferred rent & lease incentive.....	24,011	18,094
Other accrued expenses & other current liabilities.....	24,035	...
Total current liabilities.....	4,266,162	2,094,535
Deferred rent & lease incentive- non-current.....	157,456	181,162
Warrants liability, at fair value.....	...	122,226
Total liabilities.....	4,423,618	2,397,923
Common stock.....	102,549	82,972
Additional paid-in capital.....	207,421,710	147,374,028
Retained earnings (accumulated deficit).....	(126,560,447)	(108,148,070)
Total stockholders' equity (deficit).....	80,963,812	39,308,930

#### Recent Dividends:

1. Catalyst Pharmaceuticals Inc common.

No dividends paid.

#### Annual Dividends:

1. Catalyst Pharmaceuticals Inc common.

No dividends paid.

#### CDTI ADVANCED MATERIALS INC

**New Name** On Mar. 15, 2018, Co. changed its name from Clean Diesel Technologies Inc. to CDTi Advanced Materials Inc.

#### CENVEO INC

**Bankruptcy Proceedings** On Mar. 16, 2018, the U.S. Bankruptcy Court approved Brigade Capital Management's motion to appoint an examiner to Co.'s case. The order states, "The Motion is granted solely as provided herein, and the United States Trustee is directed to appoint an examiner in these chapter 11 cases. The Examiner shall prepare and file a report within 70 days of being appointed by the United States Trustee pursuant to this Order (assuming that Co.'s and the Committee's investigations of the Examination Topics will be complete within 60 days of such appointment and cooperation by Co. and the Committee with the Examiner as provided in this Order), setting forth whether the respective investigations conducted by Co. and the Committee pertaining to the Examination Topics were conducted independently and in good faith, whether the respective examinations have concluded, are complete, and in accordance with this Order, and whether Co.'s and the Committee's assessments and conclusions were reasonable. The time to file the Report may be extended by Order of the Court upon application by the Examiner for cause shown. While the Examiner is expected to communicate

on an ongoing basis with Co. and the Committee and, if appropriate and consistent with the other terms of this Order, other parties in interest, the Examiner's public disclosure with respect to his or her work shall be limited to the filing of the Report."

**CHEMBIO DIAGNOSTICS INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	<sup>1</sup> 2016 (revised)	<sup>2</sup> 2015 (revised)
Net product sales	19,322,302	13,680,107	21,886,688
License & royalty revenue	741,534	449,685	52,753
Research & development, milestone & grant revenue	3,951,591	3,739,049	2,316,044
Total revenues	24,015,427	17,868,841	24,255,485
Cost of product sales	12,921,157	9,417,505	13,768,658
Research & development expenses	8,555,381	8,427,554	6,377,839
Selling, general & administrative expenses	9,021,439	7,595,559	7,663,035
Total costs & expenses	30,497,977	25,440,618	27,809,532
Income (loss) from operations	(6,482,550)	(7,571,777)	(3,554,047)
Other income (expense)	...	...	(4,814)
Interest income	25,430	25,548	2,412
Interest expense	2,945	...	836
Total other income (expense)	22,485	25,548	(3,238)
Income (loss) before income taxes provision (benefit) - United States	(6,054,002)	(7,546,229)	(3,557,285)
Income (loss) before income taxes provision (benefit) - international	(406,063)	...	...
Income (loss) before income taxes provision (benefit) - Current federal income taxes	(97,339)	...	...
Income (loss) before income taxes provision (benefit) - Current state income taxes	9,034	...	10,726
Income (loss) before income taxes provision (benefit) - Deferred federal income taxes	(88,305)	...	10,726
Income (loss) before income taxes provision (benefit) - Deferred state income taxes	...	5,778,185	(1,171,865)
Income (loss) before income taxes provision (benefit) - Total deferred income taxes	...	22,633	896
Income (loss) before income taxes provision (benefit) - Income tax	(88,305)	5,800,818	(1,160,243)
Net income (loss)	(6,371,760)	(13,347,047)	(2,397,042)
Weighted average shares outstanding - basic	12,300,031	10,622,331	9,626,028
Weighted average shares outstanding - diluted	12,300,031	10,622,331	9,626,028
Year end shares outstanding	12,318,570	12,026,847	9,628,248
Earnings (loss) per share - basic	\$(0.52)	\$(1.26)	\$(0.25)
Earnings (loss) per share - diluted	\$(0.52)	\$(1.26)	\$(0.25)
Total number of employees	<sup>3</sup> 165	<sup>4</sup> 131	<sup>5</sup> 155
Number of common stockholders	<sup>6</sup> 1,590	<sup>7</sup> 2,030	<sup>8</sup> 139

<sup>1</sup> Reclassified to conform with 2017 presentation; <sup>2</sup> Approximately; <sup>3</sup> As of March 5, 2018; <sup>4</sup> As of March 3, 2017; <sup>5</sup> As of March 1, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	<sup>1</sup> 2016 (revised)
Cash & cash equivalents	3,790,302	10,554,464
Accounts receivables, gross	2,127,340	3,435,729
Allowance for doubtful accounts	42,000	52,000
Accounts receivable, net	2,085,340	3,383,729
Raw materials	1,767,684	1,824,248
Work in process	286,413	535,320
Finished goods	2,369,521	975,620
Inventories, net	4,423,618	3,335,188
Prepaid expenses & other current assets	554,383	840,145
Total current assets	10,853,643	18,113,526
Machinery & equipment	4,582,759	3,962,051
Furniture & fixtures	449,548	437,962
Computer & telephone equipment	422,946	343,167
Leasehold improvements	2,258,779	2,012,945
Fixed assets, gross	7,714,032	6,756,125
Less accumulated depreciation & amortization	5,804,800	5,046,804
Fixed assets, net of accumulated depreciation	1,909,232	1,709,321
Intangible assets, net	1,597,377	...
Goodwill	1,666,610	...
Deposits & other assets	589,159	752,389
Total assets	16,616,021	20,575,236
Accounts payable - suppliers	1,494,759	1,437,290
Accrued commissions	126,827	221,982
Accrued royalties/license fees	429,297	352,660
Accrued payroll	187,305	167,575
Accrued vacation	309,767	289,587
Accrued bonuses	282,500	282,500
Accrued expenses - other	215,848	261,539
Deferred revenue	50,000	392,517
Total current liabilities	3,096,303	3,405,650
Note payable	99,480	...
Deferred tax liability	341,042	...
Total liabilities	3,536,825	3,405,650
Common stock	123,185	120,268
Additional paid-in capital	62,821,288	60,721,783
Retained earnings (accumulated deficit)	(50,044,225)	(43,672,465)
Accumulated other comprehensive income	178,948	...
Total stockholders' equity (deficit)	13,079,196	17,169,586

<sup>1</sup> Reclassified to conform with 2017 presentation

**Recent Dividends:**

- 1. Chembio Diagnostics Inc series B 9% convertible preferred.**  
No dividends paid.
  - 2. Chembio Diagnostics Inc series A 8% convertible preferred.**  
No dividends paid.
  - 3. Chembio Diagnostics Inc series C 7% redeemable convertible preferred.**  
No dividends paid.
  - 4. Chembio Diagnostics Inc common.**  
No dividends paid.
- Annual Dividends:**
- 1. Chembio Diagnostics Inc series B 9% convertible preferred.**  
No dividends paid.
  - 2. Chembio Diagnostics Inc series A 8% convertible preferred.**  
No dividends paid.
  - 3. Chembio Diagnostics Inc series C 7% redeemable convertible preferred.**  
No dividends paid.
  - 4. Chembio Diagnostics Inc common.**  
No dividends paid.

**CONSUMER CAPITAL GROUP INC**

**New Accountant** On Mar. 12, 2018, Co. dismissed Wei, Wei & Co., LLP as its independent public accounting firm. On Mar. 9, 2018, Co. engaged Centurion ZD CPA Ltd. as its new independent public accounting firm.

**CONTRAFECT CORP**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Research & development	<sup>1</sup> 17,314,086	<sup>2</sup> 22,101,720	<sup>3</sup> 15,004,512
General & administrative	<sup>4</sup> 9,249,671	<sup>5</sup> 11,430,526	<sup>6</sup> 10,060,825
Total operating expenses	26,563,757	33,532,246	25,065,337
Income (loss) from operations	(26,563,757)	(33,532,246)	(25,065,337)
Interest income (expense), net	418,135	216,616	75,693
Other expense	905,014	1,569,341	...
Change in fair value of warrant & embedded derivative liabilities	11,532,978	6,346,572	(131,320)
Total other income (expense)	11,046,099	4,993,847	(55,627)
Net income (loss)	(15,517,658)	(28,538,399)	(25,120,964)
Net income (loss) attributable to common stockholders	(15,517,658)	(28,538,399)	(25,120,964)
Weighted average shares outstanding - basic	55,595,732	33,539,465	23,328,922
Weighted average shares outstanding - diluted	55,595,732	33,539,465	23,328,922
Year end shares outstanding	<sup>7</sup> 73,656,006	<sup>8</sup> 41,656,006	27,482,692
Net earnings (loss) per share - basic	\$(0.28)	\$(0.85)	\$(1.08)
Net earnings (loss) per share - diluted	\$(0.28)	\$(0.85)	\$(1.08)
Number of full time employees	<sup>9</sup> 23	<sup>10</sup> 23	<sup>11</sup> 31
Number of common stockholders	<sup>12</sup> 1,613	<sup>13</sup> 1,613	<sup>14</sup> 1,613

<sup>1</sup> Including share-based compensation expense - Reasearch & development: \$451,334; <sup>2</sup> Including share-based compensation expense - Reasearch & development: \$587,426; <sup>3</sup> Including share-based compensation expense - Reasearch & development: \$389,967; <sup>4</sup> Including share-based compensation expense - General & administrative: \$1,171,794; <sup>5</sup> Including share-based compensation expense - General & administrative: \$1,644,456; <sup>6</sup> Including share-based compensation expense - General & administrative: \$1,599,895; <sup>7</sup> Shares increased due to the effect of issuance of securities in registered offering; <sup>8</sup> Shares increased due to registered offering; <sup>9</sup> As of March 7, 2018; <sup>10</sup> As of March 7, 2017; <sup>11</sup> As of March 9, 2016; <sup>12</sup> Approximately

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	6,995,046	3,806,984
Marketable securities	39,858,864	31,354,170
Prepaid expenses & other current assets	1,848,063	1,017,645
Total current assets	48,701,973	36,178,799
Computer equipment	19,691	19,691
Furniture	434,697	434,697
Lab equipment	1,710,881	1,710,881
Leasehold improvements	1,855,004	1,855,004
Property & equipment, gross	4,020,273	4,020,273
Less: accumulated depreciation & amortization	2,926,370	2,739,121
Property & equipment, net	1,093,903	1,281,152
Other assets	393,603	164,519
Total assets	50,189,479	37,624,470
Accounts payable	1,302,431	1,549,845

Accrued compensation costs	2,107,118	1,597,414
Accrued research & development service fees	578,562	504,193
Accrued professional fees	221,103	299,912
Accrued facilities operation expenses	168,168	236,296
Accrued licensing fees	...	180,000
Other accrued liabilities	43,286	50,537
Accrued liabilities	3,118,237	2,868,352
Total current liabilities	4,420,668	4,418,197
Deferred rent	704,240	994,439
Warrant liabilities	13,549,437	12,698,980
Other liabilities	321,689	...
Total liabilities	18,996,034	18,111,616
Common stock	7,366	4,166
Additional paid-in capital	192,896,367	165,678,164
Accumulated other comprehensive income (loss)	(74,820)	(51,666)
Retained earnings (accumulated deficit)	(161,635,468)	(146,117,810)
Total stockholders' equity (deficit)	31,193,445	19,512,854

**Recent Dividends:****1. ContraFect Corp common.**

No dividends paid.

**Annual Dividends:****1. ContraFect Corp common.**

No dividends paid.

**CONVERGEONE HOLDINGS INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016
		(revised)
Operating costs	676,233	2,092
Income (loss) from operations	(676,233)	(2,092)
Interest income	1,196,495	...
Income (loss) before provision for income taxes	520,262	(2,092)
Provision for income taxes	222,480	...
<b>Net income (loss)</b>	297,782	(2,092)
Weighted average shares outstanding - basic	5,045,566	3,750,000
Weighted average shares outstanding - diluted	5,045,566	3,750,000
Year end shares outstanding	22,357,500	4,312,500
Net earnings (loss) per share - basic	\$(0.11)	\$0.00
Net earnings (loss) per share - diluted	\$(0.11)	\$0.00
Total number of employees	3	3
Number of class A common stockholders	17	...
Number of class F common stockholders	1	...
Number of units stockholders	2	...

□ From November 17, 2016 (inception); □ Reclassified to conform with 2017 presentation, □ As of February 13, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
		(revised)
Cash	115,240	25,000
Prepaid expenses	49,359	...
Total current assets	164,599	...
Cash & marketable securities held in Trust Account	175,421,495	...
Deferred offering costs	...	13,491
Total assets	175,586,094	38,491
Accounts payable & accrued expenses	212,572	2,092
Income taxes payable	222,480	...
Advances from related	...	...

parties	32,776	13,491
Total current liabilities	467,828	15,583
Total liabilities	467,828	15,583
Common stock subject to possible redemption	170,118,265	...
Class A common stock	132	...
Class F common stock	431	431
Additional paid-in capital	4,703,748	24,569
Retained earnings (accumulated deficit)	295,690	(2,092)
Total stockholder's equity	5,000,001	22,908

□ Reclassified to conform with 2017 presentation

**Recent Dividends:****1. ConvergeOne Holdings Inc class A common.**

No dividends paid.

**2. ConvergeOne Holdings Inc class F common.**

No dividends paid.

**Annual Dividends:****1. ConvergeOne Holdings Inc class A common.**

No dividends paid.

**2. ConvergeOne Holdings Inc class F common.**

No dividends paid.

**CONVERGEONE HOLDINGS INC****Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP Auditors Independentes, as it appeared in Co.'s 2017 10-K: "We have audited the accompanying consolidated balance sheets of Forum Merger Corporation and Subsidiaries (the "Company") as of December 31, 2017 and 2016, the related consolidated statements of operations, stockholders' equity and cash flows for the year ended December 31, 2017 and for the period from November 17, 2016 (inception) through December 31, 2016, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2017 and 2016, and the consolidated results of its operations and its cash flows for the year ended December 31, 2017 and for the period from November 17, 2016 (inception) through December 31, 2016, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph ¶ Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, its business plan is dependent on the completion of a business combination and the Company's cash and working capital as of December 31, 2017 are not sufficient to complete its planned activities for the upcoming year. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**CPI CARD GROUP INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2017	2016	2015
		(revised)	(revised)
Products	125,306	168,510	241,609
Services	129,556	140,190	132,501
Total net sales	254,862	308,700	374,110
Products	87,441	111,627	155,516
Services	81,180	84,453	73,111
Depreciation & amortization	11,250	10,722	9,662
Total cost of sales	179,871	206,802	238,289
Gross profit	74,991	101,898	135,821
Selling, general & administrative	67,258	64,011	61,116
Impairments	19,074	2,700	...
Depreciation & amortization	6,764	6,205	6,304
Restructuring charges	...	...	681
Total operating expenses	93,096	72,916	68,101
Income (loss) from operations	(18,105)	28,982	67,720

Interest, net	20,848	20,044	18,328
Foreign currency gain (loss)	560	(417)	59
Loss on debt modification & early extinguishment	...	...	703
Other income (expense), net	11	20	359
Total other expense	(20,277)	(20,441)	(18,613)
Income before income taxes - Domestic	(36,646)	7,437	50,692
Income before income taxes - Foreign	(1,736)	1,104	(1,585)
Income (loss) before income taxes	(38,382)	8,541	49,107
Current income tax expense (benefit) - domestic	(7,376)	4,944	16,036
Current income tax expense (benefit) - foreign	99	27	254
Total current income tax expense (benefit)	(7,277)	4,971	16,290
Deferred income tax expense (benefit) - domestic	(9,161)	(1,830)	1,656
Deferred income tax expense (benefit) - foreign	66	1	(100)
Total deferred income tax expense (benefit)	(9,095)	(1,829)	1,556
Income tax expense (benefit)	(16,372)	3,142	17,846
Net income (loss) from continuing operations	(22,010)	5,399	31,261
Income (loss) from a discontinued operation, net of taxes	...	...	(606)
Gain on sale of a discontinued operations, net of taxes	...	...	208
<b>Net income (loss)</b>	(22,010)	5,399	30,863
Preferred stock dividends	...	...	32,548
Net income (loss) attributable to common stockholders	(22,010)	5,399	(1,685)
Weighted average shares outstanding - basic	11,117	11,165	8,963
Weighted average shares outstanding - diluted	11,117	11,241	8,963
Year end shares outstanding	11,135	11,072	11,308
Earnings (loss) per share - continued operations - basic	\$(1.98)	\$0.50	\$(0.15)
Earnings (loss) per share - discontinued operations - basic	...	...	\$(0.05)
Net earnings (loss) per share - basic	\$(1.98)	\$0.50	\$(0.20)
Earnings (loss) per share - continued operations - diluted	\$(1.98)	\$0.50	\$(0.15)
Earnings (loss) per share - discontinued operations - diluted	...	...	\$(0.05)
Net earnings (loss) per share - diluted	\$(1.98)	\$0.50	\$(0.20)

Dividends per share . . .	\$0.45	□\$0.90	...
Number of full time employees . . . . .	□□1,200	□1,308	□1,386
Number of common stockholders . . . . .	□□9	□□12	□□30
Foreign currency translation adjustments . . . . .	...	(2,116)	(1,715)

□ Reclassified to conform with 2017 presentation; □ Adjusted for 1-for-5 stock split, December 20, 2017; □ As is; □ Approximately; □ As of February 22, 2018; □ As of February 20, 2017; □ As of March 4, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016	(revised)
Cash & cash equivalents . . . . .	23,205	36,955	
Accounts receivable, gross . . . . .	37,590	31,618	
Less: allowances . . . . .	53	126	
Accounts receivable, net . . . . .	37,537	31,492	
Raw materials . . . . .	6,498	8,206	
Work in process . . . . .	6,557	6,340	
Finished goods . . . . .	3,182	4,823	
Inventories . . . . .	16,237	19,369	
Prepaid expenses & other current assets . . . . .	3,960	4,601	
Income taxes receivable . . . . .	8,435	...	
Total current assets . . . . .	89,374	92,417	
Buildings . . . . .	2,318	2,077	
Machinery & equipment . . . . .	62,318	59,464	
Furniture & fixtures & computer equipment . . . . .	7,585	6,634	
Leasehold improvements . . . . .	19,754	18,655	
Construction in progress . . . . .	1,980	1,136	
Plant, equipment & leasehold improvements, gross . . . . .	93,955	87,966	
Less accumulated depreciation & amortization . . . . .	44,655	34,547	
Plant, equipment & leasehold improvements, net . . . . .	49,300	53,419	
Intangible assets, net . . . . .	41,472	46,348	
Goodwill . . . . .	53,611	71,996	
Other assets . . . . .	248	240	
Total assets . . . . .	234,005	264,420	
Accounts payable . . . . .	16,545	10,996	
Accrued expenses . . . . .	13,820	17,487	
Income taxes payable . . . . .	...	64	
Deferred revenue and customer deposits . . . . .	4,177	6,729	
Total current liabilities . . . . .	34,542	35,276	
First lien term loan . . . . .	312,500	312,500	
Unamortized discount . . . . .	(3,122)	(3,795)	
Unamortized deferred financing costs . . . . .	(5,509)	(6,783)	
Total long-term debt . . . . .	303,869	301,922	
Deferred income taxes . . . . .	12,286	21,261	
Other long-term liabilities . . . . .	2,882	1,234	
Total liabilities . . . . .	353,579	359,693	
Common stock . . . . .	11	55	
Additional paid-in capital (capital deficiency) . . . . .	(113,081)	(114,881)	
Retained earnings (accumulated deficit) . . . . .	(1,366)	25,968	
Accumulated other comprehensive income (loss) . . . . .	(5,138)	(6,415)	
Total stockholders' equity (deficit) . . . . .	(119,574)	(95,273)	

**Recent Dividends:**

**1. CPI Card Group Inc common.**  
No dividends paid.

**Annual Dividends:**

**1. CPI Card Group Inc common.**  
No dividends paid.

**CUI GLOBAL INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	□2015
Total revenue . . . . .	83,275,000	86,461,000	86,240,000
Cost of revenues . . . . .	55,406,000	54,200,000	53,948,000
Gross profit (loss) . . . . .	27,869,000	32,261,000	32,292,000
Selling, general & administrative . . . . .	33,921,000	34,239,000	33,023,000
Depreciation & amortization . . . . .	2,163,000	2,366,000	2,862,000
Research & development . . . . .	2,525,000	2,016,000	1,848,000
Provision for (credit to) bad debt . . . . .	(13,000)	93,000	195,000
Impairment of goodwill & intangible assets . . . . .	3,155,000	...	...
Other operating expenses . . . . .	47,000	57,000	58,000
Total operating expenses . . . . .	41,798,000	38,771,000	37,986,000
Income (loss) from operations . . . . .	(13,929,000)	(6,510,000)	(5,694,000)
Other income (expense) . . . . .	234,000	(251,000)	(260,000)
Interest cost incurred . . . . .	521,000	492,000	496,000
Interest cost capitalized - property & equipment . . . . .	21,000	25,000	55,000
Interest expense . . . . .	500,000	467,000	441,000
Income (loss) before taxes - U.S. operations . . . . .	(7,420,000)	(8,442,000)	(5,937,000)
Income (loss) before taxes - foreign operations . . . . .	(6,775,000)	1,214,000	(458,000)
Income (loss) before taxes . . . . .	(14,195,000)	(7,228,000)	(6,395,000)
Current income tax provision (benefit) - state & local . . . . .	60,000	81,000	59,000
Current income tax provision (benefit) - foreign . . . . .	101,000	64,000	67,000
Total current income tax provision (benefit) . . . . .	161,000	145,000	126,000
Deferred income tax provision (benefit) - federal . . . . .	(887,000)	...	...
Deferred income tax provision (benefit) - foreign . . . . .	(880,000)	(107,000)	(534,000)
Total deferred income tax provision (benefit) . . . . .	(1,767,000)	(107,000)	(534,000)
Income tax expense (benefit) . . . . .	(1,606,000)	38,000	(408,000)
<b>Net income (loss) . . . . .</b>	<b>(12,589,000)</b>	<b>(7,266,000)</b>	<b>(5,987,000)</b>
Weighted average shares outstanding - basic . . . . .	22,397,865	20,897,812	20,792,494
Weighted average shares outstanding - diluted . . . . .	22,397,865	20,897,812	20,792,494
Year end shares outstanding . . . . .	28,406,856	20,916,848	20,806,219
Net income (loss) per share - basic . . . . .	\$(0.56)	\$(0.35)	\$(0.29)
Net income (loss) per share - diluted . . . . .	\$(0.56)	\$(0.35)	\$(0.29)
Total number of employees . . . . .	333	357	352
Number of common stockholders . . . . .	□2,300	□2,300	□2,300
Number of beneficiary stockholders . . . . .	□3,000	□3,000	□3,000
Foreign currency translation			

adjustments . . . . . (4,150,000) (1,708,000)

□ Reclassified to conform with 2016 presentation; □ Approximately

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
Cash & cash equivalents . . . . .	12,646,000	4,617,000
Trade accounts receivable, gross . . . . .	10,968,000	9,526,000
Less: allowance - trade accounts receivable . . . . .	135,000	151,000
Trade accounts receivable, net . . . . .	10,833,000	9,375,000
Finished goods . . . . .	10,792,000	9,684,000
Raw materials . . . . .	3,287,000	3,357,000
Work in process . . . . .	759,000	935,000
Inventory reserves . . . . .	946,000	774,000
Inventories, net . . . . .	13,892,000	13,202,000
Costs in excess of billings . . . . .	2,299,000	2,735,000
Prepaid expenses & other current assets . . . . .	1,606,000	2,174,000
Total current assets . . . . .	41,276,000	32,103,000
Land . . . . .	1,205,000	1,170,000
Buildings & improvements . . . . .	8,476,000	8,069,000
Equipment . . . . .	5,716,000	5,012,000
Property & equipment, gross . . . . .	15,397,000	14,251,000
Less: accumulated depreciation . . . . .	4,155,000	3,299,000
Property & equipment, net . . . . .	11,242,000	10,952,000
Goodwill, net . . . . .	17,641,000	20,125,000
Other intangible assets, gross . . . . .	27,468,000	25,639,000
Less: accumulated amortization - other intangible assets . . . . .	11,900,000	9,438,000
Other intangible assets, net . . . . .	15,568,000	16,201,000
Notes receivable, less current portion . . . . .	317,000	362,000
Deposits & other assets . . . . .	1,865,000	100,000
Total assets . . . . .	87,909,000	79,843,000
Accounts payable . . . . .	5,110,000	6,170,000
Mortgage note payable, current portion . . . . .	94,000	89,000
Capital lease obligation, current portion . . . . .	4,000	28,000
Accrued expenses . . . . .	4,182,000	4,542,000
Billings in excess of costs . . . . .	1,840,000	1,977,000
Unearned revenue . . . . .	7,684,000	4,932,000
Total current liabilities . . . . .	18,914,000	17,738,000
Long term mortgage note payable, less current portion . . . . .	3,256,000	3,350,000
Long term notes payable, related party . . . . .	5,304,000	5,304,000
Capital lease obligation, less current portion . . . . .	9,000	12,000
Derivative liability . . . . .	356,000	467,000
Deferred tax liabilities . . . . .	2,414,000	4,120,000
Other long-term liabilities . . . . .	170,000	217,000
Total liabilities . . . . .	30,423,000	31,208,000
Common stock . . . . .	28,000	21,000
Additional paid-in capital . . . . .	169,527,000	150,174,000
Retained earnings (accumulated deficit) . . . . .	(108,559,000)	(95,970,000)
Foreign currency translation adjustment . . . . .	(3,510,000)	(5,590,000)
Accumulated other comprehensive income (loss) . . . . .	(3,510,000)	(5,590,000)
Total stockholders' equity (deficit) . . . . .	57,486,000	48,635,000

**Recent Dividends:**

**1. CUI Global Inc series A convertible preferred.**  
No dividends paid.

**2. CUI Global Inc common.**

No dividends paid.

**Annual Dividends:****1. CUI Global Inc series A convertible preferred.**

No dividends paid.

**2. CUI Global Inc common.**

No dividends paid.

**CURATIVE BIOSCIENCES INC**

**New Name** On Mar. 14, 2018, Co. changed its name from Amaize Beverage Corp. to Curative Biosciences Inc.

**CURATIVE BIOSCIENCES INC**

**Stock Trading Symbol** Stock symbol, CBDX.

**CYMBAY THERAPEUTICS INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)	2015 (revised)
Collaboration revenue	10,000	...	...
Research & development	18,938	15,941	17,026
General & administrative	12,387	9,645	8,871
Total operating expenses	31,325	25,586	25,897
Income (loss) from operations	(21,325)	(25,586)	(25,897)
Interest income	621	176	160
Interest expense	1,080	1,337	913
Other income, net	(5,773)	76	11,121
<b>Net income (loss)</b>	<b>(27,557)</b>	<b>(26,671)</b>	<b>(15,529)</b>
Weighted average shares outstanding - basic	34,904	23,447	18,900
Weighted average shares outstanding - diluted	34,904	23,447	18,917
Year end shares outstanding	44,409	23,447	23,447
Net income (loss) per share - basic	\$(0.79)	\$(1.14)	\$(0.82)
Net income (loss) per share - diluted	\$(0.79)	\$(1.14)	\$(0.83)
Number of full time employees	26	22	21
Number of stockholders	263	297	307

<sup>1</sup> Shares increased due to the effect of issuance of common stock upon exercise of warrants, exercise of stock options and incentive awards and issuance of common stock net issuance costs; <sup>2</sup> As is; <sup>3</sup> As of February 28, 2018; <sup>4</sup> As of March 1, 2017; <sup>5</sup> As of March 1, 2016; <sup>6</sup> Approximately

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)	2015 (revised)
Cash & cash equivalents	23,054	10,495	10,495
Marketable securities	74,156	6,499	6,499
Receivable from collaboration	5,000	...	...
Prepaid expenses	1,208	1,369	1,369
Other current assets	126	165	165
Total current assets	103,544	18,528	18,528
Office & computer equipment	177	177	177
Purchased software	83	83	83
Furniture & fixtures	65	38	38
Leasehold improvements	65	65	65
Property & equipment, gross	390	363	363
Less: accumulated depreciation & amortization	321	286	286
Property & equipment, net	69	77	77
Other assets	634	754	754
Total assets	104,247	19,359	19,359
Accounts payable	1,311	899	899
Accrued compensation	2,416	1,839	1,839
Accrued pre-clinical & clinical trial expenses	2,929	1,623	1,623
Accrued professional fees	288	982	982

Other accruals	124	57	57
Accrued liabilities	5,757	4,501	4,501
Warrant liability	6,091	1,145	1,145
Facility loan	3,108	2,700	2,700
Accrued interest payable	43	66	66
Total current liabilities	16,310	9,311	9,311
Facility loan, less current portion	2,990	6,098	6,098
Other liabilities	...	13	13
Total liabilities	19,300	15,422	15,422
Common stock	4	2	2
Additional paid-in capital	535,503	426,895	426,895
Accumulated other comprehensive income (loss)	(44)	(1)	(1)
Retained earnings (accumulated deficit)	(450,516)	(422,959)	(422,959)
Total stockholders' equity (deficit)	84,947	3,937	3,937

**Recent Dividends:****1. CymaBay Therapeutics Inc common.**

No dividends paid.

**Annual Dividends:****1. CymaBay Therapeutics Inc common.**

No dividends paid.

**CYTOSORBENTS CORP****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Sales revenue	13,381,853	8,206,036	4,043,819
Grant income	1,768,901	1,321,807	735,863
Other revenues	...	...	11,934
Total revenue	15,150,754	9,527,843	4,791,616
Cost of revenue	5,518,360	3,953,725	2,212,546
Gross profit	9,632,394	5,574,118	2,579,070
Research & development expenses	4,049,436	4,783,491	3,871,069
Legal, financial & other consulting expenses	1,339,493	1,184,788	1,089,145
Selling, general & administrative expenses	14,086,063	11,097,964	6,922,515
Total operating expenses	19,474,992	17,066,243	11,882,729
Income (loss) from operations	(9,842,598)	(11,492,125)	(9,303,659)
Interest income (expense), net	(749,076)	(231,804)	9,301
Gain (loss) on foreign currency transactions	1,454,136	(358,077)	(507,276)
Total other income (expense), net	705,060	(589,881)	(497,975)
Income (loss) before provision for (benefit from) income taxes - domestic	(6,071,009)	(9,300,042)	(6,853,093)
Income (loss) before provision for (benefit from) income taxes - foreign	(3,066,529)	(2,781,964)	(2,948,541)
Income (loss) before provision for (benefit from) income taxes	(9,137,538)	(12,082,006)	(9,801,634)
Provision for (benefit from) income taxes	(676,739)	(318,550)	(324,606)
<b>Net income (loss)</b>	<b>(8,460,799)</b>	<b>(11,763,456)</b>	<b>(9,477,028)</b>
Dividend, warrant exercise price adjustment	335,731	...	...
Net income (loss) available to common shareholders	(8,796,530)	(11,763,456)	(9,477,028)
Weighted average			

shares outstanding - basic	27,613,911	25,433,719	24,885,809
Weighted average shares outstanding - diluted	27,613,911	25,433,719	24,885,809
Year end shares outstanding	28,973,679	25,483,966	25,397,056
Net earnings (loss) per share - basic	\$(0.32)	\$(0.46)	\$(0.38)
Net earnings (loss) per share - diluted	\$(0.32)	\$(0.46)	\$(0.38)
Number of full time employees	84	...	...
Number of common stockholders	6,600	...	...
Foreign currency translation adjustments	...	314,367	356,616

<sup>1</sup> Restated to reflect adoption of Accounting Standards Update 2017-11, "Earning Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815); <sup>2</sup> As of February 1, 2018; <sup>3</sup> Approximately; <sup>4</sup> As of February 15, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	17,321,862	5,245,178
Grants & accounts receivable, gross	2,278,557	1,498,882
Allowance for doubtful accounts	72,698	65,414
Grants & accounts receivable, net	2,205,859	1,433,468
Finished goods	151,872	307,483
Work in process	528,039	467,663
Raw materials	115,746	58,830
Inventories	795,657	833,976
Prepaid expenses & other current assets	415,962	315,802
Total current assets	20,739,340	7,828,424
Furniture & fixtures	469,329	264,793
Equipment & computers	2,938,137	2,396,811
Leasehold improvements	850,744	570,678
Property & equipment, gross	4,258,210	3,232,282
Less: accumulated depreciation & amortization	2,855,428	2,662,873
Property & equipment, net	1,402,782	569,409
Intangible assets, net	1,838,052	1,191,101
Security deposits	123,133	104,910
Total assets	24,103,307	9,693,844
Accounts payable	1,244,411	1,330,072
Sales, payroll & income taxes payable	452,362	96,159
Accrued royalties	334,335	183,047
Accrued accounts payable	322,404	44,876
Accrued salaries & commissions	723,966	700,917
Professional fees	300,351	249,945
Travel & entertainment	164,985	224,621
Clinical studies	111,394	556,170
Interest	78,585	35,681
Congresses	72,291	...
Board of director fees	28,500	23,250
Customer deposits	14,747	...
Accrued expenses & other current liabilities	2,603,920	2,114,666
Current maturities of long-term debt	4,000,000	833,333
Total current liabilities	7,848,331	4,278,071
Principal amount	10,000,000	...
Less unamortized debt acquisition costs	(75,567)	...
Plus accrued final fee	67,708	...
Subtotal debt	9,992,141	...
Less current maturities	4,000,000	...
Long-term debt, net of current maturities & debt issuance costs	5,992,141	4,078,314
Total liabilities	13,840,472	8,356,385

Common stock	28,974	25,484
Additional paid-in capital	162,907,482	143,929,397
Accumulated other comprehensive income (loss)	(360,985)	898,684
Retained earnings (accumulated deficit)	(152,312,636)	(143,516,106)
Total stockholders' equity (deficiency)	10,262,835	1,337,459

Restated to reflect adoption of Accounting Standards Update 2017-11, "Earning Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815)

**Recent Dividends:**

**1. Cytosorbents Corp 10% series A preferred (stated value: \$1.00).**

No dividends paid.

**2. Cytosorbents Corp common.**

No dividends paid.

**3. Cytosorbents Corp 10% series B cumulative convertible preferred (stated value: \$100).**

No dividends paid.

**Annual Dividends:**

**1. Cytosorbents Corp 10% series A preferred (stated value: \$1.00).**

No dividends paid.

**2. Cytosorbents Corp common.**

No dividends paid.

**3. Cytosorbents Corp 10% series B cumulative convertible preferred (stated value: \$100).**

No dividends paid.

**CYTOSORBENTS CORP**

**Auditor's Report Auditor's Report**

following is an excerpt from the Report of the Independent Auditors, WithumSmith+Brown, PC, as it appeared in Co.'s 2017 10-K: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the COSO. Substantial Doubt Regarding Going Concern As disclosed in Note 1 to the consolidated financial statements, the Company sustained net losses for the years ended December 31, 2017, 2016 and 2015 of approximately \$8.5 million, \$11.8 million and \$9.5 million, respectively. Further, the Company believes it will have to raise additional capital to fund its planned operations for the twelve month period through March 2019. These matters raise substantial doubt regarding the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any adjustments related to the outcome of this uncertainty."

**CYTRX CORP**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
		(revised)	(revised)
Licensing revenue	100,000	200,000	100,000
Research & development expenses	19,840,106	35,930,212	43,395,574
General & administrative expenses	12,502,042	15,990,789	19,664,904
Depreciation & amortization	629,312	536,631	317,649
Total expenses	32,971,460	52,457,632	63,378,127
Income (loss) before other income (expense)	(32,871,460)	(52,257,632)	(63,278,127)
Interest income	365,584	255,123	233,958
Interest expense	3,831,211	2,754,677	...
Other income (expense), net	(16,322)	159,148	20,151
Gain (loss) on			

warrant liabilities	1,367,777	3,827,617	4,437,628
Income (loss) before provision (benefit) for income taxes	(34,985,632)	(50,770,421)	(58,586,390)
Provision (benefit) for income taxes	800	800	800
<b>Net income (loss)</b>	<b>(34,986,432)</b>	<b>(50,771,221)</b>	<b>(58,587,190)</b>
Weighted average shares outstanding			
- basic	24,042,293	13,510,629	10,080,525
Weighted average shares outstanding - diluted	24,042,293	13,510,629	10,080,525
Year end shares outstanding	28,037,501	18,553,816	11,080,011
Net income (loss) per share - basic	\$(1.46)	\$(3.78)	\$(5.82)
Net income (loss) per share - diluted	\$(1.46)	\$(3.78)	\$(5.82)
Total number of employees	20	27	31
Number of common stockholders	350	387	670
Foreign currency translation adjustments	...	(18,000)	...

Adjusted for 1-for-6 stock split, November 1, 2017; As of March 8, 2018; As of March 11, 2017; As of March 11, 2016; As of March 16, 2018; Approximately; As of March 15, 2017

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
		(revised)
Cash & cash equivalents	37,643,404	56,959,485
Receivables	7,529,032	183,703
Prepaid expenses & other current assets	1,914,077	3,434,238
Total current assets	47,086,513	60,577,426
Equipment & furnishings, gross	2,212,000	2,811,000
Less: accumulated depreciation - equipment & furnishings	1,169,000	851,000
Equipment & furnishings, net	1,042,892	1,959,667
Goodwill	183,780	183,780
Other assets	34,334	48,911
Total assets	48,347,519	62,769,784
Accounts payable	4,122,017	6,406,445
Accrued professional fees	209,000	193,000
Accrued research & development costs	223,000	2,208,000
Litigation settlement	6,450,000	700,000
Accrued wages, bonuses & employee benefits	396,000	487,000
Accrued royalties	626,000	...
Other accrued expenses & other current liabilities	125,000	242,000
Deferred revenue	6,924,353	...
Term loan, net - current	10,599,795	5,481,656
Warrant liabilities	527,025	3,789,391
Total current liabilities	30,202,464	19,507,990
Long term loan, net	...	18,484,510
Total liabilities	30,202,464	37,992,500
Preferred stock	...	518,000
Common stock	28,037	18,553
Additional paid-in capital	468,969,445	440,106,726
Retained earnings (accumulated deficit)	(450,852,427)	(415,865,995)
Total stockholders' equity (deficiency)	18,145,055	24,777,284

Reclassified to conform with 2017 presentation; Rounding difference, breakdown taken from notes

**Recent Dividends:**

**1. CytRx Corp common.**

No dividends paid.

**2. CytRx Corp series B convertible preferred (stated value: \$1,000).**

No dividends paid.  
**Annual Dividends:**  
**1. CytRx Corp common.**  
 No dividends paid.  
**2. CytRx Corp series B convertible preferred (stated value: \$1,000).**  
 No dividends paid.

**DEL TACO RESTAURANTS INC (NEW)**

**Annual Report**

**Consolidated Income Statement, Years Ended (\$):**

	01/02/18	01/03/17	12/29/15
		(revised)	(revised)
Company restaurant sales	452,148,000	434,064,000	206,939,000
Franchise revenue	16,464,000	15,676,000	7,328,000
Franchise sublease income	2,844,000	2,343,000	1,183,000
Total revenue	471,456,000	452,083,000	215,450,000
Restaurant operating expenses - food & paper costs	125,391,000	120,116,000	59,263,000
Restaurant operating expenses - labor & related	145,012,000	135,725,000	61,448,000
Restaurant operating expenses - occupancy & other operating	92,825,000	88,908,000	43,191,000
General & administrative	38,154,000	37,220,000	17,501,000
Depreciation & amortization	23,362,000	23,129,000	11,276,000
Occupancy & other - franchise subleases	2,608,000	2,207,000	1,140,000
Pre-opening costs	1,591,000	731,000	366,000
Restaurant closure charges, net	191,000	435,000	2,015,000
Loss (gain) on disposal of assets	(1,075,000)	(312,000)	(3,000)
Total operating expenses	430,209,000	408,783,000	196,203,000
Income (loss) from operations	41,247,000	43,300,000	19,247,000
Interest expense	7,200,000	6,327,000	3,652,000
Other income	...	...	220,000
Transaction-related costs	...	731,000	12,972,000
Debt modification costs	...	...	78,000
Total other income (expense)	(7,200,000)	(7,058,000)	(16,482,000)
Income (loss) from operations before provision for income taxes	34,047,000	36,242,000	2,765,000
Current federal income taxes	5,884,000	4,204,000	...
Current state income taxes	886,000	270,000	24,000
Current income taxes	6,770,000	4,474,000	24,000
Deferred federal income taxes (benefit)	(24,636,000)	7,145,000	(90,000)
Deferred state income taxes	2,042,000	3,710,000	178,000
Deferred income taxes (benefit)	(22,594,000)	10,855,000	88,000
Provision for income taxes (benefit)	(15,824,000)	15,329,000	112,000
<b>Net income (loss)</b>	<b>49,871,000</b>	<b>20,913,000</b>	<b>2,653,000</b>
Weighted average shares outstanding			
- basic	38,689,508	38,725,541	38,802,425
Weighted average shares outstanding - diluted	39,949,907	39,274,649	40,249,993
Year end shares outstanding	38,434,274	39,153,503	38,802,425

Net income (loss) per common share - basic	\$1.29	\$0.54	\$0.07
Net income (loss) per common share - diluted	\$1.25	\$0.53	\$0.07
Total number of employees	7,656	7,368	6,690
Number of common stockholders	18	22	73

□ Successor; □ 52 weeks; □ 53 weeks; □ 26 weeks; □ Approximately; □ As of March 7, 2018; □ As of March 6, 2017; □ As of March 4, 2016

#### Consolidated Balance Sheet, Years Ended (\$):

	□01/02/18	□01/03/17 (revised)
Cash & cash equivalents	6,559,000	8,795,000
Accounts & other receivables, net	3,828,000	4,141,000
Inventories	2,712,000	2,718,000
Prepaid expenses & other current assets	6,784,000	4,204,000
Total current assets	19,883,000	19,858,000
Land	9,800,000	13,919,000
Buildings	2,325,000	3,391,000
Restaurant & other equipment	74,075,000	58,699,000
Leasehold improvements	100,192,000	78,739,000
Buildings under capital leases	4,625,000	5,433,000
Restaurant property leased to others	3,090,000	...
Construction in progress	11,905,000	8,703,000
Property & equipment, gross	206,012,000	168,884,000
Less: accumulated depreciation	49,888,000	30,564,000
Property & equipment, net	156,124,000	138,320,000
Goodwill	320,638,000	320,025,000
Trademarks	220,300,000	220,300,000
Intangible assets, net	21,498,000	24,782,000
Other assets, net	3,881,000	3,872,000
Total assets	742,324,000	727,157,000
Accounts payable	18,759,000	16,427,000
Employee compensation & related items	12,945,000	13,783,000
Accrued insurance	7,232,000	8,192,000
Accrued sales tax	3,987,000	3,916,000
Accrued real property tax	1,331,000	1,274,000
Restaurant closure liability	794,000	875,000
Accrued advertising	728,000	1,657,000
Other accrued liabilities	8,240,000	6,956,000
Total other accrued liabilities	35,257,000	36,653,000
Current portion of capital lease obligations & deemed landlord financing liabilities	1,415,000	1,588,000
Total current liabilities	55,431,000	54,668,000
2015 senior credit facility	152,001,000	157,616,000
Total outstanding indebtedness	152,001,000	157,616,000
Obligations under capital leases & deemed landlord financing liabilities	20,053,000	17,715,000
Total debt, net	172,054,000	175,331,000
Less: amounts due within one year	1,415,000	1,588,000
Long-term debt, capital lease obligations & deemed landlord financing liabilities, excluding current portion, net	170,639,000	173,743,000
Deferred income taxes	68,574,000	91,273,000
Other non-current liabilities	31,431,000	30,140,000
Total liabilities	326,075,000	349,824,000
Del Taco Restaurants, Inc. (successor) common		

stock	4,000	4,000
Additional paid-in capital	349,334,000	360,131,000
Accumulated other comprehensive income	14,000	172,000
Retained earnings (accumulated deficit)	66,897,000	17,026,000
Total stockholders' equity	416,249,000	377,333,000

□ Successor; □ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. Del Taco Restaurants Inc (New) common stock subject to possible redemption.

No dividends paid.

##### 2. Del Taco Restaurants Inc (New) common.

No dividends paid.

#### Annual Dividends:

##### 1. Del Taco Restaurants Inc (New) common stock subject to possible redemption.

No dividends paid.

##### 2. Del Taco Restaurants Inc (New) common.

No dividends paid.

#### DELCATH SYSTEMS INC

##### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	□2016 (revised)	□2015 (revised)
Total revenue	2,715,000	1,992,000	1,747,000
Cost of goods sold	701,000	550,000	462,000
Gross profit	2,014,000	1,442,000	1,285,000
Selling, general & administrative expenses	9,684,000	9,434,000	10,009,000
Research & development expenses	10,495,000	8,448,000	6,486,000
Total operating expenses	20,179,000	17,882,000	16,495,000
Operating income (loss)	(18,165,000)	(16,440,000)	(15,210,000)
Change in fair value of warrant liability, net	15,103,000	12,780,000	564,000
Gain on warrant extinguishment	9,613,000	...	...
Loss on debt settlements and extinguishments	(29,924,000)	...	...
Other expense & interest expense	21,703,000	14,328,000	67,000
Interest income	(41,000)	17,000	9,000
Net income (loss)	(45,117,000)	(17,971,000)	(14,704,000)
Weighted average shares outstanding - basic	7,019,316	□4,847	2,887
Weighted average shares outstanding - diluted	7,019,316	□4,847	2,887
Year end shares outstanding	114,054,851	□11,750	3,886
Net earnings (loss) per share - basic	\$(6.50)	□\$(3,707.00)	\$(5,096.00)
Net earnings (loss) per share - diluted	\$(6.50)	□\$(3,707.00)	\$(5,096.00)
Number of full time employees	46	43	35
Number of common stockholders	□40	□34	□43
Foreign currency translation adjustments	83,000	(33,000)	(28,000)

□ Reclassified to conform with 2017 presentation; □ Adjusted for 1-for-350 stock split, November 6, 2017; □ As of March 16, 2018; □ As of March 28, 2017; □ As of March 18, 2016

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	□2016 (revised)
Cash & cash equivalents	3,999,000	4,409,000
Restricted cash	1,325,000	27,287,000

Accounts receivables, net	317,000	403,000
Raw materials	298,000	346,000
Work-in-process	721,000	214,000
Finished goods	229,000	100,000
Inventories	1,248,000	660,000
Insurance premiums	421,000	501,000
Financing costs	70,000	...
Security deposit	50,000	50,000
Other current assets	159,000	147,000
Deferred finance costs	...	699,000
Total current assets	7,589,000	34,156,000
Buildings & land	579,000	556,000
Enterprise hardware & software	1,744,000	1,532,000
Leaseholds	1,705,000	1,504,000
Equipment	971,000	940,000
Furniture	175,000	354,000
Property, plant & equipment, gross	5,174,000	4,886,000
Less: accumulated depreciation	3,876,000	3,803,000
Property, plant & equipment, net	1,298,000	1,083,000
Total assets	8,887,000	35,239,000
Accounts payable	3,846,000	594,000
Clinical trial expenses	869,000	1,365,000
Compensation, excluding taxes	1,124,000	933,000
Professional fees	221,000	286,000
Short-term portion of lease restructuring	209,000	216,000
Other accrued expenses	985,000	607,000
Convertible notes payable, net of debt discount	...	13,343,000
Warrant liability	560,000	18,751,000
Total current liabilities	7,814,000	36,095,000
Deferred revenue	...	30,000
Other non-current liabilities	395,000	604,000
Total liabilities	8,209,000	36,729,000
Common stock	1,141,000	...
Additional paid-in capital	324,378,000	277,790,000
Retained earnings (accumulated deficit)	(324,832,000)	(279,188,000)
Treasury stock, at cost	51,000	51,000
Accumulated other comprehensive income (loss)	42,000	(41,000)
Total stockholders' equity	678,000	(1,490,000)

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. Delcath Systems Inc common.

No dividends paid.

#### Annual Dividends:

##### 1. Delcath Systems Inc common.

No dividends paid.

#### DELCATH SYSTEMS INC

##### Auditor's Report Auditor's Report

The following is an excerpt from the Report of Independent Auditors, Grant Thornton LLP, as it appeared in Co.'s 2017 10-K report: "In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring losses from operations and as of December 31, 2017 has an accumulated deficit of \$324.8 million. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also discussed in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

#### DIVERSICARE HEALTHCARE SERVICES, INC.



**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Patient revenues, net	574,794,000	426,063,000	387,595,000
Operating expenses	458,122,000	342,932,000	311,035,000
Lease & rent expense	54,988,000	33,364,000	28,690,000
Professional liability expenses	10,764,000	8,456,000	8,122,000
General & administrative expenses	33,311,000	30,271,000	24,793,000
Depreciation & amortization	10,902,000	8,292,000	7,524,000
Lease termination costs	(180,000)	2,008,000	...
Total expenses	567,907,000	425,323,000	380,164,000
Operating income (loss)	6,887,000	740,000	7,431,000
Equity in net gain (losses) of unconsolidated affiliate	...	273,000	339,000
Gain on bargain purchase	925,000	...	...
Gain on sale of investment in unconsolidated affiliate	733,000	1,366,000	...
Hurricane costs	232,000	...	...
Interest income (expense), net	(6,369,000)	(4,802,000)	(4,102,000)
Debt retirement costs	...	351,000	...
Total other income (expense)	(4,943,000)	(3,514,000)	(3,763,000)
Income (loss) from continuing operations before income taxes	1,944,000	(2,774,000)	3,668,000
Current provision (benefit) - federal	274,000	17,000	1,191,000
Current provision (benefit) - state	472,000	522,000	947,000
Total current income taxes provision (benefit)	746,000	539,000	2,138,000
Deferred provision (benefit) - federal	6,585,000	(1,284,000)	(783,000)
Deferred provision (benefit) - state	(588,000)	(285,000)	(439,000)
Total deferred income taxes provision (benefit)	5,997,000	(1,569,000)	(1,222,000)
Provision (benefit) for income taxes	6,743,000	(1,030,000)	916,000
Income (loss) from continuing operations	(4,799,000)	(1,744,000)	2,752,000
Income (loss) from discontinued operations - operating income (loss)	(28,000)	(67,000)	(1,128,000)
Income (loss) from discontinued operations	(28,000)	(67,000)	(1,128,000)
Net income (loss)	(4,827,000)	(1,811,000)	1,624,000
Weighted average common shares outstanding - basic	6,279,000	6,199,000	6,100,000
Weighted average common shares outstanding - diluted	6,279,000	6,199,000	6,315,000
Year end common shares outstanding	6,455,000	6,361,000	6,281,000
Income (loss) per common share from continuing operations - basic	\$(0.76)	\$(0.28)	\$0.45
Income (loss) per			

common share from discontinued operations - basic	\$(0.01)	\$(0.01)	\$(0.18)
Net income (loss) per common share - basic	\$(0.77)	\$(0.29)	\$0.27
Income (loss) per common share from continuing operations - diluted	\$(0.76)	\$(0.28)	\$0.44
Income (loss) per common share from discontinued operations - diluted	\$(0.01)	\$(0.01)	\$(0.18)
Net income (loss) per share - diluted	\$(0.77)	\$(0.29)	\$0.26
Dividends per common share	\$0.22	\$0.22	\$0.22
Number of full time employees	256,300	256,700	254,500
Number of part time employees	252,500	254,700	251,800
Total number of employees	258,800	257,400	256,300
Number of common stockholders	25261	25264	25269

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	3,524,000	4,263,000
Medicare	20,007,000	20,402,000
Medicaid & other non-federal government programs	29,453,000	31,208,000
Other patient & resident receivables	29,704,000	20,868,000
Less: allowance for doubtful accounts	14,235,000	10,326,000
Receivables	64,929,000	62,152,000
Other receivables	375,000	1,193,000
Prepaid expenses & other current assets	3,248,000	3,623,000
Income tax refundable	537,000	431,000
Current assets of discontinued operations	45,000	28,000
Total current assets	72,658,000	71,690,000
Land	6,521,000	5,761,000
Buildings & leasehold improvements	98,140,000	85,660,000
Furniture, fixtures & equipment	42,888,000	37,401,000
Property & equipment, at cost	147,549,000	128,822,000
Less: accumulated depreciation	78,345,000	69,022,000
Property & equipment, net	69,204,000	59,800,000
Deferred income taxes	15,154,000	21,185,000
Deferred leasehold costs, net	137,000	193,000
Other noncurrent assets	3,725,000	3,108,000
Acquired leasehold interest, net	6,691,000	7,075,000
Total assets	167,569,000	163,051,000
Current portion of long-term debt & capitalized lease obligations	13,065,000	7,715,000
Trade accounts payable	14,080,000	12,972,000
Current liabilities of discontinued operations	461,000	427,000
Accrued payroll & employee benefits	20,013,000	20,108,000
Accrued self-insurance reserves, current portion	8,792,000	9,401,000
Provider taxes	3,090,000	3,114,000

Other current liabilities	4,766,000	4,432,000
Total current liabilities	64,267,000	58,169,000
Mortgage loan with a syndicate of banks	64,567,000	58,792,000
Acquisition loan with Canadian Imperial Bank of Commerce	7,500,000	6,289,000
Revolving credit facility borrowings payable to a bank	16,000,000	15,000,000
Loan to finance equipment	40,000	...
Less: current portion	13,065,000	7,715,000
Long-term debt & capitalized lease obligations, less current portion	75,042,000	72,366,000
Less: deferred financing costs	(1,884,000)	(2,273,000)
Plus capitalized lease obligations	1,445,000	2,052,000
Long-term debt & capitalized lease obligations, less current portion & deferred financing costs	74,603,000	72,145,000
Self-insurance reserves, noncurrent portion	13,458,000	11,766,000
Other noncurrent liabilities	8,779,000	9,551,000
Total noncurrent liabilities	96,840,000	93,462,000
Common stock	67,000	66,000
Treasury stock at cost	2,500,000	2,500,000
Paid-in capital	22,720,000	21,935,000
Retained earnings (accumulated deficit)	(14,534,000)	(8,276,000)
Accumulated other comprehensive income (loss)	709,000	195,000
Total shareholders' equity of Advocate Inc.	6,462,000	11,420,000
Total shareholders' equity	6,462,000	11,420,000

Reclassified to conform with 2017 presentation

**Recent Dividends:**

**1. Diversicare Healthcare Services, Inc. series B redeemable convertible preferred.**  
No dividends paid.

**2. Diversicare Healthcare Services, Inc. series C redeemable preferred.**  
No dividends paid.

**3. Diversicare Healthcare Services, Inc. common.**

ExDate	Amt	Declared	Record	Payable
12/29/2014	0.06	11/07/2014	12/31/2014	01/14/2015
03/27/2015	0.06	02/27/2015	03/31/2015	04/14/2015
06/26/2015	0.06	05/06/2015	06/30/2015	07/14/2015
09/28/2015	0.06	08/05/2015	09/30/2015	10/14/2015
12/29/2015	0.06	11/04/2015	12/31/2015	01/15/2016
03/29/2016	0.06	02/26/2016	03/31/2016	04/14/2016
06/28/2016	0.06	04/28/2016	06/30/2016	07/12/2016
09/28/2016	0.06	08/02/2016	09/30/2016	10/14/2016
12/28/2016	0.06	10/27/2016	12/31/2016	01/13/2017
03/29/2017	0.06	02/24/2017	03/31/2017	04/14/2017
06/28/2017	0.06	04/28/2017	06/30/2017	07/14/2017
09/28/2017	0.06	07/27/2017	09/30/2017	10/16/2017
12/28/2017	0.06	10/26/2017	12/31/2017	01/15/2018

**Annual Dividends:**

**1. Diversicare Healthcare Services, Inc. series B redeemable convertible preferred.**  
No dividends paid.

**2. Diversicare Healthcare Services, Inc. series C redeemable preferred.**  
No dividends paid.

**3. Diversicare Healthcare Services, Inc. common.**

2015	0.22	2016	0.22	2017	0.22
2018	0.06				

**EMPIRE RESORTS INC**

**Annual Report  
Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	<sup>□</sup> 2016 (revised)	<sup>□</sup> 2015 (revised)							
Revenues - gaming	60,540,000	59,633,000	60,463,000	Vehicles	355,000	307,000	administrative	12,103,423	11,248,435	8,030,995
Revenues - food, beverage, racing & other revenues	9,353,000	10,668,000	11,171,000	Furniture, fixtures & equipment	5,196,000	4,278,000	Total operating expenses	50,541,837	47,282,661	30,077,339
Less promotional allowances	4,042,000	2,847,000	3,468,000	Construction in progress	77,000	919,000	Income (loss) from operations	(49,387,828)	(45,830,720)	(27,577,339)
Net revenues	65,851,000	67,454,000	68,166,000	Property & equipment, net	26,863,000	26,415,000	Interest income (expense), net	11,679	13,326	15,637
Gaming costs & expenses	44,486,000	44,238,000	44,525,000	Capitalized project development costs	566,797,000	202,438,000	Loss on sale of property & equipment	(726)	...	...
Food, beverage, racing & other costs & expenses	9,709,000	10,174,000	10,493,000	Restricted cash & investments for Development Projects	136,431,000	26,384,000	Total other (expense) income	10,953	13,326	15,637
Selling, general & administration expense	15,743,000	19,692,000	12,648,000	Intangible assets	51,000,000	51,000,000	<b>Net income (loss)</b>	(49,376,875)	(45,817,394)	(27,561,702)
Development Projects expenses	21,558,000	12,970,000	32,514,000	Cash collateral for deposit bond	35,000,000	15,000,000	Weighted average shares outstanding - basic	21,343,001	17,649,013	13,303,715
Stock-based compensation	2,755,000	2,722,000	596,000	Other assets	251,000	1,175,000	Weighted average shares outstanding - diluted	21,343,001	17,649,013	13,303,715
Depreciation	1,517,000	1,341,000	1,350,000	Total assets	832,238,000	339,758,000	Year end shares outstanding	22,584,588	20,367,929	<sup>□</sup> 16,298,208
Total operating costs & expenses	95,768,000	91,137,000	102,126,000	Accounts payable	2,686,000	2,268,000	Net earnings (loss) per share - basic	\$(2.31)	\$(2.60)	\$(2.07)
Income (loss) from operations	(29,917,000)	(23,683,000)	(33,960,000)	Current portion of lg-term debt	14,588,000	...	Net earnings (loss) per share - diluted	\$(2.31)	\$(2.60)	\$(2.07)
Interest expense	19,269,000	524,000	2,643,000	Accrued Development Projects costs	71,712,000	41,933,000	Number of full time employees	<sup>□</sup> 68	<sup>□</sup> 73	<sup>□</sup> 52
Interest income	2,842,000	10,000	...	Liability for horseracing purses	886,000	1,139,000	Number of common stockholders	13	14	22
Income (loss) before income taxes	(46,344,000)	(24,197,000)	(36,603,000)	Accrued payroll	1,715,000	1,897,000				
Income tax provision (benefit)	...	...	7,000	Accrued redeemable points	271,000	167,000				
<b>Net income (loss)</b>	(46,344,000)	(24,197,000)	(36,610,000)	Liability to New York State Gaming Commission	1,507,000	360,000				
Undeclared dividends on preferred stock	128,000	168,000	178,000	Liability for local progressive jackpot	1,110,000	907,000				
Net income (loss) applicable to common shares	(46,472,000)	(24,365,000)	(36,788,000)	Accrued settlement liability	...	758,000				
Weighted average shares outstanding - basic	30,981,000	28,221,000	10,749,000	Accrued professional fees	744,000	308,000				
Weighted average shares outstanding - diluted	30,981,000	28,221,000	10,749,000	Federal tax withholding payable	...	78,000				
Year end shares outstanding	32,560,000	<sup>□</sup> 31,156,000	9,561,000	Accrued other expenses	1,087,000	1,733,000				
Net earnings (loss) per share - basic	\$(1.50)	\$(0.86)	\$(3.42)	Total current liabilities	96,306,000	51,548,000				
Net earnings (loss) per share - diluted	\$(1.50)	\$(0.86)	\$(3.42)	Long-term debt, less current maturities	455,148,000	...				
Number of full time employees	<sup>□</sup> 1,600	...	...	Other long-term liabilities	9,463,000	8,644,000				
Number of part time employees	<sup>□</sup> 150	...	...	Total liabilities	560,917,000	60,192,000				
Total number of employees	<sup>□</sup> 1,750	...	<sup>□</sup> 277	Common stock	326,000	312,000				
Number of common stockholders	<sup>□</sup> 183	<sup>□</sup> 204	<sup>□</sup> 211	Additional paid-in capital	572,342,000	533,813,000				

<sup>□</sup> Reclassified to conform with 2017 presentation; <sup>□</sup> Reclassified to conform with 2016 presentation; <sup>□</sup> Share increased due to the effect of conversion of Kien Huat note, issuance of common stock for exercise of rights offering; <sup>□</sup> Approximately; <sup>□</sup> As of March 15, 2018; <sup>□</sup> As of March 3, 2016; <sup>□</sup> As of March 12, 2018; <sup>□</sup> As of March 10, 2017

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	<sup>□</sup> 2016 (revised)
Cash & cash equivalents	10,380,000	11,012,000
Restricted cash	693,000	1,078,000
Accounts receivable, gross	1,444,000	1,092,000
Allowance for doubtful accounts	171,000	171,000
Accounts receivable, net	1,273,000	921,000
Prepaid expenses & other current assets	3,550,000	4,335,000
Total current assets	15,896,000	17,346,000
Land	770,000	770,000
Land improvements	1,759,000	1,758,000
Buildings	4,727,000	4,727,000
Buildings improvements	29,874,000	28,088,000

<sup>□</sup> Reclassified to conform with 2017 presentation

#### Recent Dividends:

1. Empire Resorts Inc common. No dividends paid.
2. Empire Resorts Inc series E non-convertible preferred, \$10.00 redemption value. No dividends paid.
3. Empire Resorts Inc series B convertible preferred. No dividends paid.

#### Annual Dividends:

1. Empire Resorts Inc common. No dividends paid.
2. Empire Resorts Inc series E non-convertible preferred, \$10.00 redemption value. No dividends paid.
3. Empire Resorts Inc series B convertible preferred. No dividends paid.

#### ENERGIOUS CORP

##### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	<sup>□</sup> 2015 (revised)
Revenue	1,154,009	1,451,941	2,500,000
Research & development	33,230,668	32,832,677	18,825,041
Sales & marketing	5,207,746	3,201,549	3,221,303
General &			

<sup>□</sup> Reclassified to conform with 2016 presentation; <sup>□</sup> Shares increased due to issuance of shares for services, restricted stock units, performance share units, exercise of stock options, cashless exercise of warrants & secondary offering; <sup>□</sup> As of March 2, 2018; <sup>□</sup> As of March 15, 2017; <sup>□</sup> As of March 14, 2016

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016
Cash & cash equivalents	12,795,254	31,258,637
Accounts receivable	...	149,500
Prepaid expenses & other current assets	1,026,310	1,374,585
Prepaid rent, current	80,784	80,784
Total current assets	13,902,348	32,863,506
Computer software	1,418,457	1,085,258
Computer hardware	2,289,687	2,109,983
Furniture & fixtures	529,287	533,175
Leasehold improvements	613,111	613,111
Property & equipment, gross	4,850,542	4,341,527
Less - accumulated depreciation	3,436,625	2,132,052
Property & equipment, net	1,413,917	2,209,475
Prepaid rent, non-current	56,668	137,452
Other assets	32,512	48,507
Total assets	15,405,445	35,258,940
Accounts payable	2,024,690	4,707,763
Accrued compensation	948,935	997,908
Accrued legal expenses	445,684	283,160
Accrued equipment cost	...	299,500
Other accrued expenses	227,406	287,427
Accrued expenses	1,622,025	1,867,995
Deferred revenues	...	131,959
Total current liabilities	3,646,715	6,707,717
Common stock	225	202
Additional paid-in capital	185,659,954	153,075,595
Retained earnings (accumulated deficit)	(173,901,449)	(124,524,574)
Total stockholders' equity (deficit)	11,758,730	28,551,223

#### Recent Dividends:

1. Energoous Corp common. No dividends paid.
- #### Annual Dividends:
1. Energoous Corp common. No dividends paid.

#### ENERGY FOCUS INC

##### Annual Report

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
Net sales	19,846	30,998	64,403
Cost of sales	15,025	23,321	35,111
Gross profit	4,821	7,677	29,292
Product development	2,940	3,537	2,810
Selling, general & administrative expenses	11,315	20,113	16,830
Loss on impairment	185	857	...
Restructuring expenses	1,662	...	...
Total operating expenses	16,102	24,507	19,640
Income (loss) from operations	(11,281)	(16,830)	9,652
Interest expense	2	...	85
Other income (expense)	(99)	(18)	53
Income (loss) from continuing operations before income taxes - United States	(11,382)	(16,848)	9,620
Income (loss) from continuing operations before income taxes - foreign	(11,382)	(16,848)	9,620
Current income tax expense (benefit) - state	10	26	26
Total current income tax expense (benefit)	10	27	149
Deferred income tax expense (benefit) - federal	(125)	...	...
Total deferred income tax expense (benefit)	(125)	...	...
Provision for income taxes	(115)	27	149
Net income (loss) from continuing operations	(11,267)	(16,875)	9,471
Income (loss) from discontinued operations	...	...	(167)
Gain (loss) on sale of discontinued operations	...	(12)	(534)
Discontinued operations - provision for income taxes	...	...	10
Net income (loss) from discontinued operations	...	(12)	(691)
<b>Net income (loss)</b>	<b>(11,267)</b>	<b>(16,887)</b>	<b>8,780</b>
Weighted average shares outstanding - basic	11,806	11,673	10,413
Weighted average shares outstanding - diluted	11,806	11,673	10,752
Year end shares outstanding	11,869	11,711	11,649
Income (loss) per share - continuing operations - basic	\$(0.95)	\$(1.45)	\$0.91
Income (loss) per share - discontinued operations - basic	...	...	\$(0.07)
Net income (loss) per share - basic	\$(0.95)	\$(1.45)	\$0.84
Income (loss) per share - continuing operations	...	...	...

operations - diluted	\$(0.95)	\$(1.45)	\$0.88
Income (loss) per share - discontinued operations - diluted	...	...	\$(0.06)
Net income (loss) per share - diluted	\$(0.95)	\$(1.45)	\$0.82
Number of full time employees	74	131	122
Number of common stockholders	86	93	105
Foreign currency translation adjustments	3	(1)	(469)

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
Cash & cash equivalents	10,761	16,629	...
Trade accounts receivable, gross	3,637	5,876	...
Less: allowances for doubtful accounts	42	236	...
Trade accounts receivable, net	3,595	5,640	...
Raw materials	3,316	5,049	...
Finished goods	6,598	10,016	...
Less: reserve for excess, obsolete, & slow moving inventories	4,196	5,596	...
Inventories, net	5,718	9,469	...
Prepaid & other current assets	596	882	...
Assets held for sale	225	...	...
Total current assets	20,895	32,620	...
Equipment	1,557	2,231	...
Tooling	371	863	...
Vehicles	47	39	...
Furniture & fixtures	137	170	...
Computer software	1,043	977	...
Leasehold improvements	201	256	...
Construction in progress	55	154	...
Property & equipment at cost	3,411	4,690	...
Less: accumulated depreciation	2,314	2,365	...
Property & equipment, net	1,097	2,325	...
Other assets	159	33	...
Total assets	22,151	34,978	...
Accounts payable	1,630	3,257	...
Accrued payroll & related benefits	394	522	...
Accrued sales commissions & incentives	124	325	...
Accrued warranty expense	174	331	...
Accrued severance & related benefits	...	328	...
Accrued restructuring	170	...	...
Accrued legal & professional fees	77	63	...
Accrued other expenses	53	107	...
Deferred revenue	5	...	...
Total current liabilities	2,627	4,933	...
Other liabilities	232	107	...
Total liabilities	2,859	5,040	...
Common stock	1	1	...
Additional paid-in capital	127,493	126,875	...
Accumulated other comprehensive income (loss)	2	(1)	...
Retained earnings (accumulated deficit)	(108,204)	(96,937)	...
Total stockholders' equity	19,292	29,938	...

□ Reclassified to conform with 2017 presentation

**Recent Dividends:**  
**1. Energy Focus Inc common.**  
 No dividends paid.

**Annual Dividends:**  
**1. Energy Focus Inc common.**  
 No dividends paid.

**ENUMERAL BIOMEDICAL HOLDINGS INC**  
**Bankruptcy Proceedings** On Mar. 15, 2018, Co. filed with the U.S. Bankruptcy Court a First Amended Chapter 11 Plan and related Disclosure Statement. According to the Disclosure Statement, "The Plan provides that, subject to paying the expenses of the chapter 11 case as determined by the Bankruptcy Court, all funds of the Debtors will be paid to their creditors. These funds are almost entirely attributable to the Noteholder Payment. Instead of corporate managers and a board of directors, the Debtors will be under the control of a Plan Trustee - a fiduciary who acts for the benefit of creditors, under the supervision of the Bankruptcy Court. The Plan provides for substantive consolidation of the bankruptcy estates of the three Debtors. This means that the three Debtors will be treated like a single legal entity for the purpose of allowing claims and distributing funds to creditors. Each creditor of any one (or more than one) Debtor will have a single claim against the combined bankruptcy estate, which will receive a pro rata distribution based on the Allowed Amount of its claim. If you supplied goods or services to any of the Debtors before the Debtors filed their chapter 11 petitions on Jan. 29, 2018, and you have not been paid, then the amount you are owed is likely a General Unsecured Claim. The Debtors believed that the Plan provides general unsecured creditors with the best opportunity to realize the highest possible return on account of their Claims." In a separate motion the Debtors requested that the Court schedule a Disclosure Statement hearing to take place on an expedited basis. Also on Mar. 15, 2018, Co. filed with the U.S. Bankruptcy Court settlement agreement with Co.'s noteholders. The motion explains, "The Settlement Stipulation provides a comprehensive resolution of this case, including all issues among the Debtors and Noteholders. As further explained below, the Settlement Stipulation provides that (a) the Debtors will propose and the Noteholders/Collateral Agent will support a chapter 11 plan in the form annexed to the Settlement Stipulation (the 'Agreed Plan'), (b) pursuant to the Agreed Plan, the assets associated with the Debtors' PD-1 antibody program (the 'PD-1 Assets') will be transferred to an entity formed by the Noteholders, (c) the Noteholders will release their claims and pay \$847,000 in cash to the estate, which will be used to pay administrative expenses, priority claims and a substantial distribution on account of general unsecured claims." The Debtors also filed a separate motion for expedited consideration of the settlement and Co.'s Disclosure Statement. The motion explains, "Debtors respectfully request that the Court (a) schedule a hearing on the Settlement Motion and Disclosure Statement Motion for Mar. 21, 2018 or as soon thereafter as the Court's calendar permits; (b) set an objection deadline for the Settlement Motion and Disclosure Statement Motion at 4:00 p.m. the day prior to the hearing; (c) relieve the Debtors from the requirement that they provide all equity security holders with notice of the time fixed for filing objections to and the hearing to consider approval of a disclosure statement; and (d) grant such other and further relief that this Court deems just and proper."

**ENUMERAL BIOMEDICAL HOLDINGS INC**  
**Bankruptcy Proceedings** On Mar. 16, 2018, the U.S. Bankruptcy Court issued an order denying Co.'s motion for expedited consideration of Co.'s Disclosure Statement and settlement motion. The order states, "Expedited determination is denied as to both the Motion to Approve Settlement [doc. #79] and the Motion to Approve Disclosure Statement [doc. #83]. Limitation of notice is likewise denied as to both motions. Equity security holders are entitled to notice of the proposed settlement, which obviously is highly consequential for the balance of the case. And they and all creditors are entitled to the benefit of the full notice period. The Court will set both matters for hearing in the ordinary course."

**ESPORTS ENTERTAINMENT GROUP INC**  
**Resignation of Accountant** On Mar. 8, 2018, PLS CPA resigned as Co.'s independent public accounting firm.

**EVOFEM BIOSCIENCES INC**  
**Annual Report**  
**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Research & development expenses	3,945,757	6,578,678	34,409,664

General & administrative expenses	6,098,944	5,463,622	7,639,427
Total operating expenses	10,044,701	12,042,300	42,049,091
Income (loss) from operations	(10,044,701)	(12,042,300)	(42,049,091)
Interest income	51,250	59,465	26,033
Interest expense	...	1,035,763	1,133,987
<b>Net income (loss)</b>	<b>(9,993,451)</b>	<b>(13,018,598)</b>	<b>(43,157,045)</b>
Weighted average shares outstanding - basic	2,305,817	2,300,167	2,282,672
Weighted average shares outstanding - diluted	2,305,817	2,300,167	2,282,672
Year end shares outstanding	2,308,430	2,304,749	2,291,669
Net earnings (loss) per share - basic	\$(4.33)	\$(5.66)	\$(18.91)
Net earnings (loss) per share - diluted	\$(4.33)	\$(5.66)	\$(18.91)
Number of full time employees	23	...	...
Number of common stockholders	31	...	...

<sup>1</sup> Restated to reflect the adoption of FASB ASU No 2016-18 (Topic 230); <sup>2</sup> Adjusted for 1-for-6 stock split, January 18, 2018; <sup>3</sup> As of February 9, 2018

<b>Consolidated Balance Sheet, Years Ended Dec. 31 (\$):</b>			
	2017	2016 (revised)	2015 (revised)
Cash & cash equivalents	3,416,960	11,477,852	...
Prepaid expenses & other current assets	608,432	1,029,546	...
Total current assets	4,025,392	12,507,398	...
Restricted cash	93,382	200,000	...
Office furniture & equipment	92,373	254,049	...
Less accumulated depreciation & amortization	92,373	144,729	...
Property & equipment, net	...	109,320	...
Total assets	4,118,774	12,816,718	...
Accounts payable	566,253	503,739	...
Accrued expenses	845,768	398,453	...
Total current liabilities	1,412,021	902,192	...
Common stock	231	230	...
Additional paid-in capital	138,550,328	137,764,651	...
Retained earnings (accumulated deficit)	(135,843,806)	(125,850,355)	...
Total stockholders' equity (deficit)	2,706,753	11,914,526	...

<sup>1</sup> Restated to reflect the adoption of FASB ASU No 2016-18, (Topic 230)

#### Recent Dividends:

##### 1. Evofem Biosciences Inc common.

No dividends paid.

#### Annual Dividends:

##### 1. Evofem Biosciences Inc common.

No dividends paid.

#### EVOFEM BIOSCIENCES INC

##### Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Ernst & Young LLP, as it appeared in Co.'s December 31, 2017 10-K: "Opinion on the Financial Statements: We have audited the accompanying balance sheets of Evofem Biosciences, Inc. (formerly Neothetics, Inc.), or the Company, as of December 31, 2017 and 2016, the related statements of operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles. The Company's

Ability to Continue as a Going Concern: The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

#### EVOKE PHARMA INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Research & development	7,137,493	6,951,600	8,154,144
General & administrative	4,093,189	3,592,825	3,664,159
Total operating expenses	11,230,682	10,544,425	11,818,303
Income (loss) from operations	(11,230,682)	(10,544,425)	(11,818,303)
Interest expense	...	...	303,160
Interest income (expense), net	6,519	(268,029)	...
Financing costs related to warrant liability	...	533,692	...
Change in fair value of warrant liability	(1,005,349)	597,615	...
Total other income (expense)	(998,830)	(204,106)	(303,160)
<b>Net income (loss)</b>	<b>(12,229,512)</b>	<b>(10,748,531)</b>	<b>(12,121,463)</b>
Weighted average shares outstanding - basic	14,897,885	9,338,068	6,485,794
Weighted average shares outstanding - diluted	14,951,036	9,338,068	6,485,794
Year end shares outstanding	15,413,610	12,350,360	7,201,774
Net earnings (loss) per share - basic	\$(0.82)	\$(1.15)	\$(1.87)
Net earnings (loss) per share - diluted	\$(0.90)	\$(1.15)	\$(1.87)
Number of full time employees	7	7	7
Number of common stockholders	17	17	29

<sup>1</sup> Reclassified to conform with 2017 presentation; <sup>2</sup> Reclassified to conform with 2016 presentation; <sup>3</sup> As of February 28, 2018; <sup>4</sup> As of March 10, 2017; <sup>5</sup> As of February 29, 2016

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Cash & cash equivalents	7,679,267	9,007,071	...
Prepaid expenses	251,046	267,711	...
Other current assets	...	7,997	...
Total current assets	7,930,313	9,282,779	...
Other assets	11,551	11,551	...
Total assets	7,941,864	9,294,330	...
Accounts payable & accrued expenses	1,048,927	478,223	...
Accrued compensation	1,025,911	933,450	...
Total current liabilities	2,074,838	1,411,673	...
Warrant liability	3,701,277	4,095,019	...
Total liabilities	5,776,115	5,506,692	...
Common stock	1,541	1,235	...
Additional paid-in capital	73,202,863	62,595,546	...
Retained earnings (accumulated deficit)	(71,038,655)	(58,809,143)	...
Total stockholders' equity (deficit)	2,165,749	3,787,638	...

#### Recent Dividends:

##### 1. Evoke Pharma Inc common.

No dividends paid.

#### Annual Dividends:

#### 1. Evoke Pharma Inc common.

No dividends paid.

#### EVOKE PHARMA INC

##### Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, BDO USA, LLP, as it appeared in Co.'s 2017 10-K: "In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

#### EXCO RESOURCES INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Oil	57,693,000	67,317,000	102,787,000
Natural gas	201,137,000	181,332,000	226,471,000
Purchased natural gas & marketing	24,816,000	22,352,000	26,442,000
Total revenues	283,646,000	271,001,000	355,700,000
Oil & natural gas operating costs	35,011,000	34,609,000	53,903,000
Production & ad valorem taxes	13,131,000	15,380,000	22,630,000
Gathering & transportation	111,427,000	106,460,000	99,321,000
Purchased natural gas	23,400,000	23,557,000	27,369,000
Depletion, depreciation & amortization	51,040,000	75,982,000	215,426,000
Impairment of oil & natural gas properties	...	160,813,000	1,215,370,000
Accretion of discount on asset retirement obligations	874,000	2,210,000	2,277,000
General & administrative	30,165,000	48,700,000	58,818,000
Gain (loss) on divestitures & other operating items	(59,154,000)	(24,239,000)	(461,000)
Total costs & expenses	324,202,000	491,950,000	1,695,575,000
Operating income (loss)	(40,556,000)	(220,949,000)	(1,339,875,000)
Interest expense, net	108,175,000	70,438,000	106,082,000
Gain (loss) on derivative financial instruments - commodity derivatives	24,732,000	(34,137,000)	75,869,000
Gain (loss) on derivative financial instruments - common share warrants	159,190,000	...	...
Gain on restructuring & extinguishment of debt	(6,380,000)	119,457,000	193,276,000
Other income (expense)	31,000	43,000	122,000
Equity income (loss)	(4,184,000)	(16,432,000)	(15,691,000)
Total other income (expense)	65,214,000	(1,507,000)	147,494,000
Income (loss) before income taxes	24,658,000	(222,456,000)	(1,192,381,000)

Current federal income tax expense (benefit)	(1,420,000)	...	...
Total current income tax expense (benefit)	(1,420,000)	...	...
Deferred federal income tax expense (benefit)	528,886,000	(72,020,000)	(414,834,000)
Deferred state income tax expense (benefit)	(1,496,000)	(7,637,000)	(45,009,000)
Valuation allowance	(525,674,000)	82,459,000	459,843,000
Total deferred income tax expense (benefit)	1,716,000	2,802,000	...
Income tax expense (benefit)	296,000	2,802,000	...
<b>Net income (loss)</b>	<b>24,362,000</b>	<b>(225,258,000)</b>	<b>(1,192,381,000)</b>
Net income (loss) available to common shareholders	24,362,000	(225,258,000)	(1,192,381,000)
Weighted average shares outstanding - basic	21,288,000	18,630,000	18,241,400
Weighted average shares outstanding - diluted	21,288,000	18,630,000	18,241,400
Year end shares outstanding	21,630,541	18,876,307	18,869,289
Net income (loss) per share - basic	\$1.14	\$(12.09)	\$(65.37)
Net income (loss) per share - diluted	\$1.14	\$(12.09)	\$(65.37)
Total number of employees	168	183	315
Total number of stockholders	132	127	168

□ Reclassified to conform with 2017 presentation; ▢ Adjusted for 1-for-15 stock split, June 13, 2017

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	39,597,000	9,068,000
Restricted cash	15,271,000	11,150,000
Accounts receivable, net - oil & natural gas	55,692,000	52,674,000
Accounts receivable, net - joint interest	30,570,000	25,905,000
Accounts receivable - other	1,976,000	3,813,000
Derivative financial instruments	1,150,000	...
Inventory & other current assets	23,574,000	8,007,000
Total current assets	167,830,000	110,617,000
Equity investments	14,181,000	24,365,000
Unproved oil & natural gas properties & development costs not being amortized	118,652,000	97,080,000
Proved developed & undeveloped oil & natural gas properties	3,107,566,000	2,939,923,000
Accumulated depletion	2,752,311,000	2,702,245,000
Oil & natural gas properties, net	473,907,000	334,758,000
Other property & equipment, net	21,274,000	23,661,000
Deferred financing costs, net	...	4,376,000
Derivative financial instruments	...	482,000
Goodwill	163,155,000	163,155,000
Total assets	840,347,000	661,414,000
Accounts payable & accrued liabilities	68,277,000	54,762,000
Revenues & royalties payable	207,956,000	120,845,000
Accrued interest payable	27,637,000	4,701,000
Current portion of asset retirement obligations	600,000	344,000

Derivative financial instruments - commodity derivatives	...	27,711,000
Current portion of long-term debt	1,362,500,000	50,000,000
Total current liabilities	1,666,970,000	258,363,000
Revolving credit facility under EXCO resources credit agreement	126,401,000	228,592,000
1.5 lien notes, net of unamortized discount	176,560,000	...
1.75 lien term loans, net of unamortized discount	845,763,000	...
Exchange term loan	23,543,000	590,477,000
Fairfax Financial Holdings Limited term loan	...	300,000,000
2018 notes	131,345,000	131,056,000
2022 notes	70,169,000	70,169,000
Deferred financing costs, net	(11,281,000)	(11,756,000)
Less amounts due within one year	1,362,500,000	50,000,000
Deferred income taxes	4,518,000	2,802,000
Derivative financial instruments - commodity derivatives	...	464,000
Derivative financial instruments - common share warrants	1,950,000	...
Asset retirement obligations & other long-term liabilities	13,108,000	13,153,000
Common shares	22,000	19,000
Additional paid-in capital	3,539,422,000	3,538,080,000
Retained earnings (accumulated deficit)	(4,378,011,000)	(4,402,373,000)
Treasury stock, at cost	7,632,000	7,632,000
Total shareholders' equity (deficit)	(846,199,000)	(871,906,000)

□ Reclassified to conform with 2017 presentation

**Recent Dividends:**

- EXCO Resources Inc hybrid preferred.**  
No dividends paid.
- EXCO Resources Inc common.**  
No dividends paid.
- EXCO Resources Inc 7.0% cumulative convertible perpetual preferred.**  
No dividends paid.

**Annual Dividends:**

- EXCO Resources Inc hybrid preferred.**  
No dividends paid.
- EXCO Resources Inc common.**  
No dividends paid.
- EXCO Resources Inc 7.0% cumulative convertible perpetual preferred.**  
No dividends paid.

**EXCO RESOURCES INC**

**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditor, KPMG LLP, as it appeared in Co.'s 2017 10K report: "These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well

as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in note 1 to the consolidated financial statements, the Company filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code on January 15, 2018, which raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to this matter are also described in note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**EYEGATE PHARMACEUTICALS, INC.**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015
--	------	----------------	------

Collaboration revenue	407,518	669,259	...
Research & development expenses	10,330,349	8,422,542	2,717,110
General & administrative expenses	4,636,408	5,593,563	3,960,498
Total operating expenses	14,966,757	14,016,105	6,677,608
Interest income	564	3,684	947
Change in fair value of warrant liability	...	...	223,172
Interest expense	1,215	275	1,934,493
Other income	...	...	10
Total other income (expense), net	(651)	3,409	(1,710,364)
Income (loss) before income taxes - domestic	(15,102,521)	(13,831,191)	...
Income (loss) before income taxes - foreign	542,631	487,754	...
Income (loss) before income tax benefit	(14,559,890)	(13,343,437)	...
Deferred federal income taxes	(1,160,312)	...	...
Deferred state income taxes	(181,661)	...	...
Total deferred income taxes	(1,341,973)	...	...
Income tax benefit	(1,341,973)	...	...
<b>Net income (loss)</b>	<b>(13,217,917)</b>	<b>(13,343,437)</b>	<b>(8,387,972)</b>
Deemed dividend on preferred stock	...	...	8,222,008
Net income (loss) attributable to non-controlling interest	...	...	(5,177)
Net income (loss) attributable to EyeGate Pharmaceuticals, Inc. stockholders	(13,217,917)	(13,343,437)	(16,615,157)
Weighted average shares outstanding - basic	14,260,103	8,833,898	6,164,064
Weighted average shares outstanding - diluted	14,260,103	8,833,898	6,164,064
Year end shares outstanding	17,257,255	10,130,883	7,657,287
Net income (loss) per common share - basic	\$(0.93)	\$(1.51)	\$(2.70)
Net income (loss) per common share - diluted	\$(0.93)	\$(1.51)	\$(2.70)
Number of full time employees	17	...	5
Number of common stockholders	65	...	88

□ Restated to reflect adoption of ASU No. 2016-18, Restricted

Cash; <sup>□</sup> Shares increased due to the effect of issuance of common shares, series B preferred shares and restricted stock, conversion of series B preferred stock and exercise of common stock options; <sup>□</sup> Shares increased due to the effect of issuance of common shares, holdback shares, conversion of series A preferred stock and exercise of common stock option; <sup>□</sup> Increase in shares due to IPO, secondary public offering, conversion of preferred stock and conversion of promissory notes; <sup>□</sup> As of February 28, 2018; <sup>□</sup> As of March 28, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	7,806,029	3,635,224
License & grant fees receivable	...	37,349
Prepaid expenses & other current assets	629,591	464,981
Current portion of refundable tax credit receivable	23,685	16,484
Total current assets	8,459,305	4,154,038
Laboratory equipment	42,576	42,576
Office furniture	14,430	...
Leasehold improvements	22,569	...
Property & equipment, gross	79,575	42,576
Less: accumulated depreciation	23,824	4,536
Property & equipment, net	55,751	38,040
Restricted cash	45,000	45,000
Goodwill & in-process	...	...
R&D	5,438,210	5,438,210
Other assets	307,126	55,314
Total assets	14,305,392	9,730,602
Accounts payable	706,089	1,412,128
Accrued clinical trials	807,322	770,158
Accrued payroll & benefits	788,551	668,802
Accrued professional fees	149,273	174,342
Accrued consulting	57,487	44,983
Short-term portion of capital lease obligation	11,214	12,645
Accrued expenses	1,813,847	1,670,930
Deferred revenue	12,313,600	4,225,000
Total current liabilities	14,833,536	7,308,058
Contingent consideration	1,210,000	1,210,000
Deferred tax liability	183,923	1,525,896
Long-term portion of capital lease obligation	4,855	16,069
Total non-current liabilities	1,398,778	2,751,965
Total liabilities	16,232,314	10,060,023
Preferred stock, series A	6	...
Common stock	172,573	101,309
Additional paid-in capital	89,589,681	78,106,645
Retained earnings (accumulated deficit)	(91,816,655)	(78,598,738)
Stockholders' notes receivable	...	(58,824)
Accumulated other comprehensive income (loss)	127,473	120,187
Total stockholders' equity (deficit)	(1,926,922)	(329,421)

**Recent Dividends:**

- 1. Eyegate Pharmaceuticals, Inc. common.**  
No dividends paid.
  - 2. Eyegate Pharmaceuticals, Inc. series A convertible preferred.**  
No dividends paid.
  - 3. Eyegate Pharmaceuticals, Inc. series D convertible preferred.**  
No dividends paid.
  - 4. Eyegate Pharmaceuticals, Inc. series B convertible preferred.**  
No dividends paid.
  - 5. Eyegate Pharmaceuticals, Inc. series C convertible preferred.**  
No dividends paid.
- Annual Dividends:**

**1. Eyegate Pharmaceuticals, Inc. common.**

No dividends paid.

**2. Eyegate Pharmaceuticals, Inc. series A convertible preferred.**

No dividends paid.

**3. Eyegate Pharmaceuticals, Inc. series D convertible preferred.**

No dividends paid.

**4. Eyegate Pharmaceuticals, Inc. series B convertible preferred.**

No dividends paid.

**5. Eyegate Pharmaceuticals, Inc. series C convertible preferred.**

No dividends paid.

**EYEGATE PHARMACEUTICALS, INC.**

**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, EisnerAmper LLP, as it appeared in Co.'s 2017 10-K report: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of EyeGate Pharmaceuticals, Inc. (the "Company") as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for each of the years then ended and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2017 and 2016, and the consolidated results of their operations and their cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred operating losses from operations and negative cash flows that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**FIBROGEN INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)	2015 (revised)
License & milestone revenue	<sup>□</sup> 96,056	<sup>□</sup> 137,352	<sup>□</sup> 148,093
Collaboration services & other revenue	<sup>□</sup> 29,612	<sup>□</sup> 42,225	<sup>□</sup> 32,735
Total revenue	125,668	179,577	180,828
Research & development expense	196,517	187,206	214,089
General & administrative expense	51,760	46,025	44,364
Total operating expenses	248,277	233,231	258,453
Income (loss) from operations	(122,609)	(53,654)	(77,625)
Interest expense	9,706	10,725	11,033
Interest income & other, net	6,433	2,628	3,121
Total interest & other income (expense), net	(3,273)	(8,097)	(7,912)
Income (loss) before income taxes - domestic	(101,234)	(38,156)	(66,411)
Income (loss) before income taxes - foreign	(24,648)	(23,595)	(19,126)
Income (loss) before income taxes	(125,882)	(61,751)	(85,537)
Current provision for (benefit from) income taxes - state	2	2	2
Current provision for (benefit from) income taxes - foreign	319	139	240
Total current			

provision for (benefit from) income taxes	...	141	242
Deferred provision for (benefit from) income taxes - federal	...	(212)	...
Total deferred provision for (benefit from) income taxes	...	(212)	...
Provision for (benefit from) income taxes	321	(71)	242
<b>Net income (loss)</b>	(126,203)	(61,680)	(85,779)
Weighted average shares outstanding - basic	72,987	62,744	60,337
Weighted average shares outstanding - diluted	72,987	62,744	60,337
Year end shares outstanding	82,498	63,665	61,985
Net income (loss) per share - basic	\$(1.73)	\$(0.98)	\$(1.42)
Net income (loss) per share - diluted	\$(1.73)	\$(0.98)	\$(1.42)
Number of full time employees	<sup>□</sup> 423	<sup>□</sup> 364	<sup>□</sup> 353
Number of stockholders	<sup>□</sup> 193	<sup>□</sup> 272	<sup>□</sup> 329
Foreign currency translation adjustments	...	532	1,662

<sup>□</sup> Includes amount from a related party - License & milestone revenue: \$15,307,000; <sup>□</sup> Includes amount from a related party - License & milestone revenue: \$24,421,000; <sup>□</sup> Includes amount from a related party - License & milestone revenue: \$18,701,000; <sup>□</sup> Includes amount to a related party - Collaboration services & other revenue: \$1,578,000; <sup>□</sup> Includes amount to a related party - Collaboration services & other revenue: \$1,357,000; <sup>□</sup> Includes amount to a related party - Collaboration services & other revenue: \$2,895,000; <sup>□</sup> As of January 31, 2018; <sup>□</sup> As of January 31, 2017; <sup>□</sup> As of January 31, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)
Cash	103,716	79,239
Money market funds	569,942	94,543
Cash & cash equivalents	673,658	173,782
Short-term investments	62,060	79,397
Accounts receivable	<sup>□</sup> 8,452	<sup>□</sup> 10,448
Prepaid expenses & other current assets	4,800	2,889
Total current assets	748,970	266,516
Restricted time deposit	5,181	6,217
Long-term investments	10,506	71,010
Laboratory equipment	19,497	18,533
Computer equipment	6,006	5,678
Furniture & fixtures	5,575	5,533
Leasehold improvements	93,758	93,564
Building shell	53,879	53,879
Construction in progress	10,402	109
Total property & equipment	189,117	177,296
Less: accumulated depreciation	59,641	53,639
Property & equipment, net	129,476	123,657
Other assets	4,517	2,152
Total assets	898,650	469,552
Accounts payable	5,509	6,223
Preclinical & clinical trial accruals	32,321	29,550
Payroll & related accruals	18,810	14,232
Property taxes & other	4,201	451
Professional services	1,991	1,252
Other accrued liabilities	6,458	5,429
Accrued liabilities	<sup>□</sup> 63,781	<sup>□</sup> 50,914
Deferred revenue	7,968	7,988

Total current liabilities	77,258	65,125
Long-term portion of lease financing obligations	97,763	97,352
Product development obligations	17,244	14,854
Deferred rent	3,657	4,212
Deferred revenue, net of current	112,231	106,709
Other long-term liabilities	8,047	6,191
Total liabilities	316,200	294,443
Common stock	825	637
Additional paid-in capital	1,160,094	625,903
Accumulated other comprehensive income (loss)	(1,795)	(960)
Retained earnings (accumulated deficit)	(595,945)	(469,742)
Total stockholders' equity (deficit)	563,179	155,838
Non-controlling interests	19,271	19,271
Total equity (deficit)	582,450	175,109

□ Reclassified to conform with 2017 presentation; □ Amount from a related party - Accounts receivable: \$4,004,000; □ Amount from a related party - Accounts receivable: \$4,102,000; □ Amount to related parties - Accrued liabilities: \$272,000; □ Amount to related parties - Accrued liabilities: \$1,615,000

**Recent Dividends:**

- 1. FibroGen Inc common.**  
No dividends paid.

**Annual Dividends:**

- 1. FibroGen Inc common.**  
No dividends paid.

**GORDON POINTE ACQUISITION CORP**

**Annual Report**

**Consolidated Income Statement, Years Ended May 15 (\$):**

	□2017	
Formation & operating costs	978	
Net income (loss)	(978)	
Weighted average shares outstanding - basic	3,125,000	
Weighted average shares outstanding - diluted	3,125,000	
Year end shares outstanding	3,593,750	
Net earnings per share - basic	\$0.00	
Net earnings per share - diluted	\$0.00	
Total number of employees	2	

□ For the period from April 12, 2017 (inception)

**Consolidated Balance Sheet, Years Ended May 15 (\$):**

	2017	
Cash	25,000	
Deferred offering costs	108,018	
Total assets	133,018	
Accounts payable	978	
Accrued offering costs	97,497	
Advances from related party	10,521	
Total current liabilities	108,996	
Class F common stock	359	
Additional paid-in capital	24,641	
Retained earnings (accumulated deficit)	(978)	
Total stockholders' equity	24,022	

**Recent Dividends:**

- 1. Gordon Pointe Acquisition Corp class F common.**  
No dividends paid.

- 2. Gordon Pointe Acquisition Corp class A common.**  
No dividends paid.

**Annual Dividends:**

- 1. Gordon Pointe Acquisition Corp class F common.**  
No dividends paid.

- 2. Gordon Pointe Acquisition Corp class A common.**  
No dividends paid.

**GORDON POINTE ACQUISITION CORP**

**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2017 Prospectus:

"In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Gordon Pointe Acquisition Corp., as of May 15, 2017, and the results of its operations and its cash flows for the period from April 12, 2017 (inception) to May 15, 2017 in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has no present revenue, its business plan is dependent on the completion of a financing and the Company's cash and working capital as of May 15, 2017, are not sufficient to complete its planned activities for the upcoming year. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans regarding these matters are also described in Notes 1 and 3. These financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**GT BIOPHARMA INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	□2016 (revised)	2015
License revenues	...	...	27,000
Total revenue	...	...	27,000
Gross profit (loss)	...	...	27,000
Research & development expenses	1,068,000	975,000	1,000,000
Selling, general & administrative expenses	134,502,000	8,399,000	7,954,000
Income (loss) from operations	(135,570,000)	(9,374,000)	(8,927,000)
Change in value of warrant & derivative liabilities	925,000	25,697,000	(6,760,000)
Interest income/expense	(8,602,000)	(6,555,000)	(17,039,000)
Net income (loss)	(143,247,000)	9,768,000	(32,726,000)
Weighted average shares outstanding			
- basic	16,769,431	□81,460	7,982
Weighted average shares outstanding			
- diluted	16,769,431	□81,460	7,982
Year end shares outstanding	50,117,977	□104,218	8,000
Net income (loss) per share - basic	\$(8.54)	□\$119.91	\$(4,101.00)
Net income (loss) per share - diluted	\$(8.54)	□\$119.91	\$(4,101.00)
Total number of employees	5	...	2
Number of common stockholders	31	...	1,330

□ Restated to reflect the correction of error in the reporting of the change in valuation of the warrant and derivative liabilities; □ Adjusted for 1-for-300 stock split, August, 2017; □ Shares increased due to the effect of issuance of common stock for convertible notes and interest; warrants and compensation

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	□2016 (revised)	2015 (revised)
Cash & cash equivalents	576,000	19,000	
Prepaid expenses	...	2,000	
Total current assets	576,000	21,000	
Intangible assets	253,777,000	...	
Deposits	9,000	...	
Fixed assets, net	6,000	4,000	
Total assets	254,368,000	25,000	
Accounts payable	2,546,000	2,100,000	
Accrued interest	...	3,800,000	
Accrued expenses	102,000	219,000	
Line of credit	31,000	31,000	
Warrant liability	...	417,000	
Settlement note payable	...	691,000	
Demand notes payable, net	...	452,000	
Convertible debentures, net, current portion	...	□10,350,000	
Convertible debentures	...	889,000	

Total current liabilities	2,679,000	18,949,000
Total long term liabilities	...	0
Total liabilities	2,679,000	18,949,000
Convertible series C preferred stock	1,000	1,000
Convertible series I preferred stock	...	2,000
Convertible series J preferred stock	1,000	...
Common stock	50,000	...
Additional paid-in capital	519,702,000	105,891,000
Retained earnings (accumulated deficit)	(267,896,000)	(124,649,000)
Noncontrolling interest	(169,000)	(169,000)
Total stockholders' equity (deficit)	251,689,000	(18,924,000)

□ Restated to reflect the correction of error in the reporting of the change in valuation of the warrant and derivative liabilities; □ Discount - Convertible debentures, current portion: \$794,000

**Recent Dividends:**

- 1. GT Biopharma Inc series C convertible preferred.**  
No dividends paid.
- 2. GT Biopharma Inc series H convertible preferred.**  
No dividends paid.
- 3. GT Biopharma Inc series E convertible preferred.**  
No dividends paid.
- 4. GT Biopharma Inc series I convertible preferred.**  
No dividends paid.
- 5. GT Biopharma Inc common.**  
No dividends paid.

**Annual Dividends:**

- 1. GT Biopharma Inc series C convertible preferred.**  
No dividends paid.
- 2. GT Biopharma Inc series H convertible preferred.**  
No dividends paid.
- 3. GT Biopharma Inc series E convertible preferred.**  
No dividends paid.
- 4. GT Biopharma Inc series I convertible preferred.**  
No dividends paid.
- 5. GT Biopharma Inc common.**  
No dividends paid.

**HELIOS & MATHESON ANALYTICS INC**

**Spin-Off Development**

On Mar. 15, 2018, Co. announced that its board of directors has approved a plan to spin-off its wholly-owned subsidiary, Zone Technologies, Inc. ("Zone"). Following the spin-off, Zone would become an independent publicly traded company that Co. expects to also be listed on Nasdaq. The spin-off is subject to numerous conditions, including, without limitation, the effectiveness of a Registration Statement on Form S-1 to be filed with the Securities and Exchange Commission and the approved listing of Zone's common stock on Nasdaq. Pursuant to the spin-off, Co. plans to distribute shares of Zone common stock as a dividend to persons who hold common stock of Co. as of a record date to be determined. The board of directors of Co. expects to set a record date to determine the stockholders entitled to receive shares of Zone in the spin-off for approximately 20 to 40 days before the effective date of the spin-off. Holders of any convertible notes and warrants of Co. outstanding as of the applicable record date may be entitled to participate in the dividend of Zone shares in the spin-off in accordance with the terms of such notes and warrants.

**HISTOGENICS CORP**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	2015 (revised)
Research & development expenses	15,566	21,577	23,243
General & administrative expenses	9,384	8,530	8,266
Impairment of intangible assets	...	200	310
Total operating expenses	24,950	30,307	31,819
Income (loss) from operations	(24,950)	(30,307)	(31,819)
Interest income	...	...	...





other current liabilities .....	1,139,000	
Total current liabilities .....	127,851,000	103,926,000
First lien term loan .....	993,762,000	998,750,000
Capital lease obligation .....	569,000	724,000
Unamortized debt premium & issuance costs .....	4,857,000	5,396,000
Less: amounts due within one year .....	11,268,000	11,496,000
Tax receivable agreement .....	110,160,000	165,384,000
Deferred tax liability .....	267,771,000	353,797,000
Total liabilities .....	1,493,702,000	1,616,481,000
Class A common stock .....	10,000	10,000
Class B common stock .....	3,000	3,000
Additional paid-in-capital .....	920,723,000	912,824,000
Accumulated other comprehensive income .....	1,318,000	...
Retained earnings (accumulated deficit) .....	208,279,000	(15,618,000)
Total stockholders' equity (successor)/ partners' deficit (predecessor) .....	1,130,333,000	897,219,000
Non-controlling interest .....	342,240,000	334,192,000

□ Reclassified to conform with 2017 presentation

**Recent Dividends:**

- 1. Hostess Brands Inc Class F common.**  
No dividends paid.
- 2. Hostess Brands Inc Class A common.**  
No dividends paid.
- 3. Hostess Brands Inc Class B common.**  
No dividends paid.

**Annual Dividends:**

- 1. Hostess Brands Inc Class F common.**  
No dividends paid.
- 2. Hostess Brands Inc Class A common.**  
No dividends paid.
- 3. Hostess Brands Inc Class B common.**  
No dividends paid.

**IHEARTMEDIA INC**

**Bankruptcy Proceedings** On Mar. 14, 2018, Co. and certain of its subsidiaries, AMFM Broadcasting Licenses, LLC, AMFM Broadcasting, Inc., AMFM Operating, Inc., AMFM Radio Licenses, LLC, AMFM Texas Broadcasting, LP, AMFM Texas Licenses, LLC, AMFM Texas, LLC, Capstar Radio Operating Company, Capstar TX, LLC, CC Broadcast Holdings, Inc., CC Finco Holdings, LLC, CC Licenses, LLC, Christal Radio Sales, Inc., Cine Guarantors II, Inc., Citicasters Co., Citicasters Licenses, Inc., Clear Channel Broadcasting Licenses, Inc., Clear Channel Holdings, Inc., Clear Channel Investments, Inc., Clear Channel Metro, LLC, Clear Channel Mexico Holdings, Inc., Clear Channel Real Estate, LLC, Critical Mass Media, Inc., iHeartCommunications, Inc., iHeartMedia + Entertainment, Inc., iHeartMedia Capital I, LLC, iHeartMedia Capital II, LLC, iHeartMedia Management Services, Inc., iHM Identity, Inc., Katz Communications, Inc., Katz Media Group, Inc., Katz Millennium Sales & Marketing, Inc., Katz Net Radio Sales, Inc., M Street Corporation, Premiere Networks, Inc., Terrestrial RF Licensing, Inc., TTWN Media Networks, LLC and TTWN Networks, LLC, filed for Chapter 11 protection with the U.S. Bankruptcy Court in the Southern District of Texas, lead case number 18-31274. The assets were valued at \$12,862,247,000. Clear Channel Outdoor Holdings and its subsidiaries are not included in the filing. Co., which offers media, entertainment and data services focused on radio, digital, outdoor, mobile, social, live events and on-demand entertainment is represented by Patricia B. Tomasco of Jackson Walker. Co. concurrently announced an agreement in principle with holders of more than \$10,000,000,000 of its outstanding debt and its financial sponsors. Co. notes, "The agreement reflects widespread support across the capital structure for a comprehensive balance sheet restructuring that will reduce Co.'s debt by more than \$10,000,000,000. Co., America's #1 audio company, will continue operating the business in the ordinary course as a leading global multi-platform media, entertainment and data company." Bob Pittman, chairman and C.E.O., comments, "The agreement we announced today is a significant accomplishment, as it allows us to definitively address the more than \$20,000,000,000 in debt that has burdened our capital structure." Brian Coleman, iHeartMedia's S.V.P and C.F.O., adds, "The Debtors soon expect to finalize documentation and exchange signature pages on a restructuring support agreement with these parties that will memorialize this agreement in principle. The broad consensus embod-

ied in the agreement in principle provides a necessary foundation for the Debtors' chapter 11 cases to proceed in an efficient, cost-effective, and value-maximizing manner."

**IMAGE SENSING SYSTEMS, INC.**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	□2016 (revised)	□2015 (revised)
Revenue - product sales .....	5,919,000	6,398,000	6,729,000
Revenue - royalties .....	8,605,000	7,744,000	8,486,000
Total revenue .....	14,524,000	14,142,000	15,215,000
Cost of revenues - products sales .....	2,563,000	4,008,000	3,477,000
Cost of revenue - software amortization .....	362,000	90,000	...
Total cost of revenue .....	2,925,000	4,098,000	3,477,000
Gross profit .....	11,599,000	10,044,000	11,738,000
Selling, marketing & product support .....	2,486,000	2,417,000	3,216,000
General & administrative .....	3,981,000	3,868,000	4,048,000
Research & development .....	3,010,000	2,946,000	3,520,000
Restructuring .....	...	126,000	119,000
Amortization of intangible assets .....	...	...	455,000
Total operating expenses .....	9,477,000	9,357,000	11,358,000
Operating income (loss) from operations .....	2,122,000	687,000	380,000
Other income (expense), net .....	41,000	(25,000)	21,000
Income (loss) before income taxes - domestic .....	2,364,000	801,000	1,057,000
Income (loss) before income taxes - foreign .....	(201,000)	(139,000)	(656,000)
Income (loss) from continuing operations before income taxes .....	2,163,000	662,000	401,000
Income tax expense (benefit) - current state .....	5,000	2,000	7,000
Income tax expense (benefit) - current - foreign .....	60,000	12,000	9,000
Income tax expense (benefit) - current - total .....	65,000	14,000	16,000
Income tax expense (benefit) - deferred - federal .....	(3,000)	...	...
Income tax expense (benefit) - deferred - foreign .....	23,000	(39,000)	2,000
Income tax expense (benefit) - deferred - total .....	20,000	(39,000)	2,000
Income tax expense (benefit) .....	85,000	(25,000)	18,000
Net income (loss) from continuing operations .....	...	...	383,000
Net loss from discontinued operations, net of tax .....	...	...	□(3,485,000)
<b>Net income (loss)</b> .....	<b>2,078,000</b>	<b>687,000</b>	<b>(3,102,000)</b>
Weighted average shares outstanding - basic .....	5,128,000	5,050,000	5,011,000
Weighted average shares outstanding - diluted .....	5,136,000	5,055,000	5,019,000
Year end shares outstanding .....	5,210,448	5,094,473	5,028,000
Earnings (loss) per share from			
operations- basic .....	...	...	\$0.08
Earnings (loss) per share - discontinued operations- basic .....	...	...	\$(0.70)
Net income (loss) per share - basic .....	\$0.41	\$0.14	\$(0.62)
Earnings (loss) per share from continuing operations- diluted .....	...	...	\$0.08
Earnings (loss) per share - discontinued operations- diluted .....	...	...	\$(0.69)
Net income (loss) per share - diluted .....	\$0.40	\$0.14	\$(0.61)
Total number of employees .....	59	56	69
Number of common stockholders .....	□27	□20	□20
Foreign currency translation adjustments .....	...	(105,000)	(100,000)

continuing operations- basic .....	...	...	\$0.08
Earnings (loss) per share - discontinued operations- basic .....	...	...	\$(0.70)
Net income (loss) per share - basic .....	\$0.41	\$0.14	\$(0.62)
Earnings (loss) per share from continuing operations- diluted .....	...	...	\$0.08
Earnings (loss) per share - discontinued operations- diluted .....	...	...	\$(0.69)
Net income (loss) per share - diluted .....	\$0.40	\$0.14	\$(0.61)
Total number of employees .....	59	56	69
Number of common stockholders .....	□27	□20	□20
Foreign currency translation adjustments .....	...	(105,000)	(100,000)

□ Reclassified to conform with 2017 presentation; □ Reclassified to conform with 2016 presentation; □ Including loss on disposal of: \$1,081,000; □ As of February 28, 2018; □ As of February 28, 2017; □ As of February 29, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	□2016 (revised)
Cash & cash equivalents .....	3,190,000	1,547,000
Accounts receivable, gross .....	3,359,000	3,101,000
Less: allowance for doubtful accounts .....	20,000	90,000
Accounts receivable, net .....	3,339,000	3,011,000
Finished goods .....	335,000	141,000
Inventories .....	335,000	141,000
Prepaid expenses & other current assets .....	255,000	281,000
Total current assets .....	7,119,000	4,980,000
Furniture & fixtures .....	164,000	486,000
Leasehold improvements .....	26,000	426,000
Equipment .....	998,000	3,561,000
Property & equipment, gross .....	1,188,000	4,473,000
Less: accumulated depreciation .....	702,000	4,102,000
Property & equipment, net .....	486,000	371,000
Intangible assets, net .....	3,485,000	2,795,000
Deferred income taxes .....	38,000	58,000
Total assets .....	11,128,000	8,204,000
Accounts payable .....	563,000	256,000
Warranty .....	858,000	1,223,000
Accrued compensation .....	288,000	193,000
Other current liabilities .....	778,000	323,000
Total current liabilities .....	2,487,000	1,995,000
Total liabilities .....	2,487,000	1,995,000
Common stock .....	51,000	50,000
Additional paid-in capital .....	24,355,000	24,055,000
Accumulated other comprehensive income (loss) .....	(310,000)	(363,000)
Retained earnings (accumulated deficit) .....	(15,455,000)	(17,533,000)
Total shareholders' equity (deficit) .....	8,641,000	6,209,000

□ Reclassified to conform with 2017 presentation

**Recent Dividends:**

- 1. Image Sensing Systems, Inc. common.**  
No dividends paid.

**Annual Dividends:**

- 1. Image Sensing Systems, Inc. common.**  
No dividends paid.

**IMPRIMIS PHARMACEUTICALS INC**  
**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	<sup>□</sup> 2016 (revised)	<sup>□</sup> 2015 (revised)
Sales, net.....	26,684,000	19,927,000	9,654,000
License revenues.....	90,000	15,000	62,000
Total revenues.....	26,774,000	19,942,000	9,716,000
Cost of sales.....	13,505,000	9,831,000	5,206,000
Gross profit.....	13,269,000	10,111,000	4,510,000
Selling & marketing expenses ..	7,059,000	7,382,000	6,496,000
General & administrative expenses.....	17,960,000	17,569,000	12,504,000
Research & development expenses.....	413,000	739,000	332,000
Impairment of long-lived assets.....	...	303,000	...
Total operating expenses.....	25,432,000	25,993,000	19,332,000
Income (loss) from operations.....	(12,163,000)	(15,882,000)	(14,822,000)
Interest income (expense), net.....	(3,026,000)	(2,774,000)	(1,108,000)
Early extinguishment of debt.....	(884,000)	(1,966,000)	...
Change in fair value of derivative liabilities.....	...	(113,000)	...
Investment loss from Eton Pharmaceuticals.....	2,218,000	...	...
Gain on deconsolidation of Eton Pharmaceuticals.....	5,725,000	...	...
Gain (loss) on sale & disposal of assets.....	(354,000)	...	...
Other income (expense), net.....	...	1,537,000	31,000
Total other income (expense), net.....	(757,000)	(3,316,000)	(1,077,000)
Income (loss) before income taxes ..	(12,920,000)	(19,198,000)	...
Income tax benefit ..	(935,000)	(111,000)	...
<b>Net income (loss)....</b>	<b>(11,985,000)</b>	<b>(19,087,000)</b>	<b>(15,899,000)</b>
Weighted average shares outstanding - basic.....	20,027,712	12,743,184	9,576,142
Weighted average shares outstanding - diluted.....	20,027,712	12,743,184	9,576,142
Year end shares outstanding.....	20,623,129	<sup>□</sup> 18,627,915	9,755,678
Net income (loss) per share - basic.....	\$(0.60)	\$(1.50)	\$(1.66)
Net income (loss) per share - diluted.....	\$(0.60)	\$(1.50)	\$(1.66)
Number of full time employees.....	...	<sup>□</sup> 141	<sup>□</sup> 106
Number of part time employees.....	...	<sup>□</sup> 3	<sup>□</sup> 6
Total number of employees.....	<sup>□</sup> 128	<sup>□</sup> 144	<sup>□</sup> 112
Number of common stockholders.....	<sup>□</sup> 165	<sup>□</sup> 261	<sup>□</sup> 130

<sup>□</sup> Reclassified to conform with 2017 presentation; <sup>□</sup> Reclassified to conform with 2016 presentation; <sup>□</sup> Shares increased due to the effect of exercise of stock options, vesting of RSU's, register public offering sale of stock, private placement and stock based compensation; <sup>□</sup> As of March 1, 2017; <sup>□</sup> As of March 2, 2016; <sup>□</sup> As of March 1, 2018; <sup>□</sup> Approximately; <sup>□</sup> As of March 15, 2017; <sup>□</sup> As of March 4, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents.....	4,019,000	8,853,000
Restricted cash & short-term investments.....	200,000	200,000

Accounts receivable, gross.....	1,804,000	3,343,000
Less: allowance for doubtful accounts & contractual adjustments.....	275,000	422,000
Accounts receivable, net.....	1,529,000	2,921,000
Raw materials.....	956,000	669,000
Finished goods.....	1,293,000	1,172,000
Inventories.....	2,249,000	1,841,000
Prepaid insurance.....	164,000	315,000
Other prepaid expenses.....	426,000	517,000
Deposits & other current assets.....	124,000	106,000
Notes receivable, current portion.....	95,000	...
Total current assets.....	8,806,000	14,753,000
Computer software & hardware.....	1,239,000	831,000
Furniture & equipment.....	377,000	424,000
Lab & pharmacy equipment.....	2,545,000	2,559,000
Leasehold improvements.....	4,810,000	4,836,000
Furniture & equipment, gross.....	8,971,000	8,650,000
Accumulated depreciation & amortization.....	2,756,000	1,355,000
Property, plant & equipment, net.....	6,215,000	7,295,000
Intangible assets, net.....	2,860,000	2,972,000
Investment in Eton Pharmaceuticals.....	3,507,000	...
Note receivable, less current portion.....	302,000	...
Goodwill.....	2,227,000	2,227,000
Total assets.....	23,917,000	27,247,000
Accounts payable.....	3,241,000	2,999,000
Deferred rent.....	388,000	412,000
Accrued interest.....	256,000	116,000
Accrued exit fee for note payable.....	800,000	667,000
Building lease liability.....	...	11,000
Total accounts payable & accrued expenses.....	4,685,000	4,205,000
Less non-current portion of accrued expenses.....	(800,000)	(667,000)
Accrued payroll & related liabilities.....	1,209,000	1,638,000
Deferred revenue & customer deposits.....	29,000	91,000
Current portion of deferred acquisition obligation & accrued interest.....	53,000	207,000
Current portion of note payable, net of unamortized debt discount.....	...	3,973,000
Current portion of capital lease obligations, net of unamortized discount.....	598,000	458,000
Total current liabilities.....	5,774,000	9,905,000
Capital lease obligations, net of current portion.....	720,000	1,318,000
Deferred acquisition obligation, net of current portion.....	...	52,000
Accrued expenses, net of current portion.....	800,000	667,000
Deferred tax liability.....	...	936,000
Note payable & paid-in-kind interest, net of unamortized debt discount & issuance costs.....	14,008,000	7,937,000
Total liabilities.....	21,302,000	20,815,000
Common stock.....	21,000	19,000
Additional paid-in capital.....	91,430,000	83,264,000
Retained earnings (accumulated deficit).....	(88,836,000)	(76,851,000)
Total stockholders' equity (deficit).....	2,615,000	6,432,000

**Recent Dividends:****1. Imprimis Pharmaceuticals Inc series A convertible preferred.**

No dividends paid.

**2. Imprimis Pharmaceuticals Inc common.**

No dividends paid.

**Annual Dividends:****1. Imprimis Pharmaceuticals Inc series A convertible preferred.**

No dividends paid.

**2. Imprimis Pharmaceuticals Inc common.**

No dividends paid.

**INFOSONICS CORP****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	<sup>□</sup> 2016 (revised)	<sup>□</sup> 2015 (revised)
Net sales.....	23,386,000	39,140,000	47,833,000
Cost of sales.....	21,397,000	34,547,000	40,414,000
Gross profit.....	1,989,000	4,593,000	7,419,000
Total operating expenses.....	6,461,000	6,943,000	8,339,000
Operating income (loss).....	(4,472,000)	(2,350,000)	(920,000)
Interest income (expense), net.....	(182,000)	(244,000)	(320,000)
Other income (expense), net.....	(13,000)	(334,000)	...
Income (loss) before provision (benefit) for income taxes.....	(4,667,000)	(2,928,000)	(1,240,000)
Current income tax provision (benefit) - state.....	3,000	2,000	3,000
Current income tax provision (benefit) - foreign.....	...	(95,000)	...
Total current income tax provision (benefit).....	3,000	(93,000)	3,000
Deferred income tax provision (benefit) - federal.....	1,090,000	(838,000)	31,000
Deferred income tax provision (benefit) - state.....	(72,000)	(52,000)	(12,000)
Total deferred income tax provision (benefit).....	1,018,000	(890,000)	19,000
Change in valuation allowance.....	(1,018,000)	890,000	(19,000)
Provision (benefit) for income taxes.....	3,000	(93,000)	3,000
<b>Net income (loss).....</b>	<b>(4,670,000)</b>	<b>(2,835,000)</b>	<b>(1,243,000)</b>
Weighted average shares outstanding - basic.....	<sup>□</sup> 615,400	<sup>□</sup> 575,560	575,200
Weighted average shares outstanding - diluted.....	<sup>□</sup> 615,400	<sup>□</sup> 575,560	575,200
Year end shares outstanding.....	<sup>□</sup> 675,656	<sup>□</sup> 575,549	575,549
Net earnings (loss) per share - basic.....	<sup>□</sup> \$(7.60)	<sup>□</sup> \$(5.00)	\$(2.25)
Net earnings (loss) per share - diluted.....	<sup>□</sup> \$(7.60)	<sup>□</sup> \$(5.00)	\$(2.25)
Total number of employees.....	35	41	52
Number of common stockholders.....	<sup>□</sup> 4	<sup>□</sup> 7	<sup>□</sup> 7
Foreign currency translation adjustments.....	...	1,103,000	(866,000)

<sup>□</sup> Reclassified to conform with 2017 presentation; <sup>□</sup> Adjusted for 1-for-5 stock split, March 9, 2018; <sup>□</sup> Adjusted for 1-for-5 stock split, October 11, 2017; <sup>□</sup> Approximately; <sup>□</sup> As of March 6, 2018; <sup>□</sup> As of March 7, 2017; <sup>□</sup> As of March 7, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	<sup>□</sup> 2016 (revised)
Cash & cash equivalents.....	612,000	2,200,000

Trade accounts receivable, gross	5,820,000	7,620,000
Allowance for doubtful accounts	114,000	113,000
Trade accounts receivable, net	5,706,000	7,507,000
Other accounts receivable	...	62,000
Inventory	3,879,000	4,071,000
Prepaid assets	1,782,000	1,670,000
Total current assets	11,979,000	15,510,000
Machinery & equipment	698,000	384,000
Furniture & fixtures	79,000	164,000
Property & equipment, gross	777,000	548,000
Less: accumulated depreciation	427,000	416,000
Property & equipment, net	350,000	132,000
Other assets	28,000	384,000
Total assets	12,357,000	16,026,000
Accounts payable	3,762,000	3,839,000
Accrued product costs	378,000	400,000
Accrued coop advertising	24,000	44,000
Accrued vacation pay	177,000	179,000
Income taxes payable	1,000	...
Customer deposits & overpayments	453,000	568,000
Other accruals	457,000	406,000
Accrued expenses	1,490,000	1,597,000
Total current liabilities	5,252,000	5,436,000
Common stock	3,000	3,000
Additional paid-in capital	34,243,000	33,158,000
Accumulated other comprehensive income (loss)	(2,595,000)	(2,695,000)
Retained earnings (accumulated deficit)	(24,546,000)	(19,876,000)
Total stockholders' equity	7,105,000	10,590,000

□ Reclassified to conform with 2017 presentation

**Recent Dividends:**

**1. InfoSonics Corp common.**

No dividends paid.

**Annual Dividends:**

**1. InfoSonics Corp common.**

No dividends paid.

**INTERLINK ELECTRONICS INC Annual Report**

<b>Consolidated Income Statement, Years Ended Dec. 31 (\$000):</b>			
	2017	2016	□2015
		(revised)	(revised)
Revenue, net	11,153	11,886	10,514
Cost of revenue	4,297	4,880	4,869
Gross profit	6,856	7,006	5,645
Engineering research & development	829	623	841
Selling, general & administrative	3,888	3,536	3,122
Total operating expenses	4,717	4,159	3,963
Operating income (loss)	2,139	2,847	1,682
Other income (expense), net	(5)	40	38
Income (loss) before income tax provision (benefit) - Domestic	1,071	1,903	138
Income (loss) before income tax provision (benefit) - Foreign	1,063	984	682
Income (loss) from continuing operations before provision for income taxes	2,134	2,887	1,720
Current federal income taxes	360	427	...

Current state income taxes	69	11	5
Current foreign income taxes (benefit)	263	231	(16)
Total current income taxes (benefit)	692	669	(11)
Deferred federal income taxes (benefit)	157	(429)	...
Deferred state income taxes (benefit)	30	(216)	...
Deferred foreign income taxes (benefit)	(5)	(30)	...
Total deferred income taxes (benefit)	182	(675)	...
Provision for income taxes	874	(6)	(11)
<b>Net income (loss)</b>	1,260	2,893	1,731
Weighted average shares outstanding - basic	7,333	7,327	□7,325
Weighted average shares outstanding - diluted	7,421	7,407	□7,380
Year end shares outstanding	7,336	7,328	□7,326
Net earnings (loss) per share - basic	\$0.17	\$0.39	□\$0.23
Net earnings (loss) per share - diluted	\$0.17	\$0.39	□\$0.23
Total number of employees	□97	□111	□112
Number of common stockholders	□□34	□□39	□□52
Foreign currency translation adjustments	...	(77)	(21)

□ Reclassified to conform with 2016 presentation; □ Adjusted for 5-for-4 stock split, April 4, 2016; □ As is; □ As of March 14, 2018; □ As of March 1, 2017; □ As of March 22, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016	(revised)
Cash & cash equivalents	7,772	6,009	6,009
Restricted cash	5	5	5
Accounts receivable, net	1,374	1,726	1,726
Raw material	743	738	738
Work in process	290	357	357
Finished goods	162	173	173
Inventories	1,195	1,268	1,268
Prepaid expenses & other current assets	338	377	377
Total current assets	10,684	9,385	9,385
Furniture, machinery & equipment	1,231	914	914
Leasehold improvements	551	514	514
Property & equipment, gross	1,782	1,428	1,428
Less accumulated depreciation & amortization	1,257	1,118	1,118
Property & equipment, net	525	310	310
Intangibles, net	69	44	44
Deferred income taxes	493	675	675
Other assets	59	57	57
Total assets	11,830	10,471	10,471
Accounts payable	255	324	324
Accrued warranty	3	2	2
Accrued wages & benefits	185	195	195
Accrued taxes other than income taxes	4	5	5
Accrued vacation	88	77	77
Accrued other	65	55	55
Accrued liabilities	345	334	334
Accrued income taxes	103	104	104

Deferred revenues, current	...	111	111
Total current liabilities	703	873	873
Total liabilities	703	873	873
Common stock	7	7	7
Additional paid-in capital	60,527	60,370	60,370
Accumulated other comprehensive income (loss)	41	(71)	(71)
Retained earnings (accumulated deficit)	(49,448)	(50,708)	(50,708)
Total stockholders' equity	11,127	9,598	9,598

**Recent Dividends:**

**1. Interlink Electronics Inc common.**

No dividends paid.

**Annual Dividends:**

**1. Interlink Electronics Inc common.**

No dividends paid.

**INVIVO THERAPEUTICS HOLDINGS CORP**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
		(revised)	(revised)
Research & development expenses	11,083,000	12,557,000	10,058,000
General & administrative expenses	13,510,000	11,506,000	12,340,000
Total operating expenses	24,593,000	24,063,000	22,398,000
Operating income (loss)	(24,593,000)	(24,063,000)	(22,398,000)
Interest income	189,000	187,000	60,000
Interest expense	74,000	155,000	172,000
Derivatives gain (loss)	(2,267,000)	593,000	(10,804,000)
Other income (expense), net	(2,152,000)	625,000	(10,916,000)
<b>Net income (loss)</b>	<b>(26,745,000)</b>	<b>(23,438,000)</b>	<b>(33,314,000)</b>
Weighted average common shares outstanding - basic	32,950,068	31,025,585	26,461,374
Weighted average common shares outstanding - diluted	32,950,068	31,025,585	26,461,374
Year end common share outstanding	□34,274,776	32,044,087	27,555,948
Net income (loss) per common share - basic	\$(0.81)	\$(0.76)	\$(1.26)
Net income (loss) per common share - diluted	\$(0.81)	\$(0.76)	\$(1.26)
Total number of employees	□12	37	30
Number of stockholders	□□301	□□320	□□250

□ Shares increased due to the issuance of common stock on warrant exchange, for services, upon exercise of warrants and stock options, to 401(k) plan and under ESPP; □ As of February 28, 2018; □ Approximately; □ As of March 5, 2018; □ As of March 3, 2017; □ As of February 26, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	□2016
		(revised)
Cash	23,000	111,000
Money market funds	12,887,000	21,353,000
Cash & cash equivalents	12,910,000	21,464,000
Restricted cash	361,000	361,000
Marketable securities	...	11,577,000
Prepaid expenses & other current assets	535,000	451,000
Total current assets	13,806,000	33,853,000
Computer software & hardware	241,000	606,000
Research & lab equipment	508,000	1,895,000

Leasehold improvements	431,000	431,000
Office equipment	796,000	796,000
Less: accumulated depreciation & amortization	1,819,000	3,218,000
Property & equipment, net	157,000	510,000
Other assets	82,000	421,000
Total assets	14,045,000	34,784,000
Accounts payable	988,000	1,011,000
Loan payable - current portion	452,000	423,000
Derivative warrant liability	4,000	1,314,000
Deferred rent, current portion	30,000	141,000
Accrued bonus	62,000	906,000
Accrued payroll	79,000	126,000
Accrued vacation	55,000	91,000
Accrued severance	1,160,000	385,000
Other accrued expenses	282,000	451,000
Accrued expenses	1,638,000	1,959,000
Total current liabilities	3,112,000	4,848,000
Loan payable - less current portion	400,000	852,000
Deferred rent payable, net current portion	367,000	135,000
Other liabilities	56,000	...
Total liabilities	3,935,000	5,835,000
Common stock	1,000	1,000
Additional paid-in capital	194,016,000	185,955,000
Retained earnings (accumulated deficit)	(183,907,000)	(157,007,000)
Total stockholders' equity (deficit)	10,110,000	28,949,000

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. InVivo Therapeutics Holdings Corp common.

No dividends paid.

#### Annual Dividends:

##### 1. InVivo Therapeutics Holdings Corp common.

No dividends paid.

#### INVIVO THERAPEUTICS HOLDINGS CORP

##### Auditor's Report Auditor's Report

The following is an excerpt from the Report of Independent Auditors, RSM US LLP, as it appeared in Co.'s 2017 Annual Report: "In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. Emphasis of Matter The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has limited cash and cash equivalents and has suffered recurring losses from operations. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

#### JASON INDUSTRIES INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	□2016 (revised)	□2015 (revised)
Net sales	648,616,000	705,519,000	708,366,000
Cost of goods sold	517,764,000	574,412,000	561,076,000
Gross profit	130,852,000	131,107,000	147,290,000
Selling & administrative expenses	103,855,000	113,797,000	129,371,000
Impairment charges	...	63,285,000	94,126,000
Gain (loss) on disposals of			

property, plant & equipment - net	759,000	(880,000)	(109,000)
Restructuring expenses	4,266,000	7,232,000	3,800,000
Transaction-related expenses	...	...	886,000
Operating income (loss)	23,490,000	(54,087,000)	(81,002,000)
Interest expense	33,089,000	31,843,000	31,835,000
Gain on extinguishment of debt	2,201,000	...	...
Equity income	952,000	681,000	884,000
Gain (loss) on divestiture	(8,730,000)	...	...
Other income - net	319,000	900,000	97,000
Income before income taxes - Domestic	(27,919,000)	(93,639,000)	(126,334,000)
Income before income taxes - Foreign	13,062,000	9,785,000	14,478,000
Income (loss) before income taxes	(14,857,000)	(84,349,000)	(111,856,000)
Current federal income taxes	208,000	...	161,000
Current state income taxes (benefit)	(125,000)	57,000	104,000
Current foreign income taxes	6,878,000	7,759,000	5,703,000
Total current income taxes	6,961,000	7,816,000	5,968,000
Deferred federal income taxes (benefit)	(14,864,000)	(9,059,000)	(24,548,000)
Deferred state income taxes (benefit)	(1,281,000)	(1,781,000)	(3,196,000)
Deferred foreign income taxes (benefit)	(1,200,000)	(3,272,000)	(479,000)
Total deferred income taxes (benefit)	(17,345,000)	(14,112,000)	(28,223,000)
Tax provision (benefit)	(10,384,000)	(6,296,000)	(22,255,000)
Net income (loss)	(4,473,000)	(78,053,000)	(89,601,000)
Net income (loss) attributable to noncontrolling interests	(5,000)	10,818,000	15,143,000
Net income (loss) attributable to Jason Industries	(4,478,000)	(67,235,000)	(74,458,000)
Accretion of preferred stock dividends & redemption premium	3,783,000	3,600,000	3,600,000
Net income (loss) available to common shareholders of Jason Industries	(8,261,000)	(70,835,000)	(78,058,000)
Weighted average common shares outstanding - basic	26,082,000	22,507,000	22,145,000
Weighted average common shares outstanding - diluted	26,082,000	22,507,000	22,145,000
Year end common shares outstanding	25,966,381	24,802,196	...
Net earnings (loss) per common share - basic	\$(0.32)	\$(3.15)	\$(3.53)
Net earnings (loss) per common share - diluted	\$(0.32)	\$(3.15)	\$(3.53)
Total number of employees	□4,300	...	...
Number of common stockholders	75	...	...
Number of series A preferred stockholders	12	...	...

Foreign currency translation adjustments	(4,787,000)	(11,560,000)
--	-------------	--------------

□ Restated to reflect the correction of an error in the cost of goods sold; □ Successor; □ Approximately

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	□2016 (revised)
Cash & cash equivalents	48,887,000	40,861,000
Accounts receivable, gross	71,585,000	81,229,000
Allowances for doubtful accounts	2,959,000	3,392,000
Accounts receivable, net	68,626,000	77,837,000
Raw materials	35,925,000	37,222,000
Work in process	4,375,000	4,175,000
Finished goods	30,519,000	32,204,000
Inventories - net	70,819,000	73,601,000
Other current assets	15,655,000	17,866,000
Total current assets	203,987,000	210,165,000
Land & improvements	6,556,000	9,631,000
Buildings & improvements	33,161,000	41,928,000
Machinery & equipment	191,903,000	191,770,000
Construction in progress	10,710,000	5,473,000
Property, plant & equipment, gross	242,330,000	248,802,000
Less: accumulated depreciation	88,134,000	70,979,000
Property, plant & equipment - net	154,196,000	177,823,000
Goodwill	45,142,000	42,157,000
Other intangible assets - net	131,499,000	144,258,000
Other assets - net	11,499,000	9,433,000
Total assets	546,323,000	583,836,000
Current portion of long-term debt	9,704,000	8,179,000
Accounts payable	53,668,000	61,160,000
Accrued compensation & employee benefits	17,433,000	13,207,000
Accrued interest	276,000	191,000
Other current liabilities	19,806,000	24,807,000
Total current liabilities	100,887,000	107,544,000
First lien term loans	298,018,000	303,025,000
Second lien term loans	90,007,000	110,000,000
Debt discount on first lien term loans	(3,602,000)	(5,002,000)
Deferred issuance costs on term loans	(5,586,000)	(7,503,000)
Foreign debt	21,795,000	23,303,000
Capital lease obligations	840,000	1,301,000
Total outstanding indebtedness	401,472,000	425,124,000
Less: current portion	9,704,000	8,179,000
Long-term debt	391,768,000	416,945,000
Deferred income taxes	25,699,000	42,608,000
Other long-term liabilities	22,285,000	19,881,000
Total liabilities	540,639,000	586,978,000
Preferred stock, net	49,665,000	45,899,000
Jason Industries (successor) common stock	3,000	2,000
Additional paid-in capital	143,788,000	144,666,000
Retained earnings (accumulated deficit)	(167,710,000)	(163,232,000)
Employee retirement plan adjustments	(1,517,000)	(1,777,000)
Foreign currency translation adjustments	(18,596,000)	(27,404,000)
Net unrealized gains (losses) on cash flow hedges	51,000	(1,191,000)
Accumulated other comprehensive income (loss)	(20,062,000)	(30,372,000)
Shareholders' equity (deficit) attributable to Jason Industries	5,684,000	(3,037,000)
Noncontrolling interests	...	(105,000)
Total shareholders' equity (deficit)	5,684,000	(3,142,000)

<sup>1</sup> Restated to reflect the correction of an error in the cost of goods sold

**Recent Dividends:****1. Jason Industries Inc 8% series A convertible perpetual preferred.**

No dividends paid.

**2. Jason Industries Inc common.**

No dividends paid.

**Annual Dividends:****1. Jason Industries Inc 8% series A convertible perpetual preferred.**

No dividends paid.

**2. Jason Industries Inc common.**

No dividends paid.

**KINGOLD JEWELRY INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Net sales	2,009,732,643	1,420,624,970	1,000,161,294
Cost of sales	1,808,612,014	1,273,041,387	960,562,184
Depreciation	1,193,453	1,208,998	1,284,170
Total cost of sales	1,809,805,467	1,274,250,385	961,846,354
Gross profit	199,927,176	146,374,585	38,314,940
Selling, general & administrative expenses	13,444,222	11,985,807	7,685,840
Stock compensation expenses	33,014	240,306	530,542
Depreciation	444,297	194,690	104,219
Amortization, other	11,188	11,379	12,137
Total operating expenses	13,932,721	12,432,182	8,332,738
Income (loss) from operations	185,994,455	133,942,403	29,982,202
Gain (loss) on sale of Jewelry Park	...	63,212,496	...
Other income	66,642	26,443	20,689
Interest income	2,251,972	2,904,781	208,061
Interest expense	152,945,558	74,555,096	2,310,451
Total other income (expenses), net	(150,626,944)	(8,411,376)	(2,081,701)
Income (loss) from operations before taxes - United States	(1,331,862)	(1,010,848)	(1,833,064)
Income (loss) from operations before taxes - foreign	36,699,373	126,541,875	29,733,565
Income (loss) from operations before taxes	35,367,511	125,531,027	27,900,501
Current foreign income tax provision (benefit)	17,678,757	33,055,811	4,488,815
Current income tax provision (benefit)	17,678,757	33,055,811	4,488,815
Deferred foreign income tax provision (benefit)	(8,503,898)	(428,101)	1,849,910
Deferred income tax provision (benefit)	(8,503,898)	(428,101)	1,849,910
Total income tax provision (benefit)	9,174,859	32,627,710	6,338,725
<b>Net income (loss)</b>	<b>26,192,652</b>	<b>92,903,317</b>	<b>21,561,776</b>
Less: net income attributable to the noncontrolling interest	...	6,495	296
Net income (loss) attributable to common stockholders	26,192,652	92,909,812	21,562,072
Weighted average shares outstanding - basic	66,050,498	65,991,487	65,963,502
Weighted average shares outstanding - diluted	66,472,046	66,337,129	65,963,502
Year end shares outstanding	66,113,502	66,018,867	65,963,502
Net earnings (loss) per share - basic	\$0.40	\$1.41	\$0.33
Net earnings (loss)			

per share - diluted	\$0.39	\$1.40	\$0.33
Number of full time employees	5626	5618	5568
Number of common stockholders	573	5780	580
Foreign currency translation adjustments	...	(21,461,689)	(14,740,716)

<sup>1</sup> Reclassified to conform with 2016 presentation; <sup>2</sup> Amortization of debt issuance costs - interest expense: \$10,958,016; <sup>3</sup> Amortization of debt issuance costs - interest expense: \$7,479,382; <sup>4</sup> Amortization of debt issuance costs - interest expense: \$490,870; <sup>5</sup> Approximately; <sup>6</sup> As of March 12, 2018; <sup>7</sup> As of April 14, 2017; <sup>8</sup> As of March 24, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
Cash	4,997,125	21,333,193
Restricted cash	5,534,551	52,786,257
Accounts receivable	768,167	670,878
Raw materials	...	7,167,391
Work-in-progress	90,406,021	78,813,685
Finished goods	44,636,692	33,454,519
Inventories	135,042,713	119,435,595
Investments in gold	1,562,943,153	281,895,403
Other current assets & prepaid expenses	100,592	698,217
Prepaid income taxes	...	3,330,468
Value added tax recoverable	353,732,758	272,835,051
Total current assets	2,063,119,059	752,985,062
Buildings	2,415,577	2,208,918
Plant & machinery	18,615,951	17,401,084
Motor vehicles	254,228	97,549
Office & electric equipment	1,415,194	687,901
Leasehold improvements	1,623,027	1,185,433
Less: accumulated depreciation	17,024,334	14,356,187
Restricted cash	7,392,721	7,558,173
Investments in gold	957,124,267	1,493,938,551
Other assets	302,072	283,003
Deferred income tax assets	6,677,675	...
Land use right	429,915	413,662
Total assets	3,042,345,352	2,262,403,149
Short term loans	962,101,746	234,691,670
Third parties loans	...	28,798,526
Gold leases payable - Bank	...	7,167,391
Other payables & accrued expenses	18,913,863	13,716,472
Related party loan	307,389,647	...
Due to related party	2,630,301	7,223,321
Income tax payable	1,208,742	...
Other taxes payable	2,615,463	1,518,731
Total current liabilities	1,294,859,762	293,116,111
Deferred income tax liability	...	1,249,622
Related parties loan	567,843,066	460,776,408
Loan payable to Evergrowing Bank - Qixia Branch	...	115,194,102
Loan payable to Evergrowing Bank - Yantai Huanshan Road Branch	...	143,560,650
Loan payable to Anxin Trust	461,084,471	431,977,883
Loan payable to Minsheng Trust - gross amount	...	28,798,526
Loan payable to Minsheng Trust - deferred financing cost	...	(563,984)
Loan payable to Chang' An Trust	153,694,824	28,654,533
Loan payable to Chang' An Trust - deferred financing costs	(1,563,230)	...
Loan payable to Sichuan Trust - gross amount	...	215,988,941
Loan payable to Sichuan Trust - deferred	...	...

financing cost	...	(2,359,280)
Loan payable to China Aviation Capital - gross amount	...	41,757,862
Loan payable to China Aviation Capital - deferred financing cost	...	(1,055,387)
Loan payable to China Construction Investment Trust - gross amount	...	43,197,788
Loan payable to China Construction Investment Trust - deferred financing cost	...	(371,697)
Loan payable to Zhesang Jinhui Trust	...	79,195,945
Loan payable to Hubei Assets Management	...	43,197,788
Loans payable to Zhongjiang International Trust	...	57,597,051
Loans payable to China Aviation Trust - gross amount	47,645,395	...
Loans payable to China Aviation Trust - deferred financing costs	(761,674)	...
Loans payable to National Trust - gross amount	53,793,188	...
Loans payable to National Trust - deferred financing costs	(228,068)	...
Loans payable to Zhesang Jinhui Trust (new) - gross amounts	76,847,412	...
Loans payable to Zhesang Jinhui Trust (new) - deferred financing costs	(1,102,181)	...
Total liabilities	2,652,112,965	1,979,912,862
Common stock	66,113	66,018
Additional paid-in capital	80,377,449	80,230,968
Unappropriated retained earnings	303,666,611	277,473,959
Appropriated retained earnings	967,543	967,543
Accumulated other comprehensive income (loss)	5,154,671	(76,248,201)
Total stockholders' equity	390,232,387	282,490,287
Total equity	390,232,387	282,490,287

**Recent Dividends:****1. Kingold Jewelry Inc common.**

No dividends paid.

**Annual Dividends:****1. Kingold Jewelry Inc common.**

No dividends paid.

**LA JOLLA PHARMACEUTICAL CO.****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Contract revenue - related party	...	616,000	1,057,000
Total revenue	...	616,000	1,057,000
Research & development expenses	84,575,000	62,288,000	29,092,000
General & administrative expenses	30,852,000	16,700,000	13,934,000
Total expenses	115,427,000	78,988,000	43,026,000
Income (loss) from operations	(115,427,000)	(78,372,000)	(41,969,000)
Other income (expense), net	624,000	187,000	57,000
<b>Net income (loss)</b>	<b>(114,803,000)</b>	<b>(78,185,000)</b>	<b>(41,912,000)</b>
Net income (loss) attributable to common shareholders	(114,803,000)	(78,185,000)	(41,912,000)
Weighted average			

shares outstanding - basic	21,215,000	17,228,000	15,651,000
Weighted average shares outstanding - diluted	21,215,000	17,228,000	15,651,000
Year end shares outstanding	22,167,529	18,261,557	18,244,009
Net income (loss) per share - basic	\$(5.41)	\$(4.54)	\$(2.68)
Net income (loss) per share - diluted	\$(5.41)	\$(4.54)	\$(2.68)
Number of full time employees	309	105	58
Number of common stockholders	3	5	7
Number of beneficiary stockholders	4,000	4,000	4,000

□ Shares increased due to the effect of issuance of common stock for March 2017 financing and exercise of stock options for common stock; □ As of February 16, 2018; □ As of February 17, 2017; □ As of February 22, 2016; □ Approximately; □ As of March 20, 2002

	2017	2016 (revised)
Cash & cash equivalents	90,915,000	65,726,000
Restricted cash	...	200,000
Prepays & other current assets	3,147,000	1,505,000
Total current assets	94,062,000	67,431,000
Lab equipment	7,812,000	2,610,000
Furniture & fixtures	2,282,000	389,000
Computer hardware	1,238,000	457,000
Software	619,000	309,000
Leasehold improvements	14,852,000	464,000
Total property & equipment, gross	26,803,000	4,229,000
Less: accumulated depreciation & amortization	2,235,000	1,084,000
Property & equipment, net	24,568,000	3,145,000
Restricted cash	909,000	...
Other assets	...	219,000
Total assets	119,539,000	70,795,000
Accounts payable	11,484,000	6,652,000
Accrued clinical & other expenses	703,000	905,000
Accrued payroll & related expenses	4,995,000	2,077,000
Deferred rent	1,370,000	124,000
Total current liabilities	18,552,000	9,758,000
Deferred rent	12,785,000	...
Total liabilities	31,337,000	...
Common stock	2,000	2,000
Series C-1 convertible preferred stock	3,906,000	3,906,000
Series F convertible preferred stock	2,737,000	2,737,000
Additional paid-in capital	803,071,000	661,103,000
Retained earnings (accumulated deficit)	(721,514,000)	(606,711,000)
Total stockholders' equity (deficit)	88,202,000	61,037,000

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

- 1. La Jolla Pharmaceutical Co. common.**  
No dividends paid.
- 2. La Jolla Pharmaceutical Co. series D-1 convertible preferred.**  
No dividends paid.
- 3. La Jolla Pharmaceutical Co. series F convertible preferred.**  
No dividends paid.
- 4. La Jolla Pharmaceutical Co. series C-1 redeemable convertible preferred.**  
No dividends paid.

- 5. La Jolla Pharmaceutical Co. series C-2 convertible preferred.**  
No dividends paid.
  - 6. La Jolla Pharmaceutical Co. series C-1 convertible preferred.**  
No dividends paid.
- Annual Dividends:**
- 1. La Jolla Pharmaceutical Co. common.**  
No dividends paid.
  - 2. La Jolla Pharmaceutical Co. series D-1 convertible preferred.**  
No dividends paid.
  - 3. La Jolla Pharmaceutical Co. series F convertible preferred.**  
No dividends paid.
  - 4. La Jolla Pharmaceutical Co. series C-1 redeemable convertible preferred.**  
No dividends paid.
  - 5. La Jolla Pharmaceutical Co. series C-2 convertible preferred.**  
No dividends paid.
  - 6. La Jolla Pharmaceutical Co. series C-1 convertible preferred.**  
No dividends paid.

#### LANDCADIA HOLDINGS INC

##### Annual Report

	2017	2016 (revised)	2015 (revised)
General & administrative expenses	480,303	261,253	11,905
Income (loss) from operations	(480,303)	(261,253)	(11,905)
Interest income	1,798,242	256,735	...
Income (loss) before taxes	1,317,939	(4,518)	(11,905)
Current income taxes	442,515	...	...
Deferred income taxes	11,623	...	...
Change in valuation allowance	(6,039)	...	...
Tax provision	448,099	...	...
<b>Net income (loss)</b>	<b>869,840</b>	<b>(4,518)</b>	<b>(11,905)</b>
Less: Income attributable to common stock subject to possible redemption	1,277,241	243,740	...
Net income (loss) available to common shares	(407,401)	(248,258)	(11,905)
Weighted average shares outstanding - basic	7,553,650	7,500,028	4,852,335
Weighted average shares outstanding - diluted	7,553,650	7,500,028	4,852,335
Year end shares outstanding	31,250,000	31,250,000	4,312,500
Net earnings (loss) per share - basic	\$(0.05)	\$(0.03)	\$0.00
Net earnings (loss) per share - diluted	\$(0.05)	\$(0.03)	\$0.00
Total number of employees	5	5	5
Number of class A common stockholders	1	1	...

□ Reclassified to conform with 2017 presentation; □ As of March 5, 2018; □ As of March 23, 2017

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016 (revised)
Cash	571,748	1,063,350
Prepaid expenses	43,698	153,699
Total current assets	615,446	1,217,049
Cash, cash equivalents & accrued interest held in trust account	252,054,977	250,256,735
Total assets	252,670,423	251,473,784
Accounts payable &		

accrued liabilities	460,846	134,047
Total current liabilities	460,846	134,047
Deferred underwriting commissions	8,750,000	8,750,000
Total liabilities	9,210,846	8,884,047
Class A common stock subject to possible redemption	238,459,567	237,589,727
Class A common stock	135	127
Class F common stock	625	625
Additional paid-in capital	4,145,833	5,015,681
Retained earnings (accumulated deficit)	853,417	(16,423)
Total stockholders' equity (deficit)	5,000,010	5,000,010

#### Recent Dividends:

- 1. Landcadia Holdings Inc class A common stock subject to possible redemption.**  
No dividends paid.
- 2. Landcadia Holdings Inc class F common.**  
No dividends paid.
- 3. Landcadia Holdings Inc class A common.**  
No dividends paid.

#### Annual Dividends:

- 1. Landcadia Holdings Inc class A common stock subject to possible redemption.**  
No dividends paid.
- 2. Landcadia Holdings Inc class F common.**  
No dividends paid.
- 3. Landcadia Holdings Inc class A common.**  
No dividends paid.

#### LIGHTBRIDGE CORP

##### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Consulting revenue	175,446	760,577	910,531
Cost of consulting services provided	107,091	456,565	694,292
Gross margin	68,355	304,012	216,239
General & administrative expenses	4,383,066	5,190,549	5,350,285
Research & development expenses	2,282,938	2,748,337	1,484,164
Total operating expenses	6,666,004	7,938,886	6,834,449
Operating income (loss)	(6,597,649)	(7,634,874)	(6,618,210)
Warrant revaluation	...	1,672,573	2,306,117
Warrant modification expense	...	162,398	...
Interest income	65	316	705
Financing costs	491,218	191,345	...
Interest expense	16,095	29,448	...
Interest expense & other income (expenses)	...	...	(6,762)
Total other income & (expenses)	(507,248)	1,289,698	2,300,060
Net income (loss) before income taxes	(7,104,897)	(6,345,176)	(4,318,150)
<b>Net income (loss)</b>	<b>(7,104,897)</b>	<b>(6,345,176)</b>	<b>(4,318,150)</b>
Weighted average shares outstanding - basic	10,424,481	4,728,943	3,647,860
Weighted average shares outstanding - diluted	10,424,481	4,728,943	3,647,860
Year end shares outstanding	12,737,703	7,112,143	3,725,819
Net income (loss) per share - basic	\$(0.71)	\$(1.48)	\$(1.20)
Net income (loss) per share - diluted	\$(0.71)	\$(1.48)	\$(1.20)
Number of full time employees	6	7	7
Number of part time employees	1	1	2

Number of common stockholders ..... <sup>(1)</sup>88 <sup>(2)</sup>61 <sup>(3)</sup>99

<sup>(1)</sup> Reclassified to conform with 2017 presentation; <sup>(2)</sup> Adjusted for 1-for-5 stock split, July 20, 2016; <sup>(3)</sup> Shares increase due to the issuance of consulting fee paid in stock, offering of issuance shares and cashless exercise of stock warrants; <sup>(4)</sup> Approximately; <sup>(5)</sup> As of March 8, 2018; <sup>(6)</sup> As of March 7, 2017; <sup>(7)</sup> As of March 1, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	<sup>(1)</sup> 2016 (revised)
Cash & cash equivalents	4,515,398	3,584,877
Restricted cash	...	114,012
Accounts receivable - project revenue & reimbursable	10,400	388,434
Prepaid expenses & other current assets	70,067	80,933
Deferred financing costs, net	491,168	491,168
Total current assets	5,087,033	4,659,424
Patent costs	1,367,692	1,160,465
Deferred financing costs	491,268	982,486
Total assets	6,945,993	6,802,375
Accounts payable & accrued liabilities	1,151,210	1,216,321
Total current liabilities	1,151,210	1,216,321
Deferred lease abandonment liability	...	28,464
Total liabilities	1,151,210	1,244,785
Preferred stock, net	1,020	1,020
Common stock	12,738	7,112
Additional paid in capital	93,602,539	86,266,075
Retained earnings (accumulated deficit)	(87,821,514)	(80,716,617)
Total stockholders' equity (deficit)	5,794,783	5,557,590

<sup>(1)</sup> Reclassified to conform with 2017 presentation

**Recent Dividends:**

- 1. Lightbridge Corp common.**  
No dividends paid.
- 2. Lightbridge Corp convertible Series A preferred.**  
No dividends paid.

**Annual Dividends:**

- 1. Lightbridge Corp common.**  
No dividends paid.
- 2. Lightbridge Corp convertible Series A preferred.**  
No dividends paid.

**LIVEPERSON INC Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)	2015 (revised)
Revenue	218,876	222,779	239,012
Cost of revenue	<sup>(1)</sup> 58,205	<sup>(2)</sup> 63,161	<sup>(3)</sup> 70,310
Sales & marketing expenses	<sup>(4)</sup> 90,905	<sup>(5)</sup> 89,529	<sup>(6)</sup> 94,728
General & administrative expenses	<sup>(7)</sup> 43,124	<sup>(8)</sup> 43,046	<sup>(9)</sup> 37,171
Product development expenses	<sup>(10)</sup> 40,034	<sup>(11)</sup> 40,198	<sup>(12)</sup> 38,974
Restructuring costs	2,594	2,369	3,384
Amortization of purchased intangibles	1,840	3,885	4,873
Total costs & expenses	236,702	242,188	249,440
Income (loss) from operations	(17,826)	(19,409)	(10,428)
Other income (expense), net	136	(530)	(202)
Income (loss) before provision for (benefit from) income taxes - United States	...	(40,774)	(16,362)

Income before provision for (benefit from) income taxes - foreign	...	20,835	5,732
Income (loss) before provision for (benefit from) income taxes	(17,690)	(19,939)	(10,630)
Current provision for (benefit from) income taxes - U.S. federal	...	1,829	(524)
Current provision for income taxes - state & local	47	27	309
Current provision for income taxes - foreign	2,852	2,226	1,573
Total current provision for income taxes	2,899	4,082	1,358
Deferred provision for (benefit from) income taxes - U.S. federal	(1,289)	841	13,791
Deferred provision for (benefit from) income taxes - state & local	(1,144)	99	876
Deferred provision for (benefit from) income taxes - foreign	35	912	(211)
Total deferred provision for (benefit from) income taxes	(2,398)	1,852	14,456
Provision for (benefit from) income taxes	501	5,934	15,814
<b>Net income (loss)</b>	(18,191)	(25,873)	(26,444)
Weighted average shares outstanding - basic	56,358	56,064	56,452
Weighted average shares outstanding - diluted	56,358	56,064	56,452
Year end shares outstanding	59,664	58,276	57,375
Net income (loss) per share - basic	\$(0.32)	\$(0.46)	\$(0.47)
Net income (loss) per share - diluted	\$(0.32)	\$(0.46)	\$(0.47)
Number of full time employees	<sup>(13)</sup> 981	<sup>(14)</sup> 985	<sup>(15)</sup> 1,006
Number of common stockholders	<sup>(16)</sup> 124	<sup>(17)</sup> 127	<sup>(18)</sup> 130
Foreign currency translation adjustments	...	(3,624)	(1,398)

<sup>(1)</sup> Amounts include stock compensation expense - Cost of revenue: \$448,000; <sup>(2)</sup> Amounts include depreciation expense - Cost of revenue: \$7,150,000; <sup>(3)</sup> Amounts include amortization of purchased intangibles - Cost of revenue: \$2,842,000; <sup>(4)</sup> Amounts include stock compensation expense - Cost of revenue: \$429,000; <sup>(5)</sup> Amounts include depreciation expense - Cost of revenue: \$8,234,000; <sup>(6)</sup> Amounts include amortization of purchased intangibles - Cost of revenue: \$2,788,000; <sup>(7)</sup> Amounts include stock compensation expense - Cost of revenue: \$1,396,000; <sup>(8)</sup> Amounts include depreciation expense - Cost of revenue: \$9,091,000; <sup>(9)</sup> Amounts include amortization of purchased intangibles - Cost of revenue: \$3,167,000; <sup>(10)</sup> Amounts include stock compensation - Sales and marketing: \$2,500,000; <sup>(11)</sup> Amounts include depreciation expense - Sales and marketing: \$1,625,000; <sup>(12)</sup> Amounts include stock compensation - Sales and marketing: \$2,515,000; <sup>(13)</sup> Amounts include depreciation expense - Sales and marketing: \$1,315,000; <sup>(14)</sup> Amounts include stock compensation - Sales and marketing: \$3,088,000; <sup>(15)</sup> Amounts include depreciation expense - Sales and marketing: \$1,232,000; <sup>(16)</sup> Amounts include

stock compensation - General and administrative: \$3,691,000; <sup>(17)</sup> Amounts include depreciation expense - General and administrative: \$1,226,000; <sup>(18)</sup> Amounts include stock compensation - General and administrative: \$3,304,000; <sup>(19)</sup> Amounts include depreciation expense - General and administrative: \$1,418,000; <sup>(20)</sup> Amounts include stock compensation - General and administrative: \$3,692,000; <sup>(21)</sup> Amounts include depreciation expense - General and administrative: \$893,000; <sup>(22)</sup> Amounts include stock compensation - Product development: \$2,305,000; <sup>(23)</sup> Amounts include depreciation expense - Product development: \$2,357,000; <sup>(24)</sup> Amounts include stock compensation - Product development: \$3,488,000; <sup>(25)</sup> Amounts include depreciation expense - Product development: \$1,044,000; <sup>(26)</sup> Amounts include stock compensation - Product development: \$3,638,000; <sup>(27)</sup> Amounts include depreciation expense - Product development: \$898,000; <sup>(28)</sup> As is; <sup>(29)</sup> Approximately; <sup>(30)</sup> As of February 21, 2018; <sup>(31)</sup> As of February 21, 2017; <sup>(32)</sup> As of February 26, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	<sup>(1)</sup> 2016 (revised)
Cash & cash equivalents	56,115	50,889
Cash held as collateral	1,451	3,962
Accounts receivable, gross	39,244	33,555
Less: allowance for doubtful accounts	1,318	1,732
Accounts receivable, net	37,926	31,823
Prepaid expenses & other current assets	7,352	5,477
Total current assets	102,844	92,151
Computer equipment & software	100,815	82,477
Furniture, equipment & building improvements	15,355	15,027
Property & equipment, gross	116,170	97,504
Less: accumulated depreciation	81,465	69,107
Property & equipment, net	34,705	28,397
Intangibles, net	12,366	16,510
Goodwill	80,531	80,245
Deferred tax assets, net	753	773
Other assets	1,600	1,562
Total assets	232,799	219,638
Accounts payable	5,481	7,288
Accrued payroll & other employee related costs	16,431	13,887
Accrued professional services, consulting & other vendor fees	15,674	14,559
Unrecognized tax benefits	4,924	4,240
Accrued sales commissions	5,259	3,312
Accrued contingent earn-out	...	210
Accrued restructuring	2,338	2,551
Other accrued expenses & other current liabilities	3,385	1,491
Accrued expenses & other current liabilities	48,011	40,250
Deferred revenue	35,563	27,145
Total current liabilities	89,055	74,683
Other liabilities	2,766	3,147
Deferred tax liability	915	3,332
Total liabilities	92,736	81,162
Common stock	60	58
Additional paid-in capital	305,676	289,524
Treasury stock	3	2
Retained earnings (accumulated deficit)	(163,135)	(144,944)
Accumulated other comprehensive income (loss)	(2,535)	(6,160)
Total stockholders' equity (deficit)	140,063	138,476

<sup>(1)</sup> Reclassified to conform with 2017 presentation

**Recent Dividends:**

- 1. LivePerson Inc common.**  
No dividends paid.

**Annual Dividends:****1. LivePerson Inc common.**

No dividends paid.

**LORAL SPACE & COMMUNICATIONS INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2017	2016 (revised)	2015 (revised)
General & administrative expenses	7,935	6,726	6,530
Operating income (loss)	(7,935)	(6,726)	(6,530)
Interest & investment income	2,483	194	138
Interest expense	27	20	17
Other expenses	3,291	1,449	3,779
Income (loss) from continuing operations before income taxes & equity in net income (losses) of affiliates	(8,770)	(8,001)	(10,188)
Current income tax provision (benefit) - U.S. federal	13,783	1,718	1,089
Current income tax provision (benefit) - state & local	(21,114)	(2,981)	(7,106)
Current income tax provision (benefit) - foreign	250	235	235
Total current income tax provision (benefit)	(7,081)	(1,028)	(5,782)
Deferred income tax provision (benefit) - U.S. federal	80,136	26,337	(35,721)
Deferred income tax provision (benefit) - state & local	53	3,198	(3,973)
Total deferred income tax provision (benefit)	80,189	29,535	(39,694)
Income tax provision (benefit)	73,108	28,507	(45,476)
Income (loss) from continuing operations before equity in net income (loss) of affiliates	(81,878)	(36,508)	35,288
Equity in net income (loss) of affiliates	216,347	84,078	(104,792)
Income (loss) from continuing operations	134,469	47,570	(69,504)
Income (loss) from discontinued operations, net of taxes	(5)	(370)	(778)
<b>Net income (loss)</b>	<b>134,464</b>	<b>47,200</b>	<b>(70,282)</b>
Weighted average shares outstanding - basic	30,933	30,933	30,928
Weighted average shares outstanding - diluted	31,008	31,008	30,928
Year end shares outstanding	30,933	30,933	...
Income (loss) per share - continuing operations - basic	\$4.35	\$1.54	\$(2.25)
Income (loss) per share - discontinued operations - basic	...	\$(0.01)	\$(0.03)
Net income (loss) per share - basic	\$4.35	\$1.53	\$(2.28)
Income (loss) per share - continuing			

operations - diluted	\$4.30	\$1.50	\$(2.25)
Income (loss) per share - discontinued operations - diluted	...	\$(0.01)	\$(0.03)
Net income (loss) per share - diluted	\$4.30	\$1.49	\$(2.28)
Number of full time employees	21	...	...
Number of common stockholders - voting	147	...	...
Number of common stockholders - non-voting	5	...	...

Restated to reflect the adoption of ASU No. 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash; As is; As of March 9, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)
Cash & cash equivalents	255,139	37,458
Income taxes receivable	11,105	545
Indemnification receivable from SSL for pre-closing taxes	2,410	2,410
Due from affiliates	217	225
Prepaid expenses	198	192
Other current assets	274	111
Other current assets	3,099	3,483
Total current assets	269,343	40,941
Income taxes receivable, non-current	1,550	...
Investments in affiliates	53,430	107,950
Deferred tax assets	50,016	115,285
Other assets	372	55
Total assets	374,711	264,231
Accrued employment costs	2,573	2,356
Indemnification liability relating to ViaSat Suit settlement	...	2,801
Due to affiliates	9	...
Accrued professional fees	1,117	665
Pension & other postretirement liabilities	69	108
Accrued liabilities	84	198
Total current liabilities	3,852	6,128
Pension & other postretirement liabilities	18,786	18,433
Indemnification liabilities - other	293	357
Deferred tax liability	...	6
Liabilities for uncertain tax positions	61,182	68,658
Other long-term liabilities	...	238
Total liabilities	84,113	93,820
Voting common stock	216	216
Non-voting common stock	95	95
Paid-in capital	1,019,988	1,019,988
Treasury stock, at cost	9,592	9,592
Retained earnings (accumulated deficit)	(682,831)	(826,460)
Postretirement benefits	(16,454)	(14,074)
Proportionate share of Telesat Canada other comprehensive income (loss)	(20,824)	238
Accumulated other comprehensive income (loss)	(37,278)	(13,836)
Total stockholders' equity (deficit) attributable to Loral Space & Communications Inc	290,598	170,411
Total shareholders' equity	290,598	170,411

Restated to reflect the adoption of ASU No. 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash

**Recent Dividends:****1. Loral Space & Communications Inc non-voting common.**

No dividends paid.

**2. Loral Space & Communications Inc series A-1 cumulated 7.5% convertible preferred.**

No dividends paid.

**3. Loral Space & Communications Inc series B-1 cumulative 7.5% convertible preferred.**

No dividends paid.

**4. Loral Space & Communications Inc voting common.**

No dividends paid.

**Annual Dividends:****1. Loral Space & Communications Inc non-voting common.**

No dividends paid.

**2. Loral Space & Communications Inc series A-1 cumulated 7.5% convertible preferred.**

No dividends paid.

**3. Loral Space & Communications Inc series B-1 cumulative 7.5% convertible preferred.**

No dividends paid.

**4. Loral Space & Communications Inc voting common.**

No dividends paid.

**LVIYUAN GREEN BUILDING MATERIAL TECHNOLOGY CORP****Earnings, 9 mos. to Jan 31(Consol. - \$):**

	2018	2017
Cost & expenses	18,962	34,260
Operating income	(18,962)	(34,260)
Net before taxes	(18,962)	(34,260)
<b>Net income</b>	<b>(18,962)</b>	<b>(34,260)</b>
Earnings common share		
Common Shares:		
Full Diluted	6,910,000	6,910,000
Year-end	6,910,000	6,910,000

**MEDICAL TRANSCRIPTION BILLING CORP****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Net revenue	31,810,635	24,493,443	23,079,850
Direct operating costs	17,679,070	13,416,627	11,630,070
Selling & marketing expense	1,106,698	1,224,243	467,446
General & administrative expense	11,738,201	12,458,820	11,969,177
Research & development expense	1,081,832	902,186	659,176
Change in contingent consideration	151,423	(715,495)	(1,786,367)
Depreciation & amortization expense	4,299,943	5,108,035	4,598,610
Restructuring charges	275,628	...	...
Total operating expenses	36,332,795	32,394,416	27,538,112
Operating income (loss)	(4,522,160)	(7,900,973)	(4,458,262)
Interest income	16,944	36,411	26,795
Interest expense	1,324,219	682,083	288,406
Foreign exchange gain (loss)	248,517	(92,160)	143,333
Other income (expense)	83,567	38,884	26,948
Income (loss) before income taxes - United States	(6,949,433)	(9,577,372)	(5,729,949)
Income (loss) before income taxes - foreign	1,452,082	977,451	1,180,357
Income (loss) before income taxes	(5,497,351)	(8,599,921)	(4,549,592)
Current provision (benefit) for income taxes - federal	...	(1,661)	(68,893)



Current provision (benefit) for income taxes - state	31,028	17,805	31,350
Current provision (benefit) for income taxes - foreign	10,235	6,397	4,060
Current provision (benefit) for income taxes	41,263	22,541	(33,483)
Deferred provision (benefit) for income taxes - federal	7,183	135,769	149,833
Deferred provision (benefit) for income taxes - state	19,359	38,492	21,436
Deferred provision (benefit) for income taxes	26,542	174,261	171,269
Income tax provision (benefit)	67,805	196,802	137,786
<b>Net income (loss)</b>	<b>(5,565,156)</b>	<b>(8,796,723)</b>	<b>(4,687,378)</b>
Preferred stock dividend	2,030,295	752,525	207,007
Net income (loss) attributable to common shareholders	(7,595,451)	(9,549,248)	(4,894,385)
Weighted average shares outstanding - basic	11,010,432	10,036,988	9,732,806
Weighted average shares outstanding - diluted	11,010,432	10,036,988	9,732,806
Year end shares outstanding	11,530,591	10,051,553	10,244,013
Net earnings (loss) per share - basic	\$(0.69)	\$(0.95)	\$(0.50)
Net earnings (loss) per share - diluted	\$(0.69)	\$(0.95)	\$(0.50)
Number of full time employees	1,700	2,050	1,600
Number of common stockholders	10,800	600	530
Foreign currency translation adjustments	...	22,889	(190,017)

□ Approximately; □ As of January 31, 2018; □ As of January 19, 2018; □ As of March 1, 2017; □ As of March 7, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
Cash	4,362,232	3,476,880
Accounts receivable, gross	4,064,463	4,486,901
Allowance for doubtful accounts	185,000	156,000
Accounts receivable, net	3,879,463	4,330,901
Current assets - related party	25,203	13,200
Prepaid expenses & other current assets	662,822	618,501
Total current assets	8,929,720	8,439,482
Computers	1,776,463	1,637,949
Office furniture & equipment	1,078,729	1,005,790
Transportation equipment	719,947	711,386
Leasehold improvements	880,273	777,073
Assets not placed in service	4,415	52,451
Total property, & equipment	4,459,827	4,184,649
Less accumulated depreciation	3,074,084	2,595,712
Property & equipment - net	1,385,743	1,588,937
Intangible assets - net	2,509,544	5,833,706
Goodwill	12,263,943	12,178,868
Other assets	436,713	282,713
Total assets	25,525,663	28,323,706

Accounts payable	991,859	1,905,131
Accrued compensation	1,137,351	2,009,911
Accrued expenses	616,778	1,236,609
Deferred rent	81,826	61,437
Deferred revenue	62,104	41,666
Accrued liability to related party	10,675	16,626
Borrowings under line of credit	...	2,000,000
Current portion of long-term debt	...	2,666,667
Notes payable - other (current portion)	168,718	5,181,459
Contingent consideration (current portion)	505,557	535,477
Dividend payable	747,147	202,579
Total current liabilities	4,322,015	15,857,562
Long - term debt, net of discount and debt issuance costs	...	4,033,668
Note payable - other	120,899	166,184
Deferred rent	333,788	433,186
Deferred revenue	28,615	26,673
Contingent consideration	97,854	394,072
Deferred tax liability	372,072	345,530
Total liabilities	5,275,243	21,256,875
Preferred stock	1,087	295
Common stock	12,272	10,793
Additional paid-in capital	45,129,517	26,038,063
Retained earnings (accumulated deficit)	(23,509,386)	(17,944,230)
Accumulated other comprehensive income (loss)	(721,070)	(376,090)
Treasury stock	662,000	662,000
Total shareholders' equity	20,250,420	7,066,831

**Recent Dividends:**

**1. Medical Transcription Billing Corp series A preferred.**

No dividends paid.

**2. Medical Transcription Billing Corp common.**

No dividends paid.

**Annual Dividends:**

**1. Medical Transcription Billing Corp series A preferred.**

No dividends paid.

**2. Medical Transcription Billing Corp common.**

No dividends paid.

**MIRAGEN THERAPEUTICS INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
Collaboration revenue	3,097	...	...
Grant revenue	906	...	...
Net revenue	4,003	3,337	2,538
Cost of revenue	...	2,548	2,472
Research & development	19,623	888	1,002
Selling & marketing	...	1,669	2,559
General & administrative	10,912	7,906	7,692
Exit costs	...	2,037	...
Asset impairment charges	...	797	...
Total operating expenses	30,535	15,845	13,725
Income (loss) from operations	(26,532)	(12,508)	(11,187)
Interest & other income	403	...	...
Interest & other expense	383	...	...
Interest expense	...	95	141
Loss on extinguishment of debt	...	(71)	...
Total other expense	...	(166)	(141)
<b>Net income (loss)</b>	<b>(26,512)</b>	<b>(12,674)</b>	<b>(11,328)</b>

Accretion of redeemable convertible preferred stock to redemption value	5	...	...
Net income (loss) attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	(26,517)	...	...
Weighted average shares outstanding - basic	19,245	721	539
Weighted average shares outstanding - diluted	19,245	721	539
Year end shares outstanding	22,568	742	709
Net income (loss) per share - basic	\$(1.38)	\$(17.58)	\$(21.02)
Net income (loss) per share - diluted	\$(1.38)	\$(17.58)	\$(21.02)
Number of full time employees	63	44	32
Number of part time employees	2	1	...
Total number of employees	65	45	...
Number of common stockholders	18	57	9

□ 2016 and prior periods for Signal Genetics, Inc. prior to reverse merger with Miragen Therapeutics, Inc.; □ Reclassified to conform with 2016 presentation; □ Adjusted for 1-for-15 stock split, November 7, 2016; □ As is; □ As of March 15, 2016; □ As of March 1, 2018; □ As of March 17, 2017

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016
Cash	...	3,341
Cash & cash equivalents	47,441	...
Accounts receivable, net	1,456	524
Inventory	...	64
Fixed assets held for sale	...	170
Prepaid expenses & other current assets	2,971	160
Total current assets	51,868	4,259
Lab equipment	2,229	...
Leasehold improvements	737	...
Computer hardware & software	355	...
Furniture & fixtures	77	...
Property & equipment, gross	3,398	...
Less: accumulated depreciation & amortization	2,835	...
Property & equipment, net	563	...
Other assets	50	...
Total assets	52,481	4,259
Accounts payable	906	159
Accrued employee compensation & related taxes	1,538	125
Accrued outsourced clinical & preclinical studies	581	...
Accrued other professional service fees	232	...
Accrued equipment & lab materials	197	...
Accrued legal fees & expenses	185	...
Value of liability-classified stock purchase warrants	82	...
Deferred and accrued facility lease obligations	74	...



Housing Solutions S.à r.l.....	89,529	134,999
Common shares.....	96,420	87,506
Investment in debt securities.....	44,459	40,998
Foreign currency translation.....	(3,306)	(3,180)
Accumulated other comprehensive income (loss).....	41,153	37,818
Total common shareholders' equity (deficit).....	137,573	125,324

□ Reclassified to conform with 2017 presentation; □ Includes related to consolidated funds & ventures - restricted cash: \$24,562,000; □ Includes related to consolidated funds & ventures - restricted cash: \$23,548,000; □ Includes pledged as collateral - Investments in debt securities: \$128,902,000; □ Includes pledged as collateral - Investments in debt securities: \$135,614,000; □ Includes related to CFVs - Investments in partnerships: \$29,315,000; □ Includes related to CFVs - Investments in partnerships: \$137,773,000; □ Includes related to consolidated funds & ventures - other liabilities: \$36,330,000; □ Includes related to consolidated funds & ventures - other liabilities: \$32,582,000

**Recent Dividends:**

1. MMA Capital Management LLC series D cumulative perpetual preferred.  
No dividends paid.
  2. MMA Capital Management LLC series B-3 cumulative perpetual preferred.  
No dividends paid.
  3. MMA Capital Management LLC series B-2 cumulative perpetual preferred.  
No dividends paid.
  4. MMA Capital Management LLC common.  
No dividends paid.
  5. MMA Capital Management LLC series A-4 cumulative perpetual preferred.  
No dividends paid.
  6. MMA Capital Management LLC series A-3 cumulative perpetual preferred.  
No dividends paid.
  7. MMA Capital Management LLC series C cumulative perpetual preferred.  
No dividends paid.
  8. MMA Capital Management LLC series B cumulative mandatorily redeemable preferred.  
No dividends paid.
  9. MMA Capital Management LLC series A-2 cumulative perpetual preferred.  
No dividends paid.
  10. MMA Capital Management LLC series C-3 cumulative perpetual preferred.  
No dividends paid.
  11. MMA Capital Management LLC series C-2 cumulative perpetual preferred.  
No dividends paid.
  12. MMA Capital Management LLC series A-1 mandatorily redeemable preferred.  
No dividends paid.
  13. MMA Capital Management LLC series B-1 mandatorily redeemable.  
No dividends paid.
  14. MMA Capital Management LLC series C-1 cumulative perpetual preferred.  
No dividends paid.
  15. MMA Capital Management LLC series A cumulative mandatorily redeemable preferred.  
No dividends paid.
- Annual Dividends:**
1. MMA Capital Management LLC series D cumulative perpetual preferred.  
No dividends paid.
  2. MMA Capital Management LLC series B-3 cumulative perpetual preferred.  
No dividends paid.
  3. MMA Capital Management LLC series B-2 cumulative perpetual preferred.  
No dividends paid.
  4. MMA Capital Management LLC common.  
No dividends paid.

5. MMA Capital Management LLC series A-4 cumulative perpetual preferred.  
No dividends paid.
6. MMA Capital Management LLC series A-3 cumulative perpetual preferred.  
No dividends paid.
7. MMA Capital Management LLC series C cumulative perpetual preferred.  
No dividends paid.
8. MMA Capital Management LLC series B cumulative mandatorily redeemable preferred.  
No dividends paid.
9. MMA Capital Management LLC series A-2 cumulative perpetual preferred.  
No dividends paid.
10. MMA Capital Management LLC series C-3 cumulative perpetual preferred.  
No dividends paid.
11. MMA Capital Management LLC series C-2 cumulative perpetual preferred.  
No dividends paid.
12. MMA Capital Management LLC series A-1 mandatorily redeemable preferred.  
No dividends paid.
13. MMA Capital Management LLC series B-1 mandatorily redeemable.  
No dividends paid.
14. MMA Capital Management LLC series C-1 cumulative perpetual preferred.  
No dividends paid.
15. MMA Capital Management LLC series A cumulative mandatorily redeemable preferred.  
No dividends paid.

**MONEYONMOBILE INC**

**New Accountant** On Mar. 14, 2018, Co. dismissed Liggett & Webb P.A. and engaged RBSM LLP as its new independent public accounting firm.

**MOSYS INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	□2015
		(revised)	(revised)
Net revenue - product.....	7,833	4,604	2,400
Net revenue - royalty & other.....	1,009	1,420	1,990
Total net revenue.....	8,842	6,024	4,390
Total cost of net revenue.....	4,694	3,075	2,474
Gross profit.....	4,148	2,949	1,916
Research & development expense.....	8,158	18,086	27,108
Selling, general & administrative expense.....	4,702	5,693	6,299
Impairment of goodwill.....	...	9,858	...
Restructuring charges.....	1,321	676	...
Total operating expenses.....	14,181	34,313	33,407
Income (loss) from operations.....	(10,033)	(31,364)	(31,491)
Interest expense.....	927	687	...
Income (loss) before income taxes - United States (U.S.).....	(11,063)	(31,115)	(31,580)
Income (loss) before income taxes - non-U.S.....	162	(888)	183
Income (loss) before income taxes ..	(10,901)	(32,003)	(31,397)
Current income tax provision (benefit) - state.....	3	3	3
Current income tax provision (benefit) - foreign.....	7	42	83
Total current income tax provision (benefit) ...	10	45	86
Deferred income tax			

provision (benefit) - federal.....	(243)	...	...
Income tax provision (benefit) ...	(233)	45	86
<b>Net income (loss).....</b>	<b>(10,668)</b>	<b>(32,048)</b>	<b>(31,483)</b>
Weighted average shares outstanding - basic.....	7,338	□6,601	6,249
Weighted average shares outstanding - diluted.....	7,338	□6,601	6,249
Year end shares outstanding.....	8,068	□6,630	□6,549
Net income (loss) per share - basic.....	\$(1.45)	□\$(4.86)	\$(5.04)
Net income (loss) per share - diluted.....	\$(1.45)	□\$(4.86)	\$(5.04)
Total number of employees.....	□24	□63	□104
Number of common stockholders.....	□6	□□15	□□16

□ Reclassified to conform with 2017 presentation; □ Adjusted for 1-for-10 reverse stock split, February 16, 2017; □ Shares increased due to issuance of common stock for exercise of options, employee stock purchase plan & release of awards; □ As is; □ As of March 1, 2017; □ As of March 1, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	□2016
		(revised)
Cash & cash equivalents.....	3,868	8,766
Short-term investments.....	...	1,002
Accounts receivable, gross.....	1,681	559
Accounts receivable, net.....	1,681	559
Work-in-process.....	1,612	1,270
Finished goods.....	154	181
Inventories.....	1,766	1,451
Prepaid IC material & production costs.....	1,107	3
Prepaid insurance.....	115	116
Prepaid software.....	38	250
Interest receivable.....	...	17
Other prepaid expenses & other assets.....	87	87
Total current assets.....	8,662	12,251
Equipment, furniture & fixtures & leasehold improvements.....	4,478	5,906
Acquired software.....	296	304
Property & equipment, gross.....	4,774	6,210
Less: accumulated depreciation & amortization.....	3,947	4,936
Property & equipment, net.....	827	1,274
Goodwill.....	13,276	13,276
Intangible assets, net.....	111	223
Other assets.....	263	121
Total assets.....	23,139	27,145
Accounts payable.....	170	561
Deferred revenue.....	3,938	271
Accrued wages & employee benefits.....	616	1,051
Accrued restructuring liability.....	478	5
Interest payable.....	346	314
IC development & wafer purchase costs.....	335	598
Professional fees, legal & consulting.....	182	282
Corporate taxes.....	153	52
Employee stock purchase plan withholdings.....	...	200
Other accrued expenses & other liabilities.....	397	...
Total current liabilities.....	6,615	3,334
Long-term liabilities.....	18	233
Convertible notes payable.....	9,160	8,250
Total liabilities.....	15,793	11,817
Common stock.....	8	7

Additional paid-in capital .....	232,026	229,341
Retained earnings (accumulated deficit) .....	(224,688)	(214,020)
Total stockholders' equity (deficit) .....	7,346	15,328

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. MoSys Inc common.

No dividends paid.

#### Annual Dividends:

##### 1. MoSys Inc common.

No dividends paid.

#### MULTIMEDIA PLATFORMS INC

**Bankruptcy Proceedings** On Mar. 16, 2018, Co. filed with the U.S. Bankruptcy Court a motion to continue hearings on (a) U.S. Trustee's motion to dismiss, convert or in the alternative appoint a Chapter 11 trustee and (b) the Debtors' motion to approve a compromise with White Winston Select Asset Funds. The motion explains, "Hearings are currently scheduled for Mar. 20, 2018 at 10:00 a.m. on the (a) United States Trustee's Motion to Dismiss, Convert, or in the Alternative, Motion to Appoint Chapter 11 Trustee [ECF No. 131] (the 'UST Motion'), and (b) Debtors' Motion to Approve Compromise of Controversy with White Winston Select Asset Funds, LLC [ECF No. 181] (the '9019 Motion')." The Debtors request that the Court enter and order rescheduling the hearings on the US Trustee Motion and the 9019 Motion to Apr. 11, 2018 at 10:00 a.m. Again, Undersigned counsel has communicated with counsel for the United States Trustee and White Winston Select Asset Funds, LLC, neither of whom has opposition to the relief requested. Wherefore, the Debtors respectfully request that the Court grant this Motion, and enter an order continuing the hearings on the UST Motion and the 9019 Motion to Apr. 11, 2018 at 10:00 a.m., as well as grant any other relief that the Court may deem just and proper."

#### NATURE'S SUNSHINE PRODUCTS, INC.

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2017	2016	2015
		(revised)	(revised)
Net sales .....	342,029	341,159	324,705
Cost of sales .....	91,037	90,937	85,345
Gross profit .....	250,992	250,222	239,360
Volume incentives .....	119,970	119,910	117,786
Selling, general & administrative .....	129,635	120,273	107,702
Operating income .....	1,387	10,039	13,872
Interest & other income (expense), net .....	144	591	1,486
Interest expense .....	289	16	130
Foreign exchange gains (losses), net .....	1,980	(1,348)	(1,948)
Total other income (expense) .....	1,835	(773)	(592)
Income (loss) from continuing operations before provision for income taxes - domestic .....	(2,211)	6,420	6,290
Income (loss) from continuing operations before provision for income taxes - foreign .....	5,433	2,846	6,990
Income (loss) from continuing operations before provision for income taxes .....	3,222	9,266	13,280
Current provision (benefit) for federal income taxes .....	(1,240)	1,987	537
Current provision (benefit) for state income taxes .....	(23)	498	73
Current provision (benefit) for			

foreign income taxes .....	4,168	5,345	4,503
Total current provision (benefit) for income taxes .....	2,905	7,830	5,113
Deferred provision (benefit) for federal income taxes .....	13,654	496	(3,624)
Deferred provision (benefit) for state income taxes .....	(248)	(14)	430
Deferred provision (benefit) for foreign income taxes .....	728	279	(179)
Total deferred provision (benefit) for income taxes .....	14,134	761	(3,373)
Provision (benefit) for income taxes .....	17,039	8,591	1,740
Net income (loss) from continuing operations .....	(13,817)	675	11,540
Income (loss) from discontinued operations .....	...	...	2,116
<b>Net income (loss)</b> .....	(13,817)	675	13,656
Net income (loss) attributable to noncontrolling interests .....	875	1,464	1,031
Net income attributable to common shareholders .....	(12,942)	2,139	14,687
Weighted average shares outstanding - basic .....	18,882	18,731	18,656
Weighted average shares outstanding - diluted .....	18,882	19,056	19,177
Year end shares outstanding .....	18,919	18,757	18,588
Income (loss) per share from continuing operations - basic .....	\$(0.69)	\$0.11	\$0.67
Income (loss) per share from discontinued operations - basic .....	...	...	\$0.11
Net income (loss) per share - basic .....	\$(0.69)	\$0.11	\$0.79
Income (loss) per share from continuing operations - diluted .....	\$(0.69)	\$0.11	\$0.66
Income (loss) per share from discontinued operations - diluted .....	...	...	\$0.11
Net income (loss) per share - diluted .....	\$(0.69)	\$0.11	\$0.77
Dividends declared per common share .....	\$0.10	\$0.40	\$0.40
Total number of employees .....	□911	□972	□901
Number of common stockholders .....	□□750	□□750	□□772
Foreign currency translation adjustments .....	...	(16)	233

□ As is, □ Approximately, □ As of February 17, 2018, □ As of February 17, 2017, □ As of February 19, 2016

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016	2015
		(revised)	(revised)
Cash & cash equivalents .....	42,910	32,284	...
Accounts receivable, gross .....	9,283	7,943	...

Allowance for doubtful accounts .....	395	205	...
Accounts receivable, net .....	8,888	7,738	...
Investments available for sale .....	...	1,776	...
Assets held for sale .....	998	521	...
Raw materials .....	9,522	14,995	...
Work in process .....	2,153	694	...
Finished goods .....	32,372	31,908	...
Inventories .....	44,047	47,597	...
Prepaid expenses & other current assets .....	5,666	4,585	...
Total current assets .....	102,509	94,501	...
Land & improvements .....	841	1,996	...
Buildings & improvements .....	30,760	30,277	...
Machinery & equipment .....	25,160	23,699	...
Furniture & fixtures .....	20,385	19,962	...
Computer software & hardware .....	51,632	49,340	...
Property, plant & equipment, gross .....	128,778	125,274	...
Accumulated depreciation & amortization .....	59,672	52,002	...
Property, plant & equipment, net .....	69,106	73,272	...
Investment securities - trading .....	1,980	1,391	...
Intangible assets, net .....	709	976	...
Deferred income tax assets .....	8,283	21,590	...
Other assets .....	12,608	13,840	...
Total assets .....	195,195	205,570	...
Accounts payable .....	4,215	5,305	...
Accrued volume incentives & service fees .....	18,774	16,264	...
Accrued salaries & employee benefits .....	10,289	10,670	...
Accrued sales, use & property tax .....	3,367	2,376	...
Accrued convention & meeting costs .....	4,970	5,129	...
Other accrued liabilities .....	6,354	6,225	...
Deferred revenue .....	3,348	3,672	...
Revolving credit facility .....	...	9,919	...
Related party note .....	506	...	...
Income taxes payable .....	1,834	3,475	...
Total current liabilities .....	53,657	63,035	...
Liability related to unrecognized tax benefits .....	4,633	6,755	...
Long-term debt & revolving credit facility .....	13,181	...	...
Deferred compensation payable .....	1,980	1,391	...
Long-term deferred income tax liabilities .....	770	...	...
Other liabilities .....	1,242	1,991	...
Total liabilities .....	75,463	73,172	...
Common stock .....	131,525	129,654	...
Retained earnings (accumulated deficit) .....	(2,072)	12,718	...
Noncontrolling interests .....	411	1,286	...
Foreign currency translation adjustments .....	(10,134)	(11,247)	...
Net unrealized gains (losses) on available-for-sale securities .....	2	(13)	...
Accumulated other comprehensive income (loss) .....	(10,132)	(11,260)	...
Total shareholders' equity .....	119,732	132,398	...

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. Nature's Sunshine Products, Inc. common.

ExDate	Amt	Declared	Record	Payable
03/10/2015	0.10	02/05/2015	03/12/2015	03/23/2015
05/20/2015	0.10	05/07/2015	05/22/2015	06/02/2015
08/21/2015	0.10	08/11/2015	08/25/2015	09/08/2015
11/16/2015	0.10	11/03/2015	11/18/2015	11/30/2015
03/09/2016	0.10	02/24/2016	03/11/2016	03/22/2016
05/23/2016	0.10	05/10/2016	05/25/2016	06/06/2016

08/19/2016	0.10	08/08/2016	08/23/2016	09/02/2016
11/21/2016	0.10	11/08/2016	11/23/2016	12/05/2016
03/20/2017	0.10	03/07/2017	03/22/2017	04/03/2017
	0.00		06/06/2017	

**Annual Dividends:**

**1. Nature's Sunshine Products, Inc. common.**

2015	0.40	2016	0.40	2017	0.10
------	------	------	------	------	------

**NEXTDECADE CORP**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
General & administrative expenses	34,551,000	539,568	222,402
General and administrative costs - related party	...	150,000	116,129
Land option & lease expenses	981,000	...	...
Depreciation expense	106,000	...	...
Total operating expenses	35,638,000	...	...
Total operating income (loss)	(35,638,000)	(689,568)	(338,531)
Interest income, net	343,000	254,870	75,344
Other expenses	31,000	...	...
Total other income	312,000	...	...
<b>Net income (loss)</b>	<b>(35,326,000)</b>	<b>(434,698)</b>	<b>(263,187)</b>
Weighted average shares outstanding - basic	100,926,000	4,499,001	4,061,847
Weighted average shares outstanding - diluted	100,926,000	4,499,001	4,061,847
Year end shares outstanding	106,300,000	4,511,700	4,498,966
Net earnings (loss) per share - basic	\$(0.35)	\$(0.10)	\$(0.06)
Net earnings (loss) per share - diluted	\$(0.35)	\$(0.10)	\$(0.06)
Number of full time employees	23	...	...
Number of part time employees	12	...	...
Total number of employees	...	3	3
Number of common stockholders	81	334	16
Number of beneficiary stockholders	...	300	300

2016 and prior years financials are for the Company prior to merger with NextDecade LLC; 2017 Approximately; 2018 As of March 1, 2018; 2015 As of March 1, 2017; 2016 As of March 28, 2015

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Cash & cash equivalents	35,703,000	23,865	...
Investments	5,063,000	...	...
Prepaid expenses	...	20,415	...
Rio Grande LNG site option	1,080,000	...	...
Short-term security deposits	364,000	...	...
Galveston Bay Leases	100,000	...	...
Rio Bravo Pipeline options	111,000	...	...
Prepaid insurance	208,000	...	...
Other prepaid expenses & other current assets	236,000	...	...
Prepaid expenses & other current assets	2,099,000	...	...
Total current assets	42,865,000	44,280	...
Cash, cash equivalents & securities held in Trust	...	117,507,609	...

Computers	69,000	...	...	taxes	8,461	1,564	7,910
Furniture, fixtures, & equipment	246,000	...	...	Deferred income taxes	(2,067)	(85)	378
Leasehold improvements	264,000	...	...	Income taxes	6,394	1,479	8,288
Total fixed assets	579,000	...	...	<b>Net income (loss)</b>	<b>15,612</b>	<b>4,638</b>	<b>17,585</b>
Less: accumulated depreciation	371,000	...	...	Net income attributable to non-controlling interest	379	(87)	(129)
Total fixed assets, net	208,000	...	...	Net income attributable to Nodak Mutual Insurance Company	15,991	4,551	17,456
Project Assets (not placed in service) - Rio Grande	62,866,000	...	...	Weighted average shares outstanding - basic	22,512	...	...
Project Assets (not placed in service) - Rio Bravo	10,152,000	...	...	Weighted average shares outstanding - diluted	22,513	...	...
Total project assets	73,018,000	...	...	Year end shares outstanding	22,338	23,000	...
Property, plant & equipment, net	73,226,000	...	...	Net income (loss) per share - basic	\$0.71	...	...
Total assets	116,091,000	117,551,889	...	Net income (loss) per share - diluted	\$0.71	...	...
Accounts payable	726,000	130,900	...	Number of full time employees	136	129	126
Share-based compensation liability	1,815,000	...	...	Number of stockholders	693	820	...
Employee compensation expense	1,851,000	...	...				
Project asset costs	3,317,000	...	...				
Accrued legal services	141,000	...	...				
Other accrued liabilities	547,000	...	...				
Accrued liabilities & other current liabilities	5,856,000	...	...				
Total current liabilities	8,397,000	130,900	...				
Deferred underwriters fee	...	4,325,000	...				
Note payable to stockholder	...	60,000	...				
Non-current compensation liabilities	2,015,000	...	...				
Non-current share-based compensation liability	2,587,000	...	...				
Total liabilities	12,999,000	4,515,900	...				
Common stock, subject to possible conversion	...	108,035,987	...				
Common stock	11,000	451	...				
Additional paid-in capital	158,738,000	5,698,759	...				
Retained earnings (accumulated deficit)	(55,617,000)	(699,208)	...				
Accumulated other comprehensive income (loss)	(40,000)	...	...				
Total stockholders' equity (deficit)	103,092,000	5,000,002	...				

2016 and prior years financials are for the Company prior to merger with NextDecade LLC

**Recent Dividends:**

**1. NextDecade Corp common.**

No dividends paid.

**Annual Dividends:**

**1. NextDecade Corp common.**

No dividends paid.

**NI HOLDINGS INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
Net premiums earned	179,464	152,756	139,473
Fee income	1,648	1,666	1,854
Net investment income	5,031	3,644	3,571
Net realized capital gain on investments	2,997	5,681	823
Total revenues	189,140	163,747	145,721
Losses & loss adjustment expenses	122,711	118,508	83,876
Amortization of deferred policy acquisition costs	27,750	20,423	18,621
Other underwriting & general expenses	16,673	18,699	17,351
Total expenses	167,134	157,630	119,848
Income (loss) before income taxes	22,006	6,117	25,873
Current income	...	...	...

Cash & cash equivalents	27,594	18,318	...
Fixed income securities, at fair value	236,758	161,470	...
Equity securities, at fair value	47,561	25,917	...
Other investments	1,972	1,972	...
Total cash & investments	313,885	207,677	...
Premiums & agents' balances receivable	25,632	21,986	...
Deferred policy acquisition costs	8,859	8,942	...
Reinsurance recoverable on unpaid losses	4,128	7,192	...
Accrued investment income	1,996	1,431	...
Real estate	10,633	9,578	...
Electronic data processing equipment	1,288	1,637	...
Furniture & fixtures	3,511	3,762	...
Automobiles	1,595	1,488	...
Total property & equipment, gross	17,027	16,465	...
Less: Accumulated depreciation	11,150	11,646	...
Property & equipment, net	5,877	4,819	...
Receivable from Federal Crop Insurance Co	10,501	16,761	...
Goodwill	2,628	2,628	...
Federal income tax recoverable	...	2,933	...
Other assets	3,482	4,334	...
Total assets	376,988	278,703	...
Unpaid losses & loss adjustment expenses	45,890	59,632	...
Unearned premiums	63,262	57,445	...
Reinsurance payable	428	39	...
Federal income tax payable	991	...	...
Deferred income taxes, net	2,539	2,915	...
Accrued expenses & other liabilities	8,305	5,254	...
Total liabilities	121,415	125,285	...
Common stock	230	...	...
Additional paid-in capital	93,496	...	...
Unearned employee stock	...	...	...

2016 and prior years financials are for the Company prior to merger with NextDecade LLC; 2017 Approximately; 2018 As of March 1, 2018; 2015 As of March 1, 2017; 2016 As of March 28, 2015

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
Cash & cash equivalents	27,594	18,318	...
Fixed income securities, at fair value	236,758	161,470	...
Equity securities, at fair value	47,561	25,917	...
Other investments	1,972	1,972	...
Total cash & investments	313,885	207,677	...
Premiums & agents' balances receivable	25,632	21,986	...
Deferred policy acquisition costs	8,859	8,942	...
Reinsurance recoverable on unpaid losses	4,128	7,192	...
Accrued investment income	1,996	1,431	...
Real estate	10,633	9,578	...
Electronic data processing equipment	1,288	1,637	...
Furniture & fixtures	3,511	3,762	...
Automobiles	1,595	1,488	...
Total property & equipment, gross	17,027	16,465	...
Less: Accumulated depreciation	11,150	11,646	...
Property & equipment, net	5,877	4,819	...
Receivable from Federal Crop Insurance Co	10,501	16,761	...
Goodwill	2,628	2,628	...
Federal income tax recoverable	...	2,933	...
Other assets	3,482	4,334	...
Total assets	376,988	278,703	...
Unpaid losses & loss adjustment expenses	45,890	59,632	...
Unearned premiums	63,262	57,445	...
Reinsurance payable	428	39	...
Federal income tax payable	991	...	...
Deferred income taxes, net	2,539	2,915	...
Accrued expenses & other liabilities	8,305	5,254	...
Total liabilities	121,415	125,285	...
Common stock	230	...	...
Additional paid-in capital	93,496	...	...
Unearned employee stock	...	...	...

ownership plan shares .....	2,157	...
Retained earnings (accumulated deficit) .....	152,865	139,591
Accumulated other comprehensive income, net of tax .....	15,998	10,305
Treasury stock, at cost .....	8,037	...
Non-controlling interests .....	3,178	3,522
Total equity (deficit) .....	255,573	153,418

**Recent Dividends:****1. NI Holdings Inc common.**

No dividends paid.

**Annual Dividends:****1. NI Holdings Inc common.**

No dividends paid.

**NODECHAIN INC**

**Acquisition Completed** On Mar. 15, 2018, Co. acquired forty GPU Computers built specifically for mining various types of "cryptocurrency" from Mewe World, Inc., a California Company owned and controlled by Co.'s Chairman of the Board of Directors, Alham Benyameen, for \$220,000.

**NODECHAIN INC**

**Interest Sale Completed** On Jan. 17, 2018, Co. sold 5 GPU Computers ("rigs") built specifically for mining various types of "cryptocurrency", which included a 2 year service contract whereas Co. would provide general maintenance of the mining rigs and electricity to operate them for the duration of the service contract, to an unrelated third party for a total of \$40,000.

**OTELCO INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Revenues .....	68,526,000	68,944,000	71,102,000
Cost of services .....	31,395,000	31,875,000	33,123,000
Selling, general & administrative expenses .....	10,147,000	10,234,000	9,846,000
Depreciation & amortization .....	7,377,000	8,022,000	8,878,000
Total operating expenses .....	48,919,000	50,131,000	51,847,000
Income (loss) from operations .....	19,607,000	18,813,000	19,255,000
Interest expense .....	13,249,000	10,634,000	7,894,000
Loss on debt prepayment penalty ..	2,303,000	...	...
Other income .....	204,000	625,000	1,067,000
Income before income tax benefits (expense) .....	4,259,000	8,804,000	12,428,000
Federal income tax expense (benefit) - current .....	1,201,000	1,176,000	2,552,000
Federal income tax expense (benefit) - deferred .....	(9,332,000)	1,872,000	1,661,000
Total federal income tax expense (benefit) .....	(8,131,000)	3,048,000	4,213,000
State income tax expense (benefit) - current .....	284,000	308,000	366,000
State income tax expense (benefit) - deferred .....	(9,000)	302,000	365,000
Total state income tax expense (benefit) .....	275,000	610,000	731,000
Income tax expense (benefit) .....	(7,856,000)	3,658,000	4,944,000
<b>Net income (loss) .....</b>	<b>12,115,000</b>	<b>5,146,000</b>	<b>7,484,000</b>
Weighted average shares outstanding-basic .....	3,346,689	3,283,177	3,239,306
Weighted average shares outstanding-diluted .....	3,445,632	3,404,696	3,313,641
Year end shares outstanding .....	3,346,689	3,291,750	3,247,879
Net income (loss) per share-basic .....	\$3.62	\$1.57	\$2.31

Net income (loss) per share-diluted .....	\$3.52	\$1.51	\$2.26
Number of full time employees .....	218	218	224
Number of part time employees .....	4	4	4
Total number of employees .....	222	222	228
Number of stockholders, class			
A .....	2,700	3,250	3,500
Number of common stockholders, Class B .....	...	...	0

Reclassified to conform with 2017 presentation; Approximate; As of March 13, 2018; As of March 14, 2017; As of March 11, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents .....	3,570,000	10,538,000
Accounts receivable - due from subscribers, gross .....	4,873,000	5,222,000
Allowance for doubtful accounts .....	226,000	187,000
Carrier access bills receivable .....	282,000	380,000
National Exchange Carrier Association receivable .....	1,238,000	1,028,000
Receivables from Alabama Service Fund .....	53,000	56,000
Other miscellaneous receivables .....	302,000	64,000
Materials & supplies .....	2,700,000	2,184,000
Prepaid expenses .....	3,122,000	2,912,000
Total current assets .....	15,914,000	22,197,000
Land .....	1,164,000	1,164,000
Building & improvements .....	12,999,000	12,812,000
Telephone equipment .....	239,539,000	234,422,000
Cable television equipment .....	12,417,000	12,199,000
Furniture & equipment .....	3,087,000	3,067,000
Vehicles .....	6,992,000	6,855,000
Computer software equipment .....	16,830,000	16,648,000
Internet equipment .....	3,940,000	3,891,000
Total property & equipment, gross .....	296,968,000	291,058,000
Less: accumulated depreciation & amortization .....	246,080,000	241,787,000
Property & equipment, net .....	50,888,000	49,271,000
Goodwill .....	44,976,000	44,976,000
Intangible assets, net .....	1,328,000	1,785,000
Investment in CoBank stock, at cost .....	1,311,000	1,475,000
Rental property .....	245,000	271,000
Other miscellaneous .....	76,000	75,000
Investments .....	1,632,000	1,821,000
Other assets .....	201,000	222,000
Total assets .....	114,939,000	120,272,000
Accounts payable .....	1,619,000	1,477,000
Accrued expenses .....	4,803,000	4,730,000
Advance billings & payments .....	1,684,000	1,487,000
Customer deposits .....	58,000	62,000
Current maturity of long-term notes payable .....	3,891,000	6,071,000
Total current liabilities .....	12,055,000	13,827,000
Deferred income taxes .....	18,939,000	28,280,000
Advance billings & payments .....	2,367,000	1,987,000
Other liabilities .....	13,000	26,000
New credit facility .....	81,562,000	...
Debt issuance cost .....	(1,504,000)	...
Long-term notes payable, less current maturities .....	80,058,000	86,860,000
Total liabilities .....	113,432,000	130,980,000
Class A common stock .....	34,000	33,000
Additional paid in capital .....	4,285,000	4,186,000

Retained earnings (deficit) .....	(2,812,000)	(14,927,000)
Total stockholders' equity (deficit) .....	1,507,000	(10,708,000)

Reclassified to conform with 2017 presentation

**Recent Dividends:****1. Otelco Inc class A common (new).**

No dividends paid.

**2. Otelco Inc class B common.**

No dividends paid.

**3. Otelco Inc class B common.**

No dividends paid.

**4. Otelco Inc class A common.**

No dividends paid.

**Annual Dividends:****1. Otelco Inc class A common (new).**

No dividends paid.

**2. Otelco Inc class B common.**

No dividends paid.

**3. Otelco Inc class B common.**

No dividends paid.

**4. Otelco Inc class A common.**

No dividends paid.

**PACIFIC ETHANOL INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Net sales .....	1,632,255,000	1,624,758,000	1,191,176,000
Cost of goods sold .....	1,626,324,000	1,570,400,000	1,180,810,000
Gross profit (loss) .....	5,931,000	54,358,000	10,366,000
Selling, general & administrative expenses .....	31,516,000	30,849,000	26,368,000
Asset impairments .....	...	...	1,970,000
Income (loss) from operations .....	(25,585,000)	23,509,000	(17,972,000)
Fair value adjustments & warrant inducements ..	(473,000)	557,000	(1,641,000)
Interest expense .....	12,938,000	22,406,000	12,594,000
Other income (expense), net .....	(345,000)	(1,000)	18,000
Income (loss) before provision for income taxes .....	(38,395,000)	545,000	(28,907,000)
Current provision (benefit) .....	(490,000)	141,000	(8,011,000)
Deferred provision (benefit) .....	169,000	(1,122,000)	(2,023,000)
Provision (benefit) for income taxes .....	(321,000)	(981,000)	(10,034,000)
<b>Consolidated net income (loss) .....</b>	<b>(38,074,000)</b>	<b>1,526,000</b>	<b>(18,873,000)</b>
Net income (loss) attributed to noncontrolling interests .....	3,110,000	(107,000)	87,000
Net income (loss) attributed to Pacific Ethanol, Inc. .....	(34,964,000)	1,419,000	(18,786,000)
Preferred stock dividends .....	1,265,000	1,269,000	1,265,000
Income allocated to participating securities .....	...	2,000	...
Income (loss) available to common stockholders .....	(36,229,000)	148,000	(20,051,000)
Weighted average shares outstanding - basic .....	42,745,000	42,182,000	33,173,000
Weighted average shares outstanding - diluted .....	42,745,000	42,251,000	33,173,000
Year end shares outstanding .....	43,985,871	43,312,370	42,515,104
Net earnings (loss) per share - basic .....	\$(0.85)	\$0.00	\$(0.60)
Net earnings (loss) per share - diluted .....	\$(0.85)	\$0.00	\$(0.60)

Number of full time employees.....	□ <sup>5</sup> 560	□ <sup>4</sup> 500	□ <sup>5</sup> 465
Number of common stockholders.....	□ <sup>6</sup> 230	□ <sup>4</sup> 270	□ <sup>5</sup> 340
Number of non-voting common stockholders.....	□ <sup>1</sup>	□ <sup>1</sup>	□ <sup>5</sup> 15

□ Reclassified to conform with 2017 presentation; □ Approximately; □ As of March 15, 2018; □ As of March 15, 2017; □ As of March 14, 2016; □ As of March 14, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	□ <sup>1</sup> 2017	□ <sup>2</sup> 2016 (revised)
Cash & cash equivalents.....	49,489,000	64,259,000
Accounts receivable, gross.....	80,363,000	86,606,000
Allowance for doubtful accounts.....	19,000	331,000
Accounts receivable, net.....	80,344,000	86,275,000
Finished goods.....	35,652,000	33,773,000
Work in progress.....	8,807,000	7,092,000
Raw materials.....	7,601,000	6,571,000
Low-carbon & RIN credits.....	7,952,000	10,926,000
Other inventories.....	1,538,000	1,708,000
Inventories.....	61,550,000	60,070,000
Prepaid inventory.....	3,281,000	9,946,000
Income tax receivables.....	743,000	5,730,000
Derivative assets.....	998,000	978,000
Other current assets.....	6,841,000	7,943,000
Total current assets.....	203,246,000	235,201,000
Facilities & plant equipment.....	601,156,000	530,735,000
Land.....	8,970,000	7,771,000
Other equipment, vehicles & furniture.....	10,189,000	9,714,000
Construction in progress.....	38,041,000	29,393,000
Less accumulated depreciation.....	150,004,000	112,423,000
Property & equipment, net.....	508,352,000	465,190,000
Intangible assets, net.....	2,678,000	2,678,000
Other assets.....	6,020,000	5,169,000
Total assets.....	720,296,000	708,238,000
Accounts payable - trade.....	39,738,000	37,051,000
Accrued liabilities.....	21,673,000	20,280,000
Current portion - capital leases.....	592,000	794,000
Current portion - long-term debt.....	20,000,000	10,500,000
Derivative liabilities.....	2,307,000	4,115,000
Other current liabilities.....	6,396,000	6,101,000
Total current liabilities.....	90,706,000	78,841,000
Kinergy Marketing LLC, or ("Kinergy") lines of credit.....	49,477,000	49,862,000
Pacific Ethanol Pekin, Inc. ("Pekin") term loan.....	53,500,000	64,000,000
Pekin revolving loan.....	32,000,000	32,000,000
Illinois Corn Processing, LLC ("ICP") term loan.....	22,500,000	...
ICP revolving loan.....	18,000,000	...
Pacific Aurora LLC ("Pacific Aurora") line of credit.....	...	1,000,000
Parent notes payable.....	68,948,000	55,000,000
Less unamortized debt discount.....	(1,409,000)	(1,626,000)
Less unamortized debt financing costs.....	(1,925,000)	(1,708,000)
Less: short-term portion.....	20,000,000	10,500,000
Capital leases, net of current portion.....	123,000	547,000
Warrant liabilities at fair value.....	...	651,000
Other liabilities.....	24,676,000	21,910,000
Total liabilities.....	336,596,000	289,977,000
Series B preferred stock.....	1,000	1,000
Common stock.....	44,000	40,000
Non-voting common stock.....	...	4,000
Additional paid-in capital.....	927,090,000	922,698,000
Accumulated other		

comprehensive income (loss).....	(2,234,000)	(2,620,000)
Retained earnings (accumulated deficit).....	(568,462,000)	(532,233,000)
Total Pacific Ethanol, Inc. stockholders' equity (deficit).....	356,439,000	387,890,000
Noncontrolling interests.....	27,261,000	30,371,000
Total stockholders' equity (deficit).....	383,700,000	418,261,000

□ Reclassified to conform with 2017 presentation

**Recent Dividends:**

- 1. Pacific Ethanol Inc common.**  
No dividends paid.
  - 2. Pacific Ethanol Inc series B cumulative redeemable convertible preferred.**  
No dividends paid.
  - 3. Pacific Ethanol Inc non voting common.**  
No dividends paid.
  - 4. Pacific Ethanol Inc series A cumulative redeemable convertible preferred.**  
No dividends paid.
- Annual Dividends:**
- 1. Pacific Ethanol Inc common.**  
No dividends paid.
  - 2. Pacific Ethanol Inc series B cumulative redeemable convertible preferred.**  
No dividends paid.
  - 3. Pacific Ethanol Inc non voting common.**  
No dividends paid.
  - 4. Pacific Ethanol Inc series A cumulative redeemable convertible preferred.**  
No dividends paid.

**PATRIOT NATIONAL INC**

**Bankruptcy Proceedings** On Mar. 15, 2018, Co. filed with the U.S. Bankruptcy Court a Second Amended Joint Chapter 11 Plan of Reorganization and Third Amended Disclosure Statement. The Disclosure Statement notes, "Pursuant to the Plan, all of the issued and outstanding equity interests in PNI and each of its direct and indirect subsidiaries (the 'Subsidiary Debtors') will be extinguished, and the First Lien Lenders (or their designees) will receive 100% of newly issued equity interests in Reorganized PNI and each of the Reorganized Subsidiary Debtors on account of a portion of their claims arising under their applicable financing agreements." The Disclosure Statement includes Exhibit G: Committee Letter to Unsecured Creditors. Exhibit G argues, "The Committee believes that the Plan inappropriately provides for the conversion of a portion of Cerberus' prepetition debt into equity in the reorganized Debtors at no real cost to Cerberus. In fact, many of the costs associated with the chapter 11 cases, including, among other things, payment of the certain of the indebtedness under the DIP Facility, Exit Facility and outstanding administrative claims will be borne by the Litigation Trust and thus, general unsecured creditors. In light of the flaws and defects with respect to the Plan and the information the Committee has received to date, the Committee believed that the current Plan is NOT in the best interests of the Debtors' unsecured creditors." The Court subsequently approved the Third Amended Disclosure Statement and scheduled an Apr. 24, 2018 hearing to consider the Second Amended Joint Chapter 11 Plan.

**PAVMED INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	□ <sup>1</sup> 2016 (revised)	□ <sup>2</sup> 2015 (revised)
General & administrative expenses.....	5,415,324	3,931,264	1,287,273
Research & development expenses.....	2,618,795	1,719,587	489,327
Total operating expenses.....	8,034,119	5,650,851	1,776,600
Operating income (loss).....	(8,034,119)	(5,650,851)	...
Interest expense.....	724,684	...	...
Loss on issuance of series A preferred stock units in a private placement....	3,124,285	...	...
Change in fair value of series A			

warrants derivative liability.....	1,942,501	...	...
Change in fair value of series A convertible preferred stock conversion option derivative liability.....	643,318	...	...
Modification of series A-1 warrant agreement.....	222,000	...	...
Total other income (expense), net.....	(1,485,150)	...	...
Income (loss) before income tax....	(9,519,269)	(5,650,851)	...
<b>Net income (loss)....</b>	<b>(9,519,269)</b>	<b>(5,650,851)</b>	<b>(1,776,600)</b>
Series A convertible preferred stock dividends.....	112,570	...	...
Series A-1 convertible preferred stock dividends.....	79,788	...	...
Deemed dividend series A-1 convertible preferred stock issued in a private placement.....	182,500	...	...
Deemed dividend series A-1 convertible preferred stock issued in the series A exchange offer.....	504,007	...	...
Net income (loss) attributable to common stockholders (10,398,134) (5,650,851)....			
Weighted average shares outstanding - basic.....	13,495,951	12,972,153	11,278,755
Weighted average shares outstanding - diluted.....	13,495,951	12,972,153	11,278,755
Year end shares outstanding.....	14,551,234	13,330,811	12,250,000
Net earnings (loss) per share - basic.....	\$(0.71)	\$(0.44)	\$(0.16)
Net earnings (loss) per share - diluted....	\$(0.71)	\$(0.44)	\$(0.16)
Total number of employees.....	5	7	6
Number of common stockholders.....	...	□ <sup>3</sup> 19	□ <sup>5</sup> 25
Number of beneficiary stockholders.....	□ <sup>5</sup> 1,200	□ <sup>5</sup> 600	...

□ Reclassified to conform with 2017 presentation; □ Reclassified to conform with 2016 presentation; □ As of February 10, 2017; □ As of April 11, 2016; □ Approximately; □ As of March 12, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	□ <sup>1</sup> 2016 (revised)
Cash.....	1,535,022	585,680
Security deposits.....	14,250	48,350
Prepaid insurance.....	33,175	35,947
Advanced payments to suppliers.....	41,042	71,193
Prepaid expenses & other current assets.....	88,467	155,490
Total current assets.....	1,623,489	741,170
Research & development equipment.....	13,656	10,156
Computer equipment.....	13,438	11,637
Equipment, gross.....	27,094	21,793
Less: accumulated depreciation.....	10,903	3,793
Equipment, net.....	16,191	18,000

Deferred offering costs	111,249	111,249
Total assets	1,639,680	870,419
Accounts payable	864,405	949,413
Accrued bonus	459,451	...
Accrued payroll	125,088	...
Accrued vacation	28,722	28,324
Accrued board of director fees	82,500	72,500
Accrued professional fees	...	111,249
Accrued operating expenses	10,263	28,000
Total accrued expenses & other current liabilities	706,024	240,073
Series A warrants derivative liability	761,123	...
Series A convertible preferred stock conversion option derivative liability	212,217	...
Total current liabilities	2,543,769	1,189,486
Senior secured note, net	1,944,268	...
Total liabilities	4,488,037	1,189,486
Preferred stock, net	1,032,650	...
Common stock, net	14,551	13,331
Additional paid-in capital	14,012,053	7,369,437
Retained earnings (accumulated deficit)	(17,907,611)	(7,701,835)
Total stockholders' equity (deficit)	(2,848,357)	(319,067)

<sup>1</sup> Reclassified to conform with 2017 presentation; <sup>2</sup> Net of un-amortized debt - Senior secured note: \$3,244,274

#### Recent Dividends:

**1. PAVmed Inc common.**  
No dividends paid.

#### Annual Dividends:

**1. PAVmed Inc common.**  
No dividends paid.

#### PAVmed INC

##### Auditor's Report Auditor's Report

The following is an excerpt from the Report of Independent Auditors, Citrin Cooperman & Company, LLP, as it appeared in Co.'s 2017 10-K report: "In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2017 and 2016, and the results of their consolidated operations and their cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company's recurring losses from operations, recurring cash used in operating activities, accumulated deficit and absence of revenue generation raise substantial doubt about its ability to continue as a going concern. Management's plans concerning these matters are also discussed in Note 1 to the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

#### PIERIS PHARMACEUTICALS INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	<sup>1</sup> 2016 (revised)	<sup>2</sup> 2015 (revised)
Revenue	25,275,000	5,831,000	2,931,931
Research & development	22,285,000	19,699,000	8,244,751
General & administrative expenses	17,584,000	8,891,000	8,368,215
Total operating expenses	39,869,000	28,590,000	16,612,966
Income (loss) from operations	(14,594,000)	(22,759,000)	(13,681,035)
Interest income	152,000	2,000	...
Interest expense	...	...	184,645
Other income (expense), net	(2,102,000)	120,000	10,905
Income before income taxes - Domestic	(13,840,000)	(8,725,000)	(7,563,300)
Income before	...	...	...

income taxes - United States	(2,704,000)	(13,913,000)	(6,291,475)
Income (loss) before income taxes	(16,544,000)	(22,637,000)	(13,854,775)
Current foreign income taxes	1,103,000	162,000	203,866
Total current income taxes	1,103,000	162,000	203,866
Provision (benefit) for income tax	1,103,000	162,000	203,866
Net income (loss)	(17,647,000)	(22,799,000)	(14,058,641)
Weighted average shares outstanding - basic	43,931,000	41,713,000	34,392,636
Weighted average shares outstanding - diluted	43,931,000	41,713,000	34,392,636
Year end shares outstanding	45,017,062	43,058,827	39,833,023
Net income (loss) per share - basic	\$(0.40)	\$(0.55)	\$(0.41)
Net income (loss) per share - diluted	\$(0.40)	\$(0.55)	\$(0.41)
Number of full time employees	68	<sup>3</sup> 49	<sup>4</sup> 38
Number of part time employees	...	<sup>3</sup> 3	<sup>4</sup> 1
Total number of employees	...	<sup>3</sup> 52	<sup>4</sup> 39
Number of common stockholders	<sup>5</sup> 84	<sup>6</sup> 143	<sup>7</sup> 148
Number of preferred stockholders	<sup>5</sup> 5	<sup>6</sup> 5	...

<sup>1</sup> Reclassified to conform with 2017 presentation; <sup>2</sup> Reclassified to conform with 2016 presentation; <sup>3</sup> As of March 23, 2017; <sup>4</sup> As of March 23, 2016; <sup>5</sup> As of March 12, 2018; <sup>6</sup> As of March 20, 2017; <sup>7</sup> As of March 20, 2016

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	<sup>1</sup> 2016 (revised)
Cash & cash equivalents	37,878,000	29,356,000
Short-term investments	34,751,000	...
Accounts receivables	15,546,000	57,000
Prepaid expenses & other current assets	1,615,000	3,260,000
Total current assets	89,790,000	32,673,000
Laboratory equipment	6,101,000	3,869,000
Office & computer equipment	494,000	499,000
Leasehold improvements	318,000	321,000
Property, plant & equipment, gross	6,913,000	4,689,000
Less: accumulated depreciation	2,879,000	2,425,000
Property & equipment, net	4,034,000	2,264,000
Long-term investments	9,922,000	...
Other non-current assets	130,000	126,000
Total assets	103,876,000	35,063,000
Accounts payable	2,452,000	2,386,000
Accrued compensation expense	2,325,000	1,198,000
Accrued professional fees	1,322,000	624,000
Accrued research & development fees	791,000	1,284,000
Accrued audit & tax fees	424,000	455,000
Other current liabilities	1,308,000	158,000
Accrued expenses & other current liabilities	6,170,000	3,719,000
Deferred revenues, current portion	37,153,000	2,275,000
Total current liabilities	45,775,000	8,380,000
Deferred revenue	46,542,000	1,409,000
Other long-term liabilities	37,000	47,000
Total liabilities	92,354,000	9,836,000
Common stock	45,000	43,000
Additional paid in capital	136,484,000	129,350,000
Accumulated other comprehensive income (loss)	(4,695,000)	(1,501,000)

Retained earnings (accumulated deficit)	(120,312,000)	(102,665,000)
Total stockholders' equity (deficit)	11,522,000	25,227,000

<sup>1</sup> Reclassified to conform with 2017 presentation

#### Recent Dividends:

**1. Pieris Pharmaceuticals Inc common.**  
No dividends paid.

#### Annual Dividends:

**1. Pieris Pharmaceuticals Inc common.**  
No dividends paid.

#### POINT.360 (NEW)

**Bankruptcy Proceedings** On Mar. 16, 2018, Medley Capital (MCC) and Medley Opportunity Fund II (MOF) filed with the U.S. Bankruptcy Court an objection to Co.'s motion for an order extending the plan and disclosure statement filing deadline until May 8, 2018. The objection asserts, "The Court has repeatedly stressed the need for the Debtor to 'move forward quickly' and, as such, set an Apr. 1, 2018 deadline for the Debtor to file its plan and disclosure statement. Debtor's counsel has frequently advised the Court that the Apr. 1, 2018 deadline was 'not a problem,' and reserved the Debtor's right to seek an extension of that deadline 'to the extent there's something unforeseeable that happens, so long as [the Debtor] can show cause.' The Debtor's argument that it needs additional time to value its assets prior to formulating a plan proposal and negotiating with parties in interest fails. The Debtor has on multiple occasions already taken a position on valuation that it has asked this Court to rely on. Although Medley has not yet determined its views definitively with respect to such asserted values and any diminution, the idea that the Debtor now purports to be expending scarce resources to arrive at a potentially different value than it has repeatedly asked this Court to rely on is, to say the least, concerning. Additionally, although the Debtor has retained a variety of professionals in this case, none of the professionals have been retained to perform an asset valuation (and certainly no 'valuation experts' that the Debtor refers to). Importantly, a comprehensive valuation of each and every piece of equipment owned by the Debtor is unnecessary to formulate a plan proposal and commence plan negotiations, much like a comprehensive review was not necessary (nor, upon information and belief, conducted) in reaching the valuation the Debtor previously asked the Court to rely on."

#### PREMIER EXHIBITIONS INC

**Bankruptcy Proceedings** On Mar. 16, 2018, the U.S. Bankruptcy Court approved Co.'s settlement agreement with 417 Fifth Ave Real Estate. Creditor 417 Fifth Ave Real Estate, the landlord of Co.'s former New York exhibition site, had filed proofs of claim asserting claims totaling nearly \$12,600,000 for unpaid rent and construction loads. The claim was settled after a day-long mediation. As previously reported, "On Dec. 21, 2017, in its Order Appointing Judicial Mediator ('Mediation Order') [D.E. 882], this Court directed the parties to mediate the dispute over the Construction Allowance Claim. Thereafter, the Debtors and the Landlord attended mediation on Jan. 5, 2018 pursuant to the Mediation Order. Subject to Bankruptcy Court approval, the Debtors and the Landlord successfully resolved all claims between the parties at the mediation. The Landlord's Claim No. 48-1 is hereby amended and shall be an allowed unsecured claim against Premier in the total amount of \$5,500,000; The Construction Allowance Claim (filed against RMST), the Remaining Rent Claim (filed against RMST), and Claim No. 49- 1 (filed against Premier) are withdrawn with prejudice and the Landlord shall have no further claim against the estates." The motion continues, "The settlement will result in the resolution of large and contested claims asserted against multiple Debtors by the Landlord. Specifically, it will result in the reduction of unsecured claims in excess of \$12,000,000 asserted against RMST by the Landlord as well as a reduction of the unsecured claims asserted against Premier by the Landlord by in excess of \$7,000,000."

#### PROVIDENT BANCORP INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2017	<sup>1</sup> 2016 (revised)	<sup>2</sup> 2015 (revised)
Interest & fees on loans	32,510	25,549	22,124
Interest & dividends on securities	3,172	3,312	3,290
Interest on interest-bearing	...	...	...





Total assets	15,978,000	16,663,000	income taxes	4	...	...	equity (deficit)	5,896	4,839
Loans payable, net of debt discount	3,221,000	2,586,000	Current provision (benefit) for income taxes	...	...	20			
Accounts payable	457,000	747,000	Provision (benefit) for income taxes	17	...	20			
Accrued vacation	57,000	54,000	<b>Net income (loss)</b>	640	(1,210)	(1,885)			
Accrued wages & incentive	1,113,000	796,000	Weighted average shares outstanding						
Accrued clinical & consulting	568,000	202,000	- basic	2,042	2,042	<sup>2</sup> 2,042			
Accrued legal & patent	61,000	51,000	Weighted average shares outstanding						
End of term fee	225,000	155,000	- diluted	2,042	2,042	<sup>2</sup> 2,042			
Deferred rent	68,000	46,000	Year end shares outstanding	2,042	2,042	<sup>2</sup> 2,042			
Accrued other expenses	70,000	13,000	Net income (loss) per share - basic	\$0.31	\$(0.59)	<sup>2</sup> \$(0.90)			
Accrued expenses	2,162,000	1,317,000	Net income (loss) per share - diluted	\$0.31	\$(0.59)	<sup>2</sup> \$(0.90)			
Total current liabilities	5,840,000	4,650,000	Number of full time employees	<sup>3</sup> 17	...	...			
Loan payable, net of current portion, debt discount & issuance costs	...	3,217,000	Number of part time employees	<sup>3</sup> 3	...	...			
Derivative liability	1,000	35,000	Total number of employees	<sup>3</sup> 20	<sup>3</sup> 22	<sup>3</sup> 22			
Total liabilities	5,841,000	7,902,000	Number of common stockholders	<sup>3</sup> 21	<sup>3</sup> 28	<sup>3</sup> 29			
Common stock	2,000	1,000							
Additional paid in capital	184,137,000	164,706,000							
Retained earnings (accumulated deficit)	(174,002,000)	(155,946,000)							
Total stockholders' equity (deficit)	10,137,000	8,761,000							

**Recent Dividends:****1. Pulmatrix Inc common.**

No dividends paid.

**Annual Dividends:****1. Pulmatrix Inc common.**

No dividends paid.

**PULMATRIX INC****Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2017 10-K: "In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**QUALSTAR CORP****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	<sup>1</sup> 2015
		(revised)	(revised)
Net revenues	10,641	9,417	4,924
Cost of goods sold	6,392	6,824	3,881
Gross profit (loss)	4,249	2,593	1,043
Engineering expenses	535	990	694
Sales & marketing expenses	1,239	1,229	957
General & administrative expenses	1,818	1,587	1,259
Total operating expenses	3,592	3,806	2,910
Income (loss) from operations	657	(1,213)	(1,867)
Other income (expenses)	...	3	2
Income (loss) before income taxes	657	(1,210)	(1,865)
Current state provision (benefit) for income taxes	13	...	20
Current foreign			

Cash & cash equivalents	4,698	3,691	
Restricted cash	100	100	
Accounts receivable, net	1,802	1,583	
Raw materials	55	45	
Finished goods	1,509	1,315	
Inventories, net	1,564	1,360	
Prepaid expenses & other current assets	163	166	
Total current assets	8,327	6,900	
Leasehold improvements	114	114	
Furniture & fixtures	268	314	
Machinery & equipment	842	1,039	
Property & equipment, gross	1,224	1,467	
Less: accumulated depreciation & amortization	1,052	1,181	
Property & equipment, net	172	286	
Other assets	68	77	
Total assets	8,567	7,263	
Accounts payable	1,065	888	
Accrued salaries & payroll taxes	59	62	
Accrued vacation	114	120	
Accrued bonuses	...	40	
Accrued payroll & related liabilities	173	222	
Deferred service revenue	834	787	
Accrued warranty	322	236	
Accrued outside commissions	69	28	
Accrued contingent legal fees	...	25	
Accrued deferred rent	29	37	
Other accrued liabilities	34	33	
Total current liabilities	2,526	2,256	
Other long-term liabilities	52	63	
Deferred service revenue, long-term	93	105	
Total long-term liabilities	145	168	
Total liabilities	2,671	2,424	
Common stock	19,480	19,063	
Retained earnings (accumulated deficit)	(13,584)	(14,224)	
Total shareholders'			

<sup>1</sup> For 6 months due to fiscal year end change; <sup>2</sup> Adjusted for 1-for-6 stock split, June 16, 2016; <sup>3</sup> As is; <sup>4</sup> As of March 8, 2018;

<sup>5</sup> Approximately; <sup>6</sup> As of March 8, 2017; <sup>7</sup> As of March 8, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016
		(revised)
Cash & cash equivalents	4,698	3,691
Restricted cash	100	100
Accounts receivable, net	1,802	1,583
Raw materials	55	45
Finished goods	1,509	1,315
Inventories, net	1,564	1,360
Prepaid expenses & other current assets	163	166
Total current assets	8,327	6,900
Leasehold improvements	114	114
Furniture & fixtures	268	314
Machinery & equipment	842	1,039
Property & equipment, gross	1,224	1,467
Less: accumulated depreciation & amortization	1,052	1,181
Property & equipment, net	172	286
Other assets	68	77
Total assets	8,567	7,263
Accounts payable	1,065	888
Accrued salaries & payroll taxes	59	62
Accrued vacation	114	120
Accrued bonuses	...	40
Accrued payroll & related liabilities	173	222
Deferred service revenue	834	787
Accrued warranty	322	236
Accrued outside commissions	69	28
Accrued contingent legal fees	...	25
Accrued deferred rent	29	37
Other accrued liabilities	34	33
Total current liabilities	2,526	2,256
Other long-term liabilities	52	63
Deferred service revenue, long-term	93	105
Total long-term liabilities	145	168
Total liabilities	2,671	2,424
Common stock	19,480	19,063
Retained earnings (accumulated deficit)	(13,584)	(14,224)
Total shareholders'		

**Recent Dividends:****1. Qualstar Corp common.**

No dividends paid.

**Annual Dividends:****1. Qualstar Corp common.**

No dividends paid.

**REAL INDUSTRY INC**

**Bankruptcy Proceedings** On Mar. 14, 2018, Co. filed with the U.S. Bankruptcy Court an objection to the ad hoc committee of equity security holders' motion to shorten notice with respect to the ad hoc committee's motion to (1) terminate Co.'s exclusivity and (2) adjourning the Disclosure Statement hearing. The Debtors assert, "The relief sought in the Exclusivity Termination Motion seeks to disrupt the Debtor's plan solicitation process by, among other things, adjourning the Disclosure Statement Hearing Date to an unknown date. Without any mention of the fact that such a modified timeline would cause the Debtor to default under its post-petition financing facility, to the detriment of the estate and common shareholders, the Ad Hoc Committee asserts what are essentially Plan confirmation objections as grounds to terminate exclusivity. None of these asserted grounds for termination of Co.'s exclusivity period warrant a hearing on the Exclusivity Termination Motion in advance of the Disclosure Statement Hearing Date. Therefore, not surprisingly, the Motion to Shorten does not even attempt to explain why such arguments must be heard in advance of the Disclosure Statement Hearing Date. At a minimum, the Court should require that the Exclusivity Termination Motion be heard on the Disclosure Statement Hearing Date, with objections to be filed on or before Mar. 26, 2018 at 4:00 p.m. (which is the same date as the Debtors' deadline to file a reply to any objections to the motion to approve the Disclosure Statement)." The U.S. Court subsequently issued an order denying the ad hoc committee's motion to shorten notice with respect to the exclusivity termination and Disclosure Statement adjournment motions.

**REAL INDUSTRY INC**

**Bankruptcy Proceedings** On Mar. 16, 2018, Co. filed with the U.S. Bankruptcy Court a motion to file under seal file portions of schedules related to Co.'s asset purchase agreement. The seal motion explains, "Minor portions of the Proposed Disclosure Schedules were redacted due to commercial confidentiality reasons. For example, the redacted information consists of sensitive information concerning, inter alia, the Real Alloy Debtors' bank accounts (including bank account numbers and account signatories), and business information that could put the Real Alloy business at a significant disadvantage if disclosed to competitors either before or after closing, such as sales volumes and revenues from top customers and the details associated with certain environmental matters (collectively, the 'Confidential Information'). Given the sensitivity of this information, the Debtors redacted those portions of the Proposed Disclosure Schedules that describe the Confidential Information in order to avoid the public disclosure of such information. In light of the foregoing, by this Motion, the Debtors respectfully seek the entry of the Proposed Order permitting the Debtors to file the un-redacted Proposed Disclosure Schedules under seal. Disclosure of the Confidential Information could cause significant damage to the Real Alloy Debtors' businesses by exposing to the public highly confidential financial information (most of which falls within the scope of Rule 9037(a) of the Federal Rules of Bankruptcy Procedure and is properly redacted) and/or information that would provide an unfair advantage to competitors by providing them with sensitive information concerning certain of the Real Alloy Debtors' customers and operational issues."

**RENTECH INC**

**Bankruptcy Proceedings** On Mar. 15, 2018, Co. filed with the U.S. Bankruptcy Court a Supplement to its Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation. The Supplement contains the following document: Exhibit A, draft articles of amendment of the amended and restated articles of incorporation, as amended. The Supplement notes, "Whenever the Board of Directors at any meeting thereof, by a majority vote of the whole Board, determines that it is in the best interests of Co., Co. may (1) sell, lease, exchange, or convey all of its property and assets, including its goodwill and its corporate franchises, or (2) vote or consent to the sale, lease, exchange or other disposition of all, or substantially all, of the property or assets of another entity which it controls, including its goodwill; upon such terms and conditions and for such consideration as the Board of Directors shall deem expedient; provided, however, that the sale, lease, exchange, or other disposition of all or substantially all of such property and assets, other than pursuant to a court order, shall be authorized or

ratified by the affirmative vote of the holders of at least two-thirds of the capital stock then issued and outstanding, unless any class or series of stock is entitled to vote thereon as a class, in which event the authorization shall require the affirmative vote of the holders of two-thirds of the shares of each class of shares entitled to vote as a class thereon and of the total shares entitled to vote thereon, such vote to be taken at a meeting of shareholders duly called for that purpose as provided by the statutes of the State of Colorado."

**RESONANT INC**  
**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Revenues	653,000	302,000	...
Research & development expenses	10,045,000	6,895,000	4,308,000
General & administrative expenses	9,644,000	8,697,000	4,942,000
Depreciation & amortization expenses	...	...	491,000
Total operating expenses	19,689,000	15,592,000	9,741,000
Operating income (loss)	(19,036,000)	(15,290,000)	(9,741,000)
Interest & investment income	67,000	22,000	27,000
Warrant inducement expense	2,688,000	...	...
Other income (expense)	(10,000)	(1,000)	...
Total other income (expense)	(2,631,000)	21,000	27,000
Income (loss) before income taxes	(21,667,000)	(15,269,000)	(9,714,000)
U.S. state & local provision (benefit) for income taxes - current	1,000	1,000	1,000
Total U.S. state & local income taxes	1,000	1,000	1,000
Foreign provision (benefit) for income taxes - deferred	(15,000)	(23,000)	...
Total foreign income taxes	(15,000)	(23,000)	...
Provision for (benefit from) income taxes	(14,000)	(22,000)	1,000
<b>Net income (loss)</b>	<b>(21,653,000)</b>	<b>(15,247,000)</b>	<b>(9,715,000)</b>
Weighted average shares outstanding - basic	15,015,446	9,691,115	7,160,567
Weighted average shares outstanding - diluted	15,015,446	9,691,115	7,160,567
Year end shares outstanding	19,511,276	12,468,647	7,241,949
Net earnings (loss) per share - basic	\$(1.44)	\$(1.57)	\$(1.36)
Net earnings (loss) per share - diluted	\$(1.44)	\$(1.57)	\$(1.36)
Total number of employees	53	37	27
Number of common stockholders	67	90	49

Reclassified to conform with 2017 presentation; Reclassified to conform with 2016 presentation; Shares increased due to the effect of exercise of warrants for cashless and cash; Shares increased due to the effect of exercise of stock options for cashless and cash; Shares increased due to the effect of issuance of common stock for compensation and sales of common stock; Shares increased due to the effect of issuance for compensation, services of consultants, common stock sales, and business assets acquisition

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Cash & cash equivalents	19,524,000	5,084,000	...
Accounts receivable	50,000	56,000	...
Prepaid expenses & other current assets	536,000	160,000	...
Restricted cash	100,000	...	...
Investment held-to-maturity	...	4,747,000	...
Total current assets	20,210,000	10,047,000	...
Computers, peripheral & scientific equipment	1,016,000	618,000	...
Software	1,367,000	967,000	...
Leasehold improvements	502,000	470,000	...
Office furniture & equipment	327,000	214,000	...
Fixed assets	3,212,000	2,269,000	...
Less: accumulated depreciation & amortization	1,858,000	1,275,000	...
Property & equipment, net	1,354,000	994,000	...
Intangible assets, net	1,353,000	1,253,000	...
Restricted cash	...	100,000	...
Goodwill	824,000	789,000	...
Other assets	19,000	16,000	...
Total assets	23,760,000	13,199,000	...
Accounts payable	708,000	905,000	...
Accrued expenses	314,000	35,000	...
Accrued salaries & payroll related expenses	1,936,000	1,765,000	...
Deferred revenue, current	143,000	279,000	...
Deferred rent, current	...	20,000	...
Total current liabilities	3,101,000	3,004,000	...
Deferred revenue	...	46,000	...
Deferred rent	10,000	...	...
Deferred income taxes	1,000	16,000	...
Total liabilities	3,112,000	3,066,000	...
Common stock	20,000	12,000	...
Additional paid-in capital	88,447,000	56,331,000	...
Foreign currency translation adjustments	(7,000)	(51,000)	...
Accumulated other comprehensive income (loss)	(7,000)	(51,000)	...
Retained earnings (accumulated deficit)	(67,812,000)	(46,159,000)	...
Total stockholders' equity (deficit)	20,648,000	10,133,000	...

**Annual Report**  
**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Revenues	13,355,000	12,982,000	39,896,000
Cost of goods sold	9,564,000	9,855,000	31,826,000
Gross profit	3,791,000	3,127,000	8,070,000
Sales, general & administrative expenses	9,888,000	12,384,000	12,567,000
Depreciation & amortization	...	...	1,779,000
Total operating expenses	...	...	14,346,000
Income (loss) from operations	(6,097,000)	(9,257,000)	(6,276,000)
Interest income	...	...	107,000
Interest expense - other	...	...	3,101,000
Interest expense	1,623,000	2,483,000	...
Change in fair value of derivative warrant liabilities	670,000	1,625,000	...
Gain (loss) on extinguishment of debt	(8,290,000)	...	(1,904,000)
Change in fair value of derivative warrant & conversion liabilities	...	...	1,001,000
Gain on resolution of Irgovel purchase litigation	...	1,598,000	...
Foreign currency translation gain (loss)	...	...	(370,000)
Other income	307,000	563,000	167,000
Other expense	182,000	...	376,000
Income (loss) before income taxes - foreign	...	...	(5,136,000)
Income (loss) before income taxes - domestic	...	...	(5,616,000)
Income (loss) from continuing operations before income taxes	(15,215,000)	(7,954,000)	(10,752,000)
Current state income tax provision	16,000	45,000	...
Deferred federal income taxes	(4,684,000)	(1,732,000)	...
Deferred state income taxes	(362,000)	(137,000)	...
Income tax expense (benefit)	(5,030,000)	(1,824,000)	(176,000)
Income (loss) from continuing operations before income taxes	(10,185,000)	(6,130,000)	...
Income (loss) from discontinued operations, net of tax	3,983,000	(5,120,000)	...
<b>Net income (loss)</b>	<b>(6,202,000)</b>	<b>(11,250,000)</b>	<b>(10,576,000)</b>
Net income (loss) attributable to noncontrolling interest in Nutra SA, LLC	...	...	2,308,000
Less - Net loss attributable to noncontrolling interest in discontinued operations	1,671,000	2,720,000	...
Net income (loss) attributable to RiceBran Technologies shareholders	(4,531,000)	(8,530,000)	(8,268,000)
Less - Dividends on	...	...	...

**Recent Dividends:**  
**1. Resonant Inc common.**  
No dividends paid.  
**Annual Dividends:**  
**1. Resonant Inc common.**  
No dividends paid.

**RESONANT INC**  
**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Crowe Horwath LLP, as it appeared in Co.'s 2017 10-K: "We have audited the accompanying consolidated balance sheets of Resonant Inc. (the "Company") as of December 31, 2017 and 2016, the related consolidated statements of comprehensive loss, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph - Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has earned minimal revenue since inception through December 31, 2017 and has incurred significant losses from operations since inception. In addition, the Company's operations have been funded with initial capital contributions and proceeds from the sale of equity securities and debt. These events and conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**RICEBRAN TECHNOLOGIES**

**Annual Report**  
**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
Revenues	13,355,000	12,982,000	39,896,000
Cost of goods sold	9,564,000	9,855,000	31,826,000
Gross profit	3,791,000	3,127,000	8,070,000
Sales, general & administrative expenses	9,888,000	12,384,000	12,567,000
Depreciation & amortization	...	...	1,779,000
Total operating expenses	...	...	14,346,000
Income (loss) from operations	(6,097,000)	(9,257,000)	(6,276,000)
Interest income	...	...	107,000
Interest expense - other	...	...	3,101,000
Interest expense	1,623,000	2,483,000	...
Change in fair value of derivative warrant liabilities	670,000	1,625,000	...
Gain (loss) on extinguishment of debt	(8,290,000)	...	(1,904,000)
Change in fair value of derivative warrant & conversion liabilities	...	...	1,001,000
Gain on resolution of Irgovel purchase litigation	...	1,598,000	...
Foreign currency translation gain (loss)	...	...	(370,000)
Other income	307,000	563,000	167,000
Other expense	182,000	...	376,000
Income (loss) before income taxes - foreign	...	...	(5,136,000)
Income (loss) before income taxes - domestic	...	...	(5,616,000)
Income (loss) from continuing operations before income taxes	(15,215,000)	(7,954,000)	(10,752,000)
Current state income tax provision	16,000	45,000	...
Deferred federal income taxes	(4,684,000)	(1,732,000)	...
Deferred state income taxes	(362,000)	(137,000)	...
Income tax expense (benefit)	(5,030,000)	(1,824,000)	(176,000)
Income (loss) from continuing operations before income taxes	(10,185,000)	(6,130,000)	...
Income (loss) from discontinued operations, net of tax	3,983,000	(5,120,000)	...
<b>Net income (loss)</b>	<b>(6,202,000)</b>	<b>(11,250,000)</b>	<b>(10,576,000)</b>
Net income (loss) attributable to noncontrolling interest in Nutra SA, LLC	...	...	2,308,000
Less - Net loss attributable to noncontrolling interest in discontinued operations	1,671,000	2,720,000	...
Net income (loss) attributable to RiceBran Technologies shareholders	(4,531,000)	(8,530,000)	(8,268,000)
Less - Dividends on	...	...	...

preferred stock, beneficial conversion feature	778,000	551,000	...
Net income (loss) attributable to RiceBran Technologies common shareholders	(5,309,000)	(9,081,000)	...
Weighted average shares outstanding - basic	11,923,923	9,338,370	9,187,983
Weighted average shares outstanding - diluted	11,923,923	9,338,370	9,187,983
Year end shares outstanding	18,046,731	10,790,351	9,537,415
Earnings (loss) per common share - continuing operations - basic	\$(0.92)	\$(0.72)	...
Earnings (loss) per common share - discontinued operations - basic	\$0.47	\$(0.25)	...
Earnings (loss) per share - basic	\$(0.45)	\$(0.97)	\$(0.90)
Earnings (loss) per common share - continuing operations - diluted	\$(0.92)	\$(0.72)	...
Earning per share - total discounters - diluted	\$0.47	\$(0.25)	...
Earnings (loss) per share - diluted	\$(0.45)	\$(0.97)	\$(0.90)
Total number of employees	65	...	264
Number of common stockholders	285	...	280
Number of beneficiary stockholders	7,190	...	9,300
Foreign currency translation adjustments	...	775,000	(2,573,000)

<sup>1</sup> Restated to reflect the discontinued operations of Healthy Natural, Inc. and Nutra SA; <sup>2</sup> Restated to reflect the adoption of ASU 2016-18, Topic 230; <sup>3</sup> Approximately; <sup>4</sup> As of March 8, 2018; <sup>5</sup> As of March 30, 2016

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	<sup>1</sup> 2016 (revised)
Cash & cash equivalents	6,203,000	342,000
Restricted cash	775,000	...
Accounts receivable, gross	1,281,000	1,106,000
Allowance for doubtful accounts	8,000	12,000
Accounts receivable, net	1,273,000	1,094,000
Finished goods	564,000	795,000
Packaging	114,000	138,000
Deposits & other current assets	519,000	824,000
Assets held for sale	...	4,335,000
Total current assets	9,448,000	7,528,000
Land	237,000	237,000
Furniture & fixtures	311,000	306,000
Plant	6,580,000	6,582,000
Computer & software	1,207,000	1,147,000
Leasehold improvements	274,000	261,000
Machinery & equipment	8,677,000	7,274,000
Subtotal	17,286,000	15,807,000
Less: accumulated depreciation	9,436,000	8,782,000
Property & equipment, net	7,850,000	7,025,000
Other long-term assets	63,000	242,000
Noncurrent assets held for sale	...	14,050,000
Total assets	17,361,000	28,845,000
Accounts payable	765,000	714,000

Accrued salary, wages & benefits	773,000	496,000	...
Accrued expenses	741,000	904,000	...
Unearned revenue	75,000	384,000	...
Escrow liability	258,000	...	...
Current maturities of long-term debt	4,000	3,063,000	...
Current liabilities held for sale	...	15,801,000	...
Total current liabilities	2,616,000	21,362,000	...
Senior revolving loan	...	1,725,000	...
Senior term note, net of debt issuance costs	...	917,000	...
Subordinated notes, net	...	6,310,000	...
Other debt	16,000	75,000	...
Less: current portion	4,000	3,063,000	...
Derivative warrant liabilities	...	1,527,000	...
Noncurrent liabilities held for sale	...	73,000	...
Total liabilities	2,628,000	28,926,000	...
Preferred stock, Series F, convertible	...	551,000	...
Temporary equity	...	551,000	...
Convertible, series G preferred stock	313,000	...	...
Common stock	279,548,000	264,232,000	...
Retained earnings (accumulated deficit)	(265,128,000)	(259,819,000)	...
Accumulated deficit attributable to noncontrolling interest in Nutra SA	...	(699,000)	...
Accumulated other comprehensive income (loss)	...	(4,346,000)	...
Total equity (deficit) attributable to RiceBran Technologies shareholders	14,733,000	(632,000)	...

<sup>1</sup> Restated to reflect the discontinued operations of Healthy Natural, Inc. and Nutra SA; <sup>2</sup> Restated to reflect the adoption of ASU 2016-18, Topic 230

#### Recent Dividends:

- RiceBran Technologies series F convertible preferred.**  
No dividends paid.
- RiceBran Technologies convertible series C preferred stock (\$1,000 stated value).**  
No dividends paid.
- RiceBran Technologies series D preferred.**  
No dividends paid.
- RiceBran Technologies common.**  
No dividends paid.
- RiceBran Technologies convertible series B preferred stock (\$1,000 stated value).**  
No dividends paid.
- RiceBran Technologies mandatorily redeemable common.**  
No dividends paid.

#### Annual Dividends:

- RiceBran Technologies series F convertible preferred.**  
No dividends paid.
- RiceBran Technologies convertible series C preferred stock (\$1,000 stated value).**  
No dividends paid.
- RiceBran Technologies series D preferred.**  
No dividends paid.
- RiceBran Technologies common.**  
No dividends paid.
- RiceBran Technologies convertible series B preferred stock (\$1,000 stated value).**  
No dividends paid.
- RiceBran Technologies mandatorily redeemable common.**  
No dividends paid.

#### SEQUENTIAL BRANDS GROUP INC (NEW)

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	<sup>1</sup> 2016 (revised)	<sup>2</sup> 2015 (revised)
Net revenue	167,464,000	155,528,000	88,262,000
Operating expenses	79,443,000	85,392,000	58,611,000
Impairment charges	340,628,000	...	...
Income (loss) from operations	(252,607,000)	70,136,000	29,651,000

Other income (expense)	(1,583,000)	(3,810,000)	1,133,000
Interest expense, net	59,891,000	50,538,000	29,725,000
Income (loss) before income taxes	(314,081,000)	15,788,000	1,059,000
Current provision (benefit) for federal income taxes	...	(111,000)	34,000
Deferred provision (benefit) for federal income taxes	(131,344,000)	10,145,000	9,771,000
Total provision (benefit) for federal income taxes	(131,344,000)	10,034,000	9,805,000
Current provision (benefit) for foreign income taxes	134,000	206,000	340,000
Total provision (benefit) for foreign income taxes	134,000	206,000	340,000
Current provision (benefit) for state income taxes	...	(519,000)	103,000
Deferred provision (benefit) for state income taxes	(1,325,000)	(564,000)	(11,605,000)
Total provision (benefit) for state income taxes	(1,325,000)	(1,083,000)	(11,502,000)
Provision (benefit) for income taxes	(132,535,000)	9,157,000	(1,357,000)
<b>Net income (loss)</b>	(181,546,000)	6,631,000	2,416,000
Net loss (income) attributable to noncontrolling interest	(4,172,000)	(7,452,000)	(5,287,000)
Net income (loss) attributable to Sequential Brands Group, Inc. & subsidiaries	(185,718,000)	(821,000)	(2,871,000)
Weighted average shares outstanding - basic	62,861,743	61,912,410	41,177,523
Weighted average shares outstanding - diluted	62,861,743	61,912,410	41,177,523
Year end shares outstanding	63,227,727	62,504,355	60,480,474
Net income (loss) per share - basic	\$(2.95)	\$(0.01)	\$(0.07)
Net income (loss) per share - diluted	\$(2.95)	\$(0.01)	\$(0.07)
Total number of employees	<sup>2</sup> 144	<sup>3</sup> 158	<sup>4</sup> 161
Number of common stockholders	<sup>5</sup> 1,168	<sup>6</sup> 1,193	<sup>7</sup> 1,198

<sup>1</sup> Reclassified to conform with 2017 presentation; <sup>2</sup> As of February 28, 2018; <sup>3</sup> As of February 28, 2017; <sup>4</sup> As of March 10, 2016; <sup>5</sup> Approximately

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016 (revised)
Cash	18,902,000	19,133,000
Restricted cash	1,531,000	1,521,000
Accounts receivable, gross	60,702,000	53,395,000
Less allowance for doubtful accounts	600,000	200,000
Accounts receivable, net	60,102,000	53,195,000
Available-for-sale securities	...	7,673,000
Prepaid expenses & other current assets	8,635,000	4,366,000
Total current assets	89,170,000	85,888,000
Furniture & fixtures	6,164,000	4,390,000

Computer hardware equipment	1,198,000	1,173,000
Leasehold improvements	5,937,000	4,803,000
Computer software	974,000	974,000
Websites	400,000	400,000
Automobiles & trucks	140,000	146,000
Less accumulated depreciation & amortization	7,778,000	4,212,000
Property & equipment, net	7,035,000	7,674,000
Intangible assets, net	995,170,000	1,030,212,000
Goodwill	307,744,000	307,744,000
Other assets	5,836,000	3,345,000
Total assets	1,097,211,000	1,434,863,000
Accounts payable & accrued expenses	19,126,000	18,915,000
Current portion of long-term debt	28,300,000	28,300,000
Current portion of deferred revenue	8,102,000	10,374,000
Total current liabilities	55,528,000	57,589,000
Term loans	551,913,000	582,500,000
Revolving credit facility	92,787,000	80,500,000
Unamortized deferred financing costs	(14,103,000)	(17,965,000)
Less: current portion of long-term debt	28,300,000	28,300,000
Long-term deferred revenue, net of current portion	11,845,000	13,909,000
Deferred income taxes	67,799,000	200,357,000
Other long-term liabilities	6,204,000	8,705,000
Total liabilities	743,673,000	897,295,000
Common stock	635,000	624,000
Additional paid-in capital	508,444,000	502,564,000
Accumulated other comprehensive income (loss)	80,000	(144,000)
Retained earnings (accumulated deficit)	(225,369,000)	(39,651,000)
Treasury stock, at cost	1,799,000	638,000
Total Sequential Brands Group, Inc. & subsidiaries stockholders' equity (deficit)	281,991,000	462,755,000
Noncontrolling interest	71,547,000	74,813,000
Total equity (deficit)	353,538,000	537,568,000

**Recent Dividends:**

**1. Sequential Brands Group Inc (New) series A preferred.**

No dividends paid.

**2. Sequential Brands Group Inc (New) common.**

No dividends paid.

**Annual Dividends:**

**1. Sequential Brands Group Inc (New) series A preferred.**

No dividends paid.

**2. Sequential Brands Group Inc (New) common.**

No dividends paid.

**SHARPSRING INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Revenue	13,448,752	11,541,702	9,184,307
Cost of services	4,996,745	4,462,440	2,781,691
Gross profit	8,452,007	7,079,262	6,402,616
Sales & marketing	6,983,208	5,340,351	5,039,395
Research & development	2,883,714	2,308,650	1,733,951
General & administrative	5,346,136	4,418,500	4,005,244
Change in earn out liability	...	219,473	2,555,649
Intangible asset amortization	527,468	1,360,105	1,508,616
Impairment of intangible assets	...	1,459,541	1,310,386
Total operating expenses	15,740,526	15,106,620	16,153,241

Operating income (loss)	(7,288,519)	(8,027,358)	(9,750,625)
Other income (expense), net	209,173	442,195	(231,718)
Income (loss) before income taxes	(7,079,346)	(7,585,163)	(9,982,343)
Current provision (benefit) for income tax	(2,107,804)	3,451,571	(519,437)
Payable true-up	(1,922)	101,783	119,838
Deferred provision (benefit) for income tax	5,618	179,159	861,546
Less: net income tax provision from discontinued operations	...	(5,601,701)	(822,356)
Provision (benefit) for income tax	(2,104,108)	(1,869,188)	(360,409)
Income (loss) from continuing operations	(4,975,238)	(5,715,975)	(9,621,934)
Net income from discontinued operations, net of tax	...	10,666,985	1,377,632
<b>Net income (loss)</b>	<b>(4,975,238)</b>	<b>4,951,010</b>	<b>(8,244,302)</b>
Weighted average shares outstanding - basic	8,395,319	7,895,197	6,354,134
Weighted average shares outstanding - diluted	8,395,319	7,895,197	6,354,134
Year end shares outstanding	8,436,061	8,360,663	7,233,035
Net income (loss) per share from continuing operations - basic	\$(0.59)	\$(0.72)	\$(1.51)
Net income (loss) per share from discontinued operations - basic	...	\$1.35	\$0.22
Net income (loss) per share - basic	\$(0.59)	\$0.63	\$(1.30)
Net income (loss) per share from continuing operations - diluted	\$(0.59)	\$(0.72)	\$(1.51)
Net income (loss) per share from discontinued operations - diluted	...	\$1.35	\$0.22
Net income (loss) per share - diluted	\$(0.59)	\$0.63	\$(1.30)
Total number of employees	149	144	...
Number of common stockholders	57	75	...
Foreign currency translation adjustments	...	(302,442)	35,154

□ Restated to reflect the sale of assets related to Simple Mail Transfer Protocol (SMTP) email relay business as discontinued operations; □ Approximately; □ As of February 28, 2018; □ As of March 17, 2017; □ As of March 9, 2018; □ As of March 27, 2017

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	5,399,747	8,651,374
Accounts receivable, gross	1,166,086	1,770,211
Allowance for doubtful accounts	526,127	508,288
Accounts receivable	639,959	1,261,923
Income taxes receivable	2,132,616	1,355,180
Other current assets	267,924	1,396,642
Total current assets	8,440,246	12,665,119
Leasehold improvements	128,122	128,122
Furniture & fixtures	355,033	316,819

Computer equipment & software	776,201	641,722
Property & equipment, gross	1,259,356	1,086,663
Accumulated depreciation - property & equipment	460,211	181,318
Property & equipment, net	799,145	905,345
Goodwill	8,872,898	8,845,394
Other intangible assets, net	2,326,000	2,850,635
Deferred income taxes	...	32,996
Deposits & other	25,000	30,464
Total assets	20,463,289	25,329,953
Accounts payable	504,901	498,534
Accrued expenses & other current liabilities	625,680	953,171
Deferred revenue	279,818	280,159
Income taxes payable	171,384	484,349
Total current liabilities	1,581,783	2,216,213
Deferred income taxes	168,132	195,495
Total liabilities	1,749,915	2,411,708
Common stock	8,456	8,381
Additional paid in capital	28,362,397	27,556,398
Foreign currency translation adjustment	(480,762)	(445,055)
Accumulated other comprehensive income (loss)	(480,762)	(445,055)
Retained earnings (accumulated deficit)	(9,092,717)	(4,117,479)
Treasury stock	84,000	84,000
Total shareholders' equity (deficit)	18,713,374	22,918,245

**Recent Dividends:**

**1. SharpSpring Inc common.**

No dividends paid.

**Annual Dividends:**

**1. SharpSpring Inc common.**

No dividends paid.

**SPYR INC**

**New Accountant** On Mar. 10, 2018, Weinberg & Company, P.A. resigned as Co.'s independent public accounting firm. On Mar. 13, 2018, Co. engaged Soles, Heyn & Co. as its new independent public accounting firm.

**STEMLINE THERAPEUTICS INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Grant revenue	898,199	1,041,354	654,160
Research & development expenses	50,242,386	27,869,921	29,458,676
General & administrative expenses	19,214,207	12,056,890	8,828,843
Total operating expenses	69,456,593	39,926,811	38,287,519
Income (loss) from operations	(68,558,394)	(38,885,457)	(37,633,359)
Other income	(6,330)	11,438	1,609
Interest income	736,330	545,718	387,889
Net income (loss) before income taxes	(67,828,394)	(38,328,301)	(37,243,861)
Income tax benefit (expense) - deferred - federal	(8,370,870)	(16,917,231)	(17,654,150)
Income tax benefit (expense) - deferred - state & local	4,968,667	(3,063,684)	(3,735,379)
Income tax benefit (expense) - deferred	(3,402,203)	(19,980,915)	(21,389,529)
Increase in valuation allowance	3,402,203	19,955,619	21,389,529
Income tax benefit (expense)	...	(25,296)	...
<b>Net income (loss)</b>	<b>(67,828,394)</b>	<b>(38,303,005)</b>	<b>(37,243,861)</b>
Weighted average			

shares outstanding-basic	23,056,928	17,804,681	17,289,021
Weighted average shares outstanding-diluted	23,056,928	17,804,681	17,289,021
Year end shares outstanding	25,313,595	19,219,223	18,235,020
Net earnings (loss) per share - basic	\$(2.94)	\$(2.15)	\$(2.15)
Net earnings (loss) per share - diluted	\$(2.94)	\$(2.15)	\$(2.15)
Number of full time employees	137	129	124
Number of common stockholders	137	134	117

As of March 16, 2018; As of Mar. 16, 2017; As of March 14, 2016

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016 (revised)
Cash & cash equivalents	4,795,098	10,316,064
Short-term investments	46,924,612	36,562,900
Prepaid expenses & other current assets	469,067	290,747
Total current assets	52,188,777	47,169,711
Office furniture & fixtures	519,675	486,586
Leasehold improvements	82,694	...
Manufacturing equipment	13,000	...
Less accumulated depreciation	478,697	464,055
Furniture & fixtures, net	136,672	22,531
Long-term investments	14,468,414	20,714,551
Other assets	212,305	212,305
Total assets	67,006,168	68,119,098
Accrued research & development costs	14,841,071	6,792,947
Accrued compensation	2,940,039	1,975,037
Accrued legal	780,664	71,554
Other accrued liabilities	1,180,313	444,976
Current portion of deferred grant revenue	...	898,199
Other current liabilities	96,826	71,100
Total current liabilities	19,838,913	10,253,813
Other liabilities	96,826	142,200
Total liabilities	19,935,739	10,396,013
Common stock	2,531	1,922
Additional paid-in capital	251,489,546	193,563,572
Accumulated other comprehensive income (loss)	(145,958)	(99,802)
Retained earnings (accumulated deficit)	(204,275,690)	(135,742,607)
Total stockholders' equity (deficit)	47,070,429	57,723,085

#### Recent Dividends:

##### 1. Stemline Therapeutics Inc common.

No dividends paid.

##### Annual Dividends:

##### 1. Stemline Therapeutics Inc common.

No dividends paid.

#### TEARLAB CORP

##### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016 (revised)	2015 (revised)
Revenues - product sales	24,237,000	23,809,000	20,325,000
Revenues - reader equipment rentals	2,882,000	4,205,000	4,831,000
Total revenues	27,119,000	28,014,000	25,156,000
Cost of goods sold (excluding amortization of intangibles)	10,993,000	10,188,000	10,825,000
Cost of goods sold - reader equipment depreciation	2,121,000	2,130,000	1,732,000

Gross profit (loss)	14,005,000	15,696,000	12,599,000
Sales & marketing expenses	12,330,000	14,397,000	19,349,000
Clinical, regulatory & research & development expenses	4,691,000	5,152,000	6,951,000
General & administrative expenses	8,772,000	11,057,000	14,935,000
Amortization of intangible assets	...	1,066,000	1,501,000
Impairment of long-lived assets	...	...	1,372,000
Income (loss) from operations	(11,788,000)	(15,976,000)	(31,509,000)
Interest expense	4,269,000	4,003,000	2,023,000
Changes in fair value of warrant obligation	...	28,000	227,000
Other income (expense), net	(44,000)	31,000	76,000
Total other income (expense)	(4,313,000)	(3,944,000)	(1,720,000)
Net income (loss) & comprehensive income (loss)	(16,101,000)	(19,920,000)	(33,229,000)
Weighted average shares outstanding - basic	5,789,714	4,647,983	3,369,809
Weighted average shares outstanding - diluted	5,789,714	4,647,983	3,373,181
Year end shares outstanding	7,986,998	5,360,198	3,376,090
Net earnings (loss) per share - basic	\$(2.78)	\$(4.29)	\$(9.86)
Net earnings (loss) per share - diluted	\$(2.78)	\$(4.29)	\$(9.92)
Number of full time employees	39	75	118
Number of part time employees	3	...	...
Number of common stockholders	64	80	75

Reclassified to conform with 2016 presentation; Adjusted for 1-for-10 stock split, February 27, 2017; Approximately; As of February 26, 2018; As of March 3, 2017; As of March 4, 2016

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016 (revised)
Cash	7,272,000	15,471,000
Trade receivable, gross	2,044,000	2,928,000
Less: allowance for doubtful accounts	508,000	649,000
Finished goods	2,125,000	3,210,000
Less: inventory reserves	127,000	17,000
Inventory, net	1,998,000	3,193,000
Prepaid trade shows	14,000	217,000
Prepaid insurance	313,000	326,000
Manufacturing deposits	...	282,000
Subscriptions	311,000	297,000
Other fees & services	52,000	66,000
Other current assets	...	38,000
Prepaid expenses & other current assets	690,000	1,226,000
Total current assets	...	22,169,000
Capitalized TearLab equipment readers	8,437,000	9,095,000
Leasehold improvements	60,000	60,000
Computer equipment & software	915,000	932,000
Furniture & office equipment	436,000	271,000
Medical equipment	1,180,000	500,000
Fixed assets, gross	11,028,000	10,858,000
Less: accumulated depreciation	8,289,000	6,680,000
Fixed assets, net	2,739,000	4,178,000
Intangible asset, net	10,000	60,000

Other non-current assets	100,000	220,000
Total assets	14,345,000	26,627,000
Accounts payable	1,720,000	1,858,000
Accrued liabilities due to professionals	193,000	81,000
Accrued liabilities due to employees & directors	944,000	2,200,000
Accrued sales & use tax liabilities	253,000	247,000
Accrued royalty liability	447,000	854,000
Accrued warranty	131,000	124,000
Accrued restructuring	200,000	...
Accrued liabilities - other	691,000	452,000
Accrued liabilities	2,859,000	3,958,000
Deferred rent	42,000	83,000
Total current liabilities	4,621,000	5,899,000
Long-term debt	28,290,000	26,449,000
Total liabilities	32,911,000	32,348,000
Common stock	8,000	5,000
Additional paid-in capital	510,235,000	506,982,000
Retained earnings (accumulated deficit)	(528,809,000)	(512,708,000)
Total stockholders' equity (deficit)	(18,566,000)	(5,721,000)

Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. TearLab Corp series A convertible preferred.

No dividends paid.

##### 2. TearLab Corp common.

No dividends paid.

#### Annual Dividends:

##### 1. TearLab Corp series A convertible preferred.

No dividends paid.

##### 2. TearLab Corp common.

No dividends paid.

#### TEARLAB CORP

##### Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Mayer Hoffman McCann P.C., as it appeared in Co.'s 2017 10-K: "In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2017 and 2016, and the consolidated results of their operations and their cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring operating losses and is dependent on additional financing to fund operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are described in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty."

#### TELLURIAN INC

##### Annual Report

#### Consolidated Income Statement, Years Ended (\$):

	12/31/17	12/31/16 (revised)	06/30/16 (revised)
Natural gas sales	503,000	...	...
Liquid natural gas sales ("LNG")	3,273,000	...	...
Other LNG revenue	1,665,000	...	...
Total revenues	5,441,000	...	...
Cost of sales	7,565,000	...	...
Depreciation	...	...	54,000
Exploration	...	...	71,000
Development expenses	59,498,000	47,146,000	...
Depreciation, depletion & amortization	479,000	69,000	...
General & administrative expenses	98,874,000	46,515,000	5,214,000

Goodwill impairment	77,592,000	...	...	Income (loss) per share - continuing operations - basic	...	...	\$(0.17)	Total liabilities	52,936,000	24,726,000
Total operating expense	...	...	5,339,000	Income (loss) per share - discontinued operations - basic	...	...	\$(2.48)	Embedded derivative	...	8,753,000
Total costs & expenses	244,008,000	93,730,000	...	Net income (loss) per share - diluted	...	...	\$(1.23)	Series A convertible preferred stock	...	5,000
Income (loss) from operations	(238,567,000)	(93,730,000)	(5,339,000)	Net income (loss) per share - basic	\$(1.23)	\$(1.01)	\$(2.65)	Common stock	2,043,000	101,000
Net interest income (expense)	...	...	(4,000)	Income (loss) per share - continuing operations - diluted	...	...	\$(0.17)	Additional paid-in capital	549,958,000	102,148,000
Gain (loss) on investment in securities	...	...	(587,000)	Income (loss) per share - discontinued operations - diluted	...	...	\$(2.48)	Retained earnings (accumulated deficit)	(328,114,000)	(96,655,000)
Gain on sale of bonus rights	...	...	2,514,000	Number of full time employees	...	...	13	Total stockholders' equity (deficit)	223,887,000	5,599,000
Loss on preferred stock exchange feature	(2,209,000)	3,308,000	...	Total number of employees	126	...	13			
Other income (expenses)	5,084,000	217,000	88,000	Number of common stockholders	540	...	484			
Total other income (expense)	...	...	2,011,000	Number of beneficiary stockholders	...	...	5,590			
Income (loss) before income taxes - United States	...	...	(4,454,000)	Foreign currency translation adjustments	...	...	(125,000)			
Income (loss) before income taxes - Domestic	(223,991,000)	(95,739,000)	...							
Income (loss) before income taxes - Australia	...	...	1,497,000							
Income (loss) before income taxes - United Kingdom	...	...	(371,000)							
Income (loss) before income taxes - foreign	(7,283,000)	(1,082,000)	...							
Income (loss) from continuing operations before tax	(231,274,000)	(96,821,000)	(3,328,000)							
Current income tax provision (benefit) - state	...	4,000	...							
Current income tax provision (benefit) - foreign	185,000	...	...							
Current income tax provision (benefit) - United States	185,000	4,000	...							
Deferred federal income tax provision (benefit) - United States	...	(170,000)	...							
Deferred income tax provision (benefit) - United States	...	(170,000)	...							
Income tax provision (benefit) from continuing operations, net of tax	185,000	(166,000)	...							
Income (loss) from discontinued operations, net of tax	...	...	(14,249,000)							
Net income (loss) from discontinued operations	(231,459,000)	(96,655,000)	(17,577,000)							
Preferred stock dividends	...	...	1,858,000							
Adjustment of preferred stock to redemption value	...	...	(4,207,000)							
Net income (loss) attributable to common stockholders	(231,459,000)	(96,655,000)	(15,228,000)							
Weighted average shares outstanding - basic	188,536,000	95,795,000	5,746,307							
Weighted average shares outstanding - diluted	188,536,000	95,795,000	5,746,307							
Year end shares outstanding	222,749,000	109,609,000	5,762,634							

Restated to reflect reverse merger with Magellan Petroleum Corporation

**Recent Dividends:**

1. Tellurian Inc series A convertible preferred. No dividends paid.

2. Tellurian Inc common. No dividends paid.

**Annual Dividends:**

1. Tellurian Inc series A convertible preferred. No dividends paid.

2. Tellurian Inc common. No dividends paid.

**TG THERAPEUTICS INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
License revenue	152,381	152,381	152,381
Research & development - noncash compensation	5,646,716	2,742,354	4,261,406
Research & development - other research & development	96,886,134	66,489,820	43,445,817
Total research & development	102,532,850	69,232,174	47,707,223
General & administrative - noncash compensation	10,298,568	4,767,645	11,435,686
General & administrative - other general & administrative	6,032,714	5,121,690	4,189,488
Total general & administrative	16,331,282	9,889,335	15,625,174
Total costs & expenses	118,864,132	79,121,509	63,332,397
Operating income (loss)	(118,711,751)	(78,969,128)	(63,180,016)
Interest income	294,478	323,032	174,653
Other income (expense)	(58,739)	393,202	56,717
Total other income (expense), net	235,739	716,234	231,370
Net income (loss)	(118,476,012)	(78,252,894)	(62,948,646)
Weighted average shares outstanding - basic	62,069,570	49,041,354	45,646,414
Weighted average shares outstanding - diluted	62,069,570	49,041,354	45,646,414
Year end shares outstanding	73,140	56,779,114	54,053,801
Net income (loss) per share - basic	\$(1.91)	\$(1.60)	\$(1.38)
Net income (loss) per share - diluted	\$(1.91)	\$(1.60)	\$(1.38)
Total number of employees	75	64	40
Number of common stockholders	271	276	299

Reclassified to conform with 2017 presentation; As of March 1, 2018; As of March 1, 2017; As of March 1, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)
Cash & cash equivalents	128,273,000	21,398,000
Accounts receivable	583,000	...
Accounts receivable due from related parties	1,377,000	1,333,000
Prepaid & other current assets	3,458,000	2,012,000
Total current assets	133,691,000	24,743,000
Land	9,491,000	9,491,000
Proved oil & natural gas properties	90,869,000	...
Unproved oil & natural gas properties	13,000,000	...
Wells in progress	345,000	...
Corporate & other	2,693,000	1,571,000
Property, plant & equipment, gross	116,398,000	11,062,000
Less: accumulated depreciation & depletion	542,000	69,000
Net property, plant & equipment	115,856,000	10,993,000
Deferred engineering costs	18,000,000	...
Other non-current assets	9,276,000	3,342,000
Total assets	276,823,000	39,078,000
Project development activities	14,870,000	12,549,000
Payroll & compensation	25,833,000	6,311,000
Accrued taxes	2,764,000	...
Professional services	3,696,000	2,323,000
Contingency loss	...	2,560,000
Other accounts payable & accrued liabilities	3,400,000	660,000
Accounts payable & accrued liabilities	50,563,000	24,403,000
Accounts payable due to related parties	...	323,000
Other current liabilities	1,735,000	...
Total current liabilities	52,298,000	24,726,000
Asset retirement obligations	638,000	...

Checking & bank deposits	55,681,820	4,052,333	Net income (loss)				Less accumulated		
Money market funds	1,036,027	20,978,947	before income taxes	744,527	(17,245,708)	(361,662)	depreciation &		
Cash & cash equivalents	56,717,847	25,031,280	Current income				amortization	5,690,265	5,682,286
Short-term investment			taxes (benefit) -				Property & equipment,		
securities	27,998,810	19,853,860	state & local	...	...	0	net	2,751,812	3,550,007
Interest receivable	108,468	83,852	Current income				Marketable securities	1,680,000	1,550,000
Prepaid research &			taxes (benefit) -				Other assets	306,465	285,843
development	8,055,486	5,678,755	foreign	197,000	139,000	4,000	Goodwill	29,419,522	29,183,141
Other current assets	436,789	216,397	Total current				Other intangibles, gross	37,584,496	35,261,996
Total current assets	93,317,400	50,864,144	income taxes				Less: accumulated		
Restricted cash	587,291	583,208	(benefit)	197,000	139,000	4,000	amortization - other		
Leasehold interest, net	2,429,434	2,042,281	Deferred income				intangibles	23,563,514	20,134,178
Equipment, net	248,020	328,148	taxes (benefit) -				Other intangibles, net	14,020,982	15,127,818
Goodwill	799,391	799,391	U.S. federal	(335,000)	38,000	809,000	Deferred tax asset	1,865,453	...
Other assets	...	164,375	Deferred income				Restricted cash	500,000	500,000
Total assets	97,381,536	54,781,547	taxes (benefit) -				Total assets	69,010,548	78,463,112
Accounts payable &			state & local	231,000	92,000	368,000	Accounts payable	2,013,797	2,526,034
accrued expenses	25,877,218	15,267,668	Deferred income				Accrued payroll &		
Accrued compensation	1,800,000	1,389,516	taxes (benefit) -				related costs	2,010,745	2,261,401
Current portion of			foreign	(1,975,000)	...	...	Accrued professional fees	449,394	531,876
deferred revenue	152,381	152,381	Total deferred				Accrued tax related	296,606	531,609
Notes payable	127,614	68,875	income taxes				Accrued business		
Total current liabilities	27,957,213	16,878,440	(benefit)	(2,079,000)	130,000	1,177,000	development	173,840	440,668
Deferred rent	1,364,601	816,257	Provision (benefit)				Accrued data related		
Deferred revenue, net of			for income taxes	(1,882,310)	(269,007)	(1,181,341)	costs	129,483	338,064
current portion	1,066,667	1,219,048	Net income (loss)	2,626,837	(17,514,715)	(1,543,003)	Other accrued liabilities	705,727	1,011,940
Total liabilities	30,388,481	18,913,745	Preferred stock				Accrued expenses	3,765,795	5,115,558
Common stock	73,182	56,820	cash dividends	...	...	385,696	Deferred revenue	23,308,678	22,476,962
Additional paid-in			Capital				Other current liabilities	1,904,614	983,799
capital	422,017,042	272,432,139	contribution				Total current liabilities	30,992,884	31,102,353
Treasury stock, at cost	234,337	234,337	attributable to				Deferred tax liability	1,932,606	2,036,487
Retained earnings			preferred				Deferred rent	1,374,385	1,904,319
(accumulated deficit)	(354,862,832)	(236,386,820)	stockholders	(22,367,520)	...	...	Acquisition contingent		
Total stockholders'			Net income (loss)				earn out	...	907,657
equity (deficiency)	66,993,055	35,867,802	attributable to				Deferred revenue	687,632	460,748
			common stockholders	24,994,357	(17,514,715)	(1,928,699)	Other liabilities	2,092	2,092
			Weighted average				Total liabilities	34,989,599	36,413,656
			shares outstanding				Convertible preferred		
			- basic	37,624,103	35,236,113	34,839,233	stock	...	55
			Weighted average				Common stock	568,916	429,369
			shares outstanding				Additional paid-in		
			- diluted	37,624,103	35,236,113	34,839,233	capital	259,569,737	271,143,445
			Year end shares				Accumulated comprehensive		
			outstanding	49,181,462	35,421,217	35,123,132	income (loss)	(4,845,650)	(5,898,305)
			Net income (loss)				Treasury stock at cost	13,484,924	13,211,141
			per share - basic	\$0.66	\$(0.50)	\$(0.06)	Retained earnings		
			Net income (loss)				(accumulated deficit)	(207,787,130)	(210,413,967)
			per share - diluted	\$0.66	\$(0.50)	\$(0.06)	Total stockholders'		
			Cash dividends				equity (deficit)	34,020,949	42,049,456
			declared & paid						
			per common share	...	...	\$0.10			
			Number of full time						
			employees	597	...	...			
			Total number of						
			employees	...	(650)	651			
			Number of common						
			stockholders	(179)	(179)	(181)			
			Foreign currency						
			translation						
			adjustments	...	(3,859,279)	(1,797,794)			

Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. TG Therapeutics Inc common.

No dividends paid.

##### 2. TG Therapeutics Inc series A convertible preferred.

No dividends paid.

##### 3. TG Therapeutics Inc preferred.

No dividends paid.

#### Annual Dividends:

##### 1. TG Therapeutics Inc common.

No dividends paid.

##### 2. TG Therapeutics Inc series A convertible preferred.

No dividends paid.

##### 3. TG Therapeutics Inc preferred.

No dividends paid.

#### THE STREET INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	2015
		(revised)	(revised)
Business to business	31,450,697	29,323,401	28,992,120
Business to consumer	31,018,693	34,176,130	38,663,780
Total net revenue	62,469,390	63,499,531	67,655,900
Cost of services	27,115,500	32,440,598	33,615,867
Sales & marketing expenses	13,559,393	15,697,065	16,190,749
General & administrative expenses	15,494,219	16,157,151	15,000,439
Depreciation & amortization			
expenses	5,132,259	5,681,563	4,309,094
Impairment of goodwill	...	11,583,000	...
Change in fair value of contingent consideration	...	1,807,945	...
Restructuring & other charges	470,299	959,686	(1,221,224)
Total operating expense	61,771,670	80,711,118	67,894,925
Operating income (loss)	697,720	(17,211,587)	(239,025)
Net interest (expense) income	46,807	(34,121)	(122,637)

Reclassified to conform with 2016 presentation; Rounding difference, breakdown taken from notes; Approximately; As of March 8, 2018; As of March 15, 2017; As of March 3, 2016

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016
		(revised)
Cash & cash equivalents	11,684,817	21,371,122
Accounts receivable, gross	4,963,567	5,436,163
Less: allowance for doubtful accounts	278,997	316,204
Account receivable, net	4,684,570	5,119,959
Prepaid expenses & other current assets	1,707,574	1,416,956
Total current assets	18,466,314	28,266,303
Computer equipment & software	2,005,226	2,516,189
Furniture and fixtures & telephone equipment	1,916,158	2,080,658
Leasehold improvements	4,520,693	4,635,446
Property & equipment, gross	8,442,077	9,232,293

Less accumulated depreciation & amortization	5,690,265	5,682,286
Property & equipment, net	2,751,812	3,550,007
Marketable securities	1,680,000	1,550,000
Other assets	306,465	285,843
Goodwill	29,419,522	29,183,141
Other intangibles, gross	37,584,496	35,261,996
Less: accumulated amortization - other intangibles	23,563,514	20,134,178
Other intangibles, net	14,020,982	15,127,818
Deferred tax asset	1,865,453	...
Restricted cash	500,000	500,000
Total assets	69,010,548	78,463,112
Accounts payable	2,013,797	2,526,034
Accrued payroll & related costs	2,010,745	2,261,401
Accrued professional fees	449,394	531,876
Accrued tax related	296,606	531,609
Accrued business development	173,840	440,668
Accrued data related costs	129,483	338,064
Other accrued liabilities	705,727	1,011,940
Accrued expenses	3,765,795	5,115,558
Deferred revenue	23,308,678	22,476,962
Other current liabilities	1,904,614	983,799
Total current liabilities	30,992,884	31,102,353
Deferred tax liability	1,932,606	2,036,487
Deferred rent	1,374,385	1,904,319
Acquisition contingent earn out	...	907,657
Deferred revenue	687,632	460,748
Other liabilities	2,092	2,092
Total liabilities	34,989,599	36,413,656
Convertible preferred stock	...	55
Common stock	568,916	429,369
Additional paid-in capital	259,569,737	271,143,445
Accumulated comprehensive income (loss)	(4,845,650)	(5,898,305)
Treasury stock at cost	13,484,924	13,211,141
Retained earnings (accumulated deficit)	(207,787,130)	(210,413,967)
Total stockholders' equity (deficit)	34,020,949	42,049,456

Restated to reflect adoption of FASB ASU No. 2016-18 (Topic 230)

#### Recent Dividends:

##### 1. TheStreet Inc series B convertible preferred.

No dividends paid.

##### 2. TheStreet Inc common.

ExDate	Amt	Declared	Record	Payable
03/12/2015	0.03	03/05/2015	03/16/2015	03/31/2015
06/11/2015	0.03	06/01/2015	06/15/2015	06/30/2015
09/10/2015	0.03	08/31/2015	09/14/2015	09/30/2015
12/10/2015	0.03	12/01/2015	12/14/2015	12/31/2015
	0.00			12/31/2015

#### Annual Dividends:

##### 1. TheStreet Inc series B convertible preferred.

No dividends paid.

##### 2. TheStreet Inc common.

2015: 0.10

#### UFP TECHNOLOGIES INC.

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	2015
		(revised)	(revised)
Net sales	147,843,000	146,132,000	138,850,000
Cost of sales	112,356,000	111,482,000	101,396,000
Gross profit (loss)	35,487,000	34,650,000	37,454,000
Selling, general & administrative expenses	23,845,000	24,105,000	24,008,000
Restructuring costs	63,000	420,000	1,756,000
Material overcharge			



settlement	121,000	2,114,000	...
Gain (loss) on sales of property, plant & equipment	(7,000)	(2,000)	24,000
Operating income (loss)	11,693,000	12,237,000	11,714,000
Interest income	216,000	149,000	114,000
Interest expense	50,000	69,000	87,000
Total other income (expense)	166,000	80,000	27,000
Income (loss) before income tax provision (benefit)	11,859,000	12,317,000	11,741,000
Current federal income tax expense (benefit)	3,117,000	3,120,000	3,131,000
Current state income tax expense (benefit)	551,000	651,000	580,000
Total current income tax expense (benefit)	3,668,000	3,771,000	3,711,000
Deferred federal income tax expense (benefit)	(1,091,000)	546,000	508,000
Deferred state income tax expense (benefit)	72,000	30,000	(71,000)
Total deferred income tax expense (benefit)	(1,019,000)	576,000	437,000
Income tax expense (benefit)	2,649,000	4,347,000	4,148,000
<b>Net income (loss) from consolidated operations</b>	<b>9,210,000</b>	<b>7,970,000</b>	<b>7,593,000</b>
Weighted average shares outstanding - basic	7,248,000	7,190,000	7,102,000
Weighted average shares outstanding - diluted	7,337,000	7,275,000	7,206,000
Year end shares outstanding	7,280,350	7,212,464	7,140,818
Net income (loss) per share - basic	\$1.27	\$1.11	\$1.07
Net income (loss) per share - diluted	\$1.26	\$1.10	\$1.05
Number of full time employees	796	805	722
Number of common stockholders	68	71	73

Reclassified to conform with 2016 presentation; As of January 27, 2018; As of January 28, 2017; As of January 30, 2016; As of March 5, 2018; As of March 2, 2017; As of March 2, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016 (revised)	2015 (revised)
Cash & cash equivalents	37,978,000	31,359,000	31,359,000
Accounts receivable - trade	22,033,000	21,816,000	21,816,000
Less allowance for doubtful receivables	652,000	567,000	567,000
Receivables, net	21,381,000	21,249,000	21,249,000
Raw materials	6,898,000	7,111,000	7,111,000
Work in process	1,207,000	1,354,000	1,354,000
Finished goods	4,758,000	5,686,000	5,686,000
Inventories	12,863,000	14,151,000	14,151,000
Prepaid expenses	1,835,000	2,281,000	2,281,000
Refundable income taxes	1,017,000	807,000	807,000
Total current assets	75,074,000	69,847,000	69,847,000
Land & improvements	3,191,000	3,191,000	3,191,000
Buildings & improvements	28,939,000	28,241,000	28,241,000
Leasehold improvements	2,553,000	2,759,000	2,759,000
Machinery & equipment	58,602,000	54,633,000	54,633,000
Furniture & fixtures, computers & software	6,820,000	6,419,000	6,419,000
Construction in progress - equipment	...	1,563,000	...
Construction in progress	6,611,000	...	...
Property, plant &	...	...	...

equipment	106,716,000	96,806,000	96,806,000
Less accumulated depreciation & amortization	53,064,000	48,290,000	48,290,000
Net property, plant & equipment	53,652,000	48,516,000	48,516,000
Goodwill	7,322,000	7,322,000	7,322,000
Intangible assets, net	...	318,000	318,000
Non-qualified deferred compensation plan	2,015,000	1,778,000	1,778,000
Other assets	144,000	153,000	153,000
Total assets	138,207,000	127,934,000	127,934,000
Accounts payable	4,180,000	4,002,000	4,002,000
Accrued compensation	2,536,000	2,144,000	2,144,000
Accrued benefits or self-insurance reserve	334,000	180,000	180,000
Accrued paid time off	990,000	990,000	990,000
Accrued commissions payable	309,000	260,000	260,000
Other accrued expenses	1,594,000	1,124,000	1,124,000
Current installments of long-term debt	...	856,000	856,000
Total current liabilities	9,943,000	9,556,000	9,556,000
Equipment loans	...	856,000	856,000
Less current installments	...	856,000	856,000
Deferred income taxes	2,440,000	3,459,000	3,459,000
Non-qualified deferred compensation plan	2,030,000	1,682,000	1,682,000
Other liabilities	82,000	184,000	184,000
Total liabilities	14,495,000	14,881,000	14,881,000
Common stock	73,000	72,000	72,000
Additional paid-in capital	26,664,000	25,216,000	25,216,000
Retained earnings (accumulated deficit)	97,562,000	88,352,000	88,352,000
Treasury stock, at cost	587,000	587,000	587,000
Total stockholders' equity (deficit)	123,712,000	113,053,000	113,053,000

Reclassified to conform with 2017 presentation

**Recent Dividends:**  
**1. UFP Technologies Inc. common.**  
 No dividends paid.

**Annual Dividends:**  
**1. UFP Technologies Inc. common.**  
 No dividends paid.

**URBAN ONE INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)	2015 (revised)
Net revenue	440,041	456,219	450,861
Programming & technical expenses	130,417	134,000	134,410
Selling, general & administrative expenses	148,725	147,905	151,726
Corporate selling, general & administrative expenses	45,016	50,636	51,992
Depreciation & amortization	34,016	34,247	35,355
Impairment of long-lived assets	29,148	1,287	41,211
Total operating expenses	387,322	368,075	414,694
Operating income (loss)	52,719	88,144	36,167
Interest income	200	214	102
Interest expense	79,420	81,636	80,038
Gain (loss) on retirement of debt	(5,219)	2,646	(7,091)
Gain on sale-leaseback	14,411	...	...
Other income (expense), net	6,608	928	(216)
Income (loss) before provision for (benefit from) income taxes & noncontrolling	...	...	...

interests in income (loss) of subsidiaries	(10,701)	10,296	(51,076)
Federal income tax provision (benefit) - current	677	158	...
Federal income tax provision (benefit) - deferred	(125,040)	7,212	15,161
State income tax provision (benefit) - current	301	308	572
State income tax provision (benefit)- deferred	899	1,902	(675)
Provision for (benefit from) income taxes	(123,163)	9,580	15,058
<b>Consolidated net income (loss)</b>	<b>112,462</b>	<b>716</b>	<b>(66,134)</b>
Less: net income (loss) attributable to noncontrolling interests	(575)	(1,139)	(7,888)
Consolidated net income (loss) attributable to common stockholders	111,887	(423)	(74,022)
Weighted average shares outstanding - basic	47,170	47,925	48,028
Weighted average shares outstanding - diluted	49,633	47,925	48,028
Year end shares outstanding	48,447	48,643	49,991
Net income (loss) per share - basic	\$2.37	\$(0.01)	\$(1.54)
Net income (loss) per share - diluted	\$2.25	\$(0.01)	\$(1.54)
Number of full time employees	1,058	994	962
Number of part time employees	408	354	344
Number of class A common stockholders	1,843	1,653	1,584
Number of class B common stockholders	2	2	2
Number of class C common stockholders	3	3	3
Number of class D common stockholders	2,106	1,960	1,834

Reclassified to conform with 2016 presentation; Including stock-based compensation - selling, general and administrative expenses: \$802,000; Including stock-based compensation - selling, general and administrative expenses: \$306,000; Including stock-based compensation - selling, general and administrative expenses: \$367,000; Including stock-based compensation - corporate selling, general and administrative expenses: \$3,845,000; Including stock-based compensation - corporate selling, general and administrative expenses: \$3,104,000; Including stock-based compensation - corporate selling, general and administrative expenses: \$4,740,000; As is; Approximately; As of February 20, 2018; As of February 24, 2017; As of February 11, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016 (revised)
Cash & cash equivalents	37,009	45,812
Restricted cash	802	969
Trade accounts receivable, gross	119,667	111,342
Less: allowance for doubtful accounts	8,071	6,991
Trade accounts receivable, net	111,596	104,351
Prepaid expenses	9,013	7,902
Current portion of content assets	37,549	35,854
Other current assets	3,766	4,772
Total current assets	199,735	199,660
Content assets, net	74,508	66,822

Land & improvements	2,391	2,830
Buildings	2,660	1,264
Transmitters & towers	40,343	39,266
Equipment	59,024	57,218
Furniture & fixtures	10,354	10,153
Software & web development	25,398	23,679
Leasehold improvements	24,543	24,248
Construction-in-progress	184	135
Property & equipment, gross	164,897	158,793
Less: accumulated depreciation & amortization	139,716	133,942
Property & equipment, net	25,181	24,851
Goodwill	262,894	258,284
Radio broadcasting licenses	614,535	643,449
Other intangible assets, net	94,055	116,600
Other assets	45,847	49,120
Total assets	1,316,755	1,358,786
Accounts payable	8,127	7,555
Accrued interest	15,428	16,691
Accrued compensation & related benefits	8,648	15,199
Current portion of content payables	17,891	22,872
Deferred revenue	9,070	8,693
Deferred barter revenue	1,730	1,337
Deferred rent	764	736
Employment Agreement award	2,973	2,511
Accrued national representative fees	755	563
Accrued miscellaneous taxes	302	223
Income taxes payable	1,082	689
Deferred gain on sale-leaseback	809	...
Contingent consideration	850	...
Tenant allowance	...	115
Reserve for audience deficiency	4,427	6,521
Other current liabilities	4,474	5,259
Current portion of long-term debt	3,500	3,500
Total current liabilities	80,830	92,464
Credit facilities	347,375	344,750
Senior subordinated notes	275,000	315,000
Senior secured notes	350,000	350,000
Comcast note	11,872	11,872
Less: current portion of long-term debt	3,500	3,500
Less: original issue discount & issuance costs	(13,581)	(15,386)
Content payables, net of current portion	21,879	16,135
Other long-term liabilities	44,853	33,434
Deferred tax liabilities	148,592	272,733
Total liabilities	1,263,320	1,417,502
Redeemable noncontrolling interests	10,780	12,410
Class A common stock	2	2
Class B common stock	3	3
Class C common stock	3	3
Class D common stock	41	41
Additional paid-in capital	983,582	981,688
Retained earnings (accumulated deficit)	(940,976)	(1,052,863)
Total stockholders' equity (deficit)	42,655	(71,126)
Total (deficit) equity	42,655	(71,126)

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

- Urban One Inc non-voting class C common.**  
No dividends paid.
- Urban One Inc non-voting class D common.**  
No dividends paid.

#### 3. Urban One Inc class B common.

No dividends paid.

#### 4. Urban One Inc class A common.

No dividends paid.

#### Annual Dividends:

##### 1. Urban One Inc non-voting class C common.

No dividends paid.

##### 2. Urban One Inc non-voting class D common.

No dividends paid.

##### 3. Urban One Inc class B common.

No dividends paid.

##### 4. Urban One Inc class A common.

No dividends paid.

#### VEMANTI GROUP INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	□2015
Sales	455,122	499,710	(revised) 629,508
Cost of sales	107,189	127,607	(revised) 212,313
Gross profit	347,933	372,103	(revised) 417,195
General & administrative expenses	730,027	535,407	420,784
Total operating expenses	730,027	535,407	420,784
Income (loss) from operations	(382,094)	(163,304)	(3,589)
Interest expense	4,898	9,277	14,713
Other income	4,038	1,258	4,556
Unrealized gain	2,149	...	...
Total other income (expense)	1,289	(8,019)	(10,157)
Income (loss) before provision for income taxes	(380,805)	(171,323)	(13,746)
<b>Net income (loss)</b>	<b>(380,805)</b>	<b>(171,323)</b>	<b>(13,746)</b>
Weighted average shares outstanding - basic	48,173,512	44,106,202	41,970,000
Weighted average shares outstanding - diluted	48,173,512	44,106,202	41,970,000
Year end shares outstanding	□57,482,000	45,270,000	41,970,000
Income (loss) per share - basic	\$(0.01)	\$0.00	\$0.00
Income (loss) per share - diluted	\$(0.01)	\$0.00	\$0.00
Number of common stockholders	395	53	...

□ Reclassified to conform with 2016 presentation; □ Shares increased due to the effect of issuance for cash and stock-based compensation

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	□2016
Cash	489,266	(revised) 47,964
Account receivable	5,571	1,797
Other current assets	4,742	20,028
Digital assets, at fair value	17,149	...
Total current assets	516,728	69,789
Intangible asset, net	...	8,891
Software licenses	32,188	32,188
Computer equipment	17,080	13,323
Equipment, gross	49,268	45,511
Less accumulated depreciation	45,672	45,511
Equipment, net	3,596	...
Total assets	520,324	78,680
Accounts payable	9,810	4,287
Accrued expenses	14,838	18,562
Advance from stockholder	500	1,340
Note payable, current portion	33,531	50,558
Total current liabilities	58,679	74,747
Note payable	33,531	99,241
Note payable - non-interest bearing	...	3,000
Total notes payable	33,531	102,241
Total net of discount	33,531	102,241

Less: current portion	33,531	50,558
Note payable, net of current portion	...	51,683
Total liabilities	58,679	126,430
Preferred stock	4,000	4,000
Common stock	5,748	4,527
Additional paid-in capital	1,182,612	293,633
Retained earnings (accumulated deficit)	(730,715)	(349,910)
Total stockholders' equity (deficit)	461,645	(47,750)

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. Vemanti Group Inc common.

No dividends paid.

##### 2. Vemanti Group Inc preferred.

No dividends paid.

#### Annual Dividends:

##### 1. Vemanti Group Inc common.

No dividends paid.

##### 2. Vemanti Group Inc preferred.

No dividends paid.

#### VICAL INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	□2015
Contract & grant revenue	13,401,000	12,804,000	(revised) 18,860,000
License & royalty revenue	418,000	1,727,000	(revised) 2,090,000
Total revenues	13,819,000	14,531,000	(revised) 20,950,000
Research & development	14,391,000	10,355,000	11,061,000
Manufacturing & production	6,479,000	6,291,000	10,927,000
General & administrative	6,335,000	7,062,000	8,366,000
Total operating expenses	27,205,000	23,708,000	30,354,000
Income (loss) from operations	(13,386,000)	(9,177,000)	(9,404,000)
Investment & other income, net	426,000	204,000	166,000
<b>Net income (loss)</b>	<b>(12,960,000)</b>	<b>(8,973,000)</b>	<b>(9,238,000)</b>
Weighted average shares outstanding - basic	12,888,000	10,019,000	□9,175,000
Weighted average shares outstanding - diluted	12,888,000	10,019,000	□9,175,000
Year end shares outstanding	□21,802,000	□11,052,000	□9,154,000
Net income (loss) per share - basic	\$(1.01)	\$(0.90)	□\$(1.01)
Net income (loss) per share - diluted	\$(1.01)	\$(0.90)	□\$(1.01)
Number of full time employees	74	...	...
Number of common stockholders	□□134	...	...

□ Restated to reflect adoption of FASB issued ASU No. 2016-18, "Statement of Cash Flows (Topic 230): Restricted Cash"; □ Adjusted for 1-for-10 stock split, May 27, 2016; □ Shares increased due to the effect of issuance of common stock; □ Approximately; □ As of February 28, 2018

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	□2016
Cash & cash equivalents	24,841,000	5,069,000
Marketable securities, available-for-sale	35,658,000	30,552,000
Restricted cash	192,000	3,311,000
Deferred contract costs	10,502,000	5,513,000
Receivables & other assets	5,124,000	3,422,000
Total current assets	76,317,000	47,867,000
Long-term investments	2,209,000	2,046,000

Equipment	16,908,000	17,043,000
Leasehold improvements	8,144,000	8,144,000
Property & equipment, gross	25,052,000	25,187,000
Less accumulated depreciation & amortization	24,446,000	24,014,000
Property & equipment, net	606,000	1,173,000
Intangible assets, net	703,000	810,000
Other assets	659,000	388,000
Total assets	80,494,000	52,284,000
Accrued employee compensation	2,654,000	2,518,000
Clinical trial accruals	1,017,000	446,000
Accounts payable	1,213,000	326,000
Deferred rent	...	223,000
Other accrued liabilities	333,000	614,000
Deferred revenue	11,700,000	3,018,000
Total current liabilities	16,917,000	7,145,000
Common stock	218,000	111,000
Additional paid-in capital	489,975,000	458,881,000
Retained earnings (accumulated deficit)	(426,738,000)	(413,878,000)
Accumulated other comprehensive income (loss)	122,000	25,000
Total stockholders' equity	63,577,000	45,139,000

<sup>¶</sup> Restated to reflect adoption of FASB issued ASU No. 2016-18, "Statement of Cash Flows (Topic 230): Restricted Cash"

**Recent Dividends:**

**1. Vical Inc common.**

No dividends paid.

**Annual Dividends:**

**1. Vical Inc common.**

No dividends paid.

**VOLT INFORMATION SCIENCES INC**

Earnings, 3 mos. to (Consol. - \$000):

	01/28/18	01/29/17
Total revenues	253,338	313,024
Cost & expenses	264,785	315,648
Operating income	(11,447)	(2,624)
Other income (expense), net	(528)	(599)
Foreign currency	703	127
Net before taxes	(12,054)	(3,954)
Income taxes	(1,360)	623
Net income	(10,694)	(4,577)
Earnings common share		
Primary	\$(0.51)	\$(0.22)
Fully Diluted	\$(0.51)	\$(0.22)
Common Shares:		
Full Diluted	21,029	20,918
Year-end	21,029	20,918

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	53,868
Current assets	258,419
Net property & equip.	27,487
Total assets	297,207
Liabilities:	
Current liabilities	138,181
Long-term debt	48,673
Stockholders' equity	75,139
Net current assets	120,238

**WALKING COMPANY HOLDINGS INC**

**Bankruptcy Proceedings** On Mar. 14, 2018, Co. filed with the U.S. Bankruptcy Court Exhibit B to the Disclosure Statement for the Debtors' Joint Plan of Reorganization. The notice states, "Exhibit B to the Disclosure Statement was not finalized at the time of filing as the Debtors were still in the process of reviewing the liquidation and recovery analysis. This review has now been completed and attached as Exhibit B to the Disclosure Statement." The exhibit notes, "In preparing this Liquidation Analysis, the Debtors have preliminarily estimated an amount of Allowed Claims for each indicated type of Claim based upon a review of the Debtor's estimated balance sheet. This hypothetical liquidation analysis assumes that the Chapter 7 trustee would sell the estate's remaining owned inventory to a third-party liquidation specialist who would provide the Chapter 7 trustee with cash

equalling the estimated gross purchase price of the owned merchandise inventory, less projected operating costs of the liquidator pertaining to the going-out-of-business sales using the Debtors' employees, retail store locations and e-commerce websites. This appraisal specialist concluded that the Debtors would likely recover, on a net basis, (a) approximately 77.3% of the cost value of its footwear merchandise inventories at its stores and distribution center if such a court-ordered going-out-of-business sale was conducted beginning in July 2018 and continued for approximately 15 weeks, and (b) approximately 54.5% of the cost value of its Big Dog apparel merchandise inventories if such a court-ordered going-out-of-business sale was conducted beginning in July 2018 and continued for approximately 16 weeks."

**WHITE SMILE GLOBAL INC**

**Name Change Development** On Mar. 9, 2018, Co. announced that it is in the process of changing Co.'s name to Williamsville Sears Management Inc.

**WORKHORSE GROUP INC**

**Annual Report**

**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	<sup>¶</sup> 2016	2015
		(revised)	(revised)
Sales	10,846,460	6,414,800	139,980
Cost of sales	24,516,863	13,578,262	...
Gross loss	(13,670,403)	(7,163,462)	...
Selling, general & administrative expenses	10,328,211	6,202,569	3,860,618
Research & development expenses	18,060,180	6,145,801	4,740,331
Total operating expenses	28,388,391	12,348,370	8,600,949
Interest expense, net	180,437	44,036	965,884
Net income (loss)	(42,239,231)	(19,555,868)	(9,426,853)
Weighted average shares outstanding			
- basic	38,755,796	25,201,261	17,293,394
Weighted average shares outstanding			
- diluted	38,755,796	25,201,261	17,293,394
Year end shares outstanding	<sup>¶</sup> 41,529,181	<sup>¶</sup> 27,578,864	18,204,923
Net income (loss) per share - basic	\$(1.09)	\$(0.78)	\$(0.55)
Net income (loss) per share - diluted	\$(1.09)	\$(0.78)	\$(0.55)
Number of full time employees	109	79	15
Number of part time employees	9	<sup>¶</sup> 19	<sup>¶</sup> 20
Number of common stockholders	<sup>¶</sup> 327	<sup>¶</sup> 209	<sup>¶</sup> 278

<sup>¶</sup> Shares increased due to the effect of issuance of common stock, exercises of stock options and warrants, and conversion of account payable; <sup>¶</sup> Shares increased due to the effect of issuance of common stock, exercises of stock options and warrants, and conversion of account payable; <sup>¶</sup> Shares increased due to the effect of issuance of common stock, and fulfillment of stock subscriptions receivable, exercises of stock options and warrants and concersion of account payable; <sup>¶</sup> Approximately; <sup>¶</sup> As of March 8, 2018; <sup>¶</sup> As of March 14, 2017; <sup>¶</sup> As of March 27, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	<sup>¶</sup> 2016
		(revised)
Cash & cash equivalents	4,069,477	469,570
Accounts receivable	1,013,423	628,700
Lease receivable current	45,300	98,400
Finished goods	...	212,884
Work in process	1,416,324	987,665
Parts	2,820,182	1,264,286
Inventory	4,236,506	2,464,835
Prepaid expenses & deposits	946,134	255,163
Total current assets	10,310,840	3,916,668
Land	700,000	700,000
Buildings	5,900,000	5,900,000
Leasehold improvements	19,225	19,225
Software	86,050	57,587
Equipment	829,742	808,512
Vehicles & prototypes	156,567	62,905

Property, plant & equipment, gross	7,691,584	7,548,229
Less: accumulated depreciation	2,095,571	1,545,598
Property, plant & equipment, net	5,596,013	6,002,631
Lease receivable long-term	212,004	320,494
Total assets	16,118,857	10,239,793
Accounts payable	5,539,864	3,121,518
Accrued liabilities	1,126,675	802,240
Accounts payable, related parties	54,914	101,339
Customer deposits	54,405	...
Shareholder advances	...	229,772
Current portion of long term debt	381,497	79,521
Total current liabilities	7,157,355	4,334,390
Principal amount of notes payable	5,750,000	...
Less: unamortized discount & debt issuance costs	(987,500)	...
Notes payable less unamortized discount & debt issuance costs	4,762,500	...
Secured mortgage payable	1,741,379	1,767,950
Note payable	350,000	350,000
Unsecured notes payable	...	50,000
Less: current portion	381,497	79,521
Long-term debt	<sup>¶</sup> 1,709,881	2,088,429
Common stock	41,529	27,579
Additional paid in capital	107,760,036	66,862,608
Retained earnings (accumulated deficit)	(105,312,444)	(63,073,213)
Total stockholders' equity (deficit)	2,489,121	3,816,974

<sup>¶</sup> Shares increased due to the effect of issuance of common stock, exercises of stock options and warrants, and conversion of account payable; <sup>¶</sup> As reported by Company

**Recent Dividends:**

**1. Workhorse Group Inc series A preferred.**

No dividends paid.

**2. Workhorse Group Inc common.**

No dividends paid.

**Annual Dividends:**

**1. Workhorse Group Inc series A preferred.**

No dividends paid.

**2. Workhorse Group Inc common.**

No dividends paid.

**WORKHORSE GROUP INC**

**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of Independent Auditors, Clark, Schaefer, Hackett & Co., as it appeared in the 2017 10-K report: "Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As described in Note 1 to the consolidated financial statements, the Company has not had positive cash flows from operations and has incurred significant net losses which have caused a significant accumulated deficit. These conditions raise substantial doubt

about its ability to continue as a going concern. Management's plans regarding those matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to that matter."

#### ZOSANO PHARMA CORP Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2017	2016 (revised)	2015 (revised)
License fees revenue	...	...	170
Collaboration revenue	...	...	143
Total revenue	...	...	313
Research & development expenses	20,188	20,457	20,366
General & administrative expenses	8,182	8,176	6,315
Total operating expenses	28,370	28,633	26,681
Income (loss) from operations	(28,370)	(28,633)	(26,368)
Interest expense, net	742	1,192	1,564
Other expense, net	(7)	7	97
Warrant revaluation income (expense)	...	...	48
Gain (loss) on debt extinguishment	...	...	(446)
Income (loss) before provision for income taxes	(29,105)	(29,832)	...
<b>Net income (loss)</b>	<b>(29,105)</b>	<b>(29,832)</b>	<b>(28,427)</b>
Weighted average shares outstanding - basic	1,730	688	571
Weighted average shares outstanding - diluted	1,730	688	571
Year end shares outstanding	1,973	841	598
Net earnings (loss) per share - basic	\$(16.82)	\$43.36	\$(49.80)
Net earnings (loss) per share - diluted	\$(16.82)	\$43.36	\$(49.80)
Number of full time employees	51	38	...
Total number of employees	51	38	67
Number of common stockholders	17	41	35

□ Reclassified to conform with 2017 presentation; □ Reclassified to conform with 2016 presentation; □ Adjusted for 1-for-20 stock split, January 25, 2018; □ Shares increased due to the effect of issuance for private investment in public equity (PIPE) offering, and to employees upon stock options exercised; □ As is; □ As of March 1, 2018; □ As of February 20, 2017; □ As of March 10, 2016

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016 (revised)
Cash & cash equivalents	11,651	15,003
Prepaid expenses & other current assets	1,742	273
Total current assets	13,393	15,276
Restricted cash	35	35
Laboratory & office equipment	1,159	1,127
Manufacturing equipment	10,387	10,857
Computer equipment & software	209	314
Leasehold improvements	15,660	15,694
Construction in progress	2,351	1,961
Property & equipment, gross	29,766	29,953
Less: accumulated		

depreciation	25,614	24,498
Property & equipment, net	4,152	5,455
Other long-term assets	420	140
Total assets	18,000	20,906
Accounts payable	1,511	1,445
Accrued compensation	1,571	1,377
Secured promissory note (including accrued interest), current portion	6,687	5,992
Other accrued liabilities	688	1,005
Total current liabilities	10,457	9,819
Deferred rent	495	52
Secured promissory note (including accrued interest), net of issuance cost	...	6,550
Total liabilities	10,952	16,421
Additional paid-in capital	232,922	201,254
Retained earnings (accumulated deficit)	(225,874)	(196,769)
Stockholders' equity (deficit)	7,048	4,485

□ Reclassified to conform with 2017 presentation

##### Recent Dividends:

1. Zosano Pharma Corp common.

No dividends paid.

##### Annual Dividends:

1. Zosano Pharma Corp common.

No dividends paid.

##### ZOSANO PHARMA CORP

##### Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2017 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Zosano Pharma Corporation (the "Company") as of December 31, 2017 and 2016, the related consolidated statements of operations, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph ¶ Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has negative cash flows from operations, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

\*

*MERGENT OTC UNLISTED News Reports 0895-3252* is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC UNLISTED Manual and provide periodic updates. Send address changes to MERGENT OTC UNLISTED, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2018 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.